CA2601979A1 - 2,3 substituted pyrazine sulfonamides - Google Patents
2,3 substituted pyrazine sulfonamides Download PDFInfo
- Publication number
- CA2601979A1 CA2601979A1 CA002601979A CA2601979A CA2601979A1 CA 2601979 A1 CA2601979 A1 CA 2601979A1 CA 002601979 A CA002601979 A CA 002601979A CA 2601979 A CA2601979 A CA 2601979A CA 2601979 A1 CA2601979 A1 CA 2601979A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- methyl
- pyrazin
- benzenesulfonamide
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XTIHOBZPEKJCRA-UHFFFAOYSA-N pyrazine-2-sulfonamide Chemical class NS(=O)(=O)C1=CN=CC=N1 XTIHOBZPEKJCRA-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 208000026935 allergic disease Diseases 0.000 claims abstract description 19
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 16
- 208000017520 skin disease Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 102000009389 Prostaglandin D receptors Human genes 0.000 claims abstract description 4
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 158
- -1 C3-heterocycloalkyl Chemical group 0.000 claims description 101
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 94
- 238000000034 method Methods 0.000 claims description 83
- 125000003118 aryl group Chemical group 0.000 claims description 65
- 125000001072 heteroaryl group Chemical group 0.000 claims description 53
- 238000006243 chemical reaction Methods 0.000 claims description 39
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 30
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 18
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 16
- 208000006673 asthma Diseases 0.000 claims description 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 150000002431 hydrogen Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 201000004624 Dermatitis Diseases 0.000 claims description 11
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 229940124530 sulfonamide Drugs 0.000 claims description 11
- 206010012442 Dermatitis contact Diseases 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 201000009961 allergic asthma Diseases 0.000 claims description 9
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 9
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 8
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 201000002481 Myositis Diseases 0.000 claims description 8
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 8
- 208000024780 Urticaria Diseases 0.000 claims description 8
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 8
- 201000010105 allergic rhinitis Diseases 0.000 claims description 8
- 201000010435 allergic urticaria Diseases 0.000 claims description 8
- 208000003455 anaphylaxis Diseases 0.000 claims description 8
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 8
- 208000010668 atopic eczema Diseases 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000009610 hypersensitivity Effects 0.000 claims description 8
- 201000008482 osteoarthritis Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 150000003456 sulfonamides Chemical class 0.000 claims description 8
- 125000004001 thioalkyl group Chemical group 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- GLAOKVJBKVYORF-UHFFFAOYSA-N n-[3-[4-(indol-1-ylmethyl)phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1CN1C2=CC=CC=C2C=C1 GLAOKVJBKVYORF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- ZGNFSQOWZVCFES-UHFFFAOYSA-N 4-phenoxy-n-[3-[4-(quinolin-2-ylmethyl)piperazin-1-yl]pyrazin-2-yl]benzenesulfonamide Chemical compound N=1C=CN=C(N2CCN(CC=3N=C4C=CC=CC4=CC=3)CC2)C=1NS(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 ZGNFSQOWZVCFES-UHFFFAOYSA-N 0.000 claims description 5
- UTTZATRZTXNAFP-UHFFFAOYSA-N 2-chloro-n-[3-[4-(5,6,7,8-tetrahydronaphthalen-2-yloxymethyl)phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound ClC1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1COC1=CC=C(CCCC2)C2=C1 UTTZATRZTXNAFP-UHFFFAOYSA-N 0.000 claims description 4
- WDABFZMYVIPINV-UHFFFAOYSA-N 2-chloro-n-[3-[4-(indol-1-ylmethyl)phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound ClC1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1CN1C2=CC=CC=C2C=C1 WDABFZMYVIPINV-UHFFFAOYSA-N 0.000 claims description 4
- JICJPQPYGABFFN-UHFFFAOYSA-N 2-chloro-n-[3-[4-(naphthalen-2-yloxymethyl)phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound ClC1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1COC1=CC=C(C=CC=C2)C2=C1 JICJPQPYGABFFN-UHFFFAOYSA-N 0.000 claims description 4
- KYAYPIPAYGFMQF-UHFFFAOYSA-N 2-chloro-n-[3-[4-[(2,4-difluoro-n-methylanilino)methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=C(F)C=C(F)C=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl KYAYPIPAYGFMQF-UHFFFAOYSA-N 0.000 claims description 4
- NSVOPLXMHFTYPZ-UHFFFAOYSA-N 2-chloro-n-[3-[4-[(2-ethylbenzimidazol-1-yl)methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound CCC1=NC2=CC=CC=C2N1CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl NSVOPLXMHFTYPZ-UHFFFAOYSA-N 0.000 claims description 4
- ARTDRSOXFXPENH-UHFFFAOYSA-N 2-chloro-n-[3-[4-[(2-methylindol-1-yl)methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound CC1=CC2=CC=CC=C2N1CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl ARTDRSOXFXPENH-UHFFFAOYSA-N 0.000 claims description 4
- NIHWMQBNJSHNSU-UHFFFAOYSA-N 2-chloro-n-[3-[4-[(5-fluoroindol-1-yl)methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C1=CC2=CC(F)=CC=C2N1CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl NIHWMQBNJSHNSU-UHFFFAOYSA-N 0.000 claims description 4
- NRXMKCQHCMGTLI-UHFFFAOYSA-N 2-chloro-n-[3-[4-[(n-methylanilino)methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl NRXMKCQHCMGTLI-UHFFFAOYSA-N 0.000 claims description 4
- IIFMRCKHFBJBGB-UHFFFAOYSA-N 2-chloro-n-[3-[4-[[ethyl(pyridin-2-yl)amino]methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=CC=NC=1N(CC)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl IIFMRCKHFBJBGB-UHFFFAOYSA-N 0.000 claims description 4
- LKWDHHXCUITAGL-UHFFFAOYSA-N 4-chloro-n-[3-[4-[(n-methylanilino)methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 LKWDHHXCUITAGL-UHFFFAOYSA-N 0.000 claims description 4
- BLDGNBNAKLYLFI-UHFFFAOYSA-N 4-cyano-n-[3-[4-[[n-methyl-4-(trifluoromethoxy)anilino]methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=C(C#N)C=C1 BLDGNBNAKLYLFI-UHFFFAOYSA-N 0.000 claims description 4
- WCQQNKBIIBHILP-UHFFFAOYSA-N 4-methyl-n-[3-[4-[[n-methyl-4-(trifluoromethoxy)anilino]methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=C(C)C=C1 WCQQNKBIIBHILP-UHFFFAOYSA-N 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- CUGRVWOJFYHAGN-UHFFFAOYSA-N n-[3-[4-(2,3-dihydroindol-1-ylmethyl)phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1CN1C2=CC=CC=C2CC1 CUGRVWOJFYHAGN-UHFFFAOYSA-N 0.000 claims description 4
- LADJXPBENVWQSH-UHFFFAOYSA-N n-[3-[4-(phenoxymethyl)phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1COC1=CC=CC=C1 LADJXPBENVWQSH-UHFFFAOYSA-N 0.000 claims description 4
- UORDNOQGYTYXLZ-UHFFFAOYSA-N n-[3-[4-[(1,3-benzodioxol-5-ylamino)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1CNC1=CC=C(OCO2)C2=C1 UORDNOQGYTYXLZ-UHFFFAOYSA-N 0.000 claims description 4
- HZFVBIWYOXIAFA-UHFFFAOYSA-N n-[3-[4-[(2,4-dichloro-n-methylanilino)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F HZFVBIWYOXIAFA-UHFFFAOYSA-N 0.000 claims description 4
- WGGWLGNXHFUCOM-UHFFFAOYSA-N n-[3-[4-[(2-ethylbenzimidazol-1-yl)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound CCC1=NC2=CC=CC=C2N1CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F WGGWLGNXHFUCOM-UHFFFAOYSA-N 0.000 claims description 4
- CLPBOGUIFOKTHW-UHFFFAOYSA-N n-[3-[4-[(2-methylindol-1-yl)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CC2=CC=CC=C2N1CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F CLPBOGUIFOKTHW-UHFFFAOYSA-N 0.000 claims description 4
- LHDGNNKVCYWAGN-UHFFFAOYSA-N n-[3-[4-[(2-pyridin-2-ylindol-1-yl)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1CN1C2=CC=CC=C2C=C1C1=CC=CC=N1 LHDGNNKVCYWAGN-UHFFFAOYSA-N 0.000 claims description 4
- BYESASWLZSCSKE-UHFFFAOYSA-N n-[3-[4-[(3,4-dichloro-n-methylanilino)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F BYESASWLZSCSKE-UHFFFAOYSA-N 0.000 claims description 4
- BJDULRFTCORWTA-UHFFFAOYSA-N n-[3-[4-[(3-chlorophenoxy)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1COC1=CC=CC(Cl)=C1 BJDULRFTCORWTA-UHFFFAOYSA-N 0.000 claims description 4
- XEDHXTVXKPWUAQ-UHFFFAOYSA-N n-[3-[4-[(3-fluoro-n-methylanilino)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C=CC(F)=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F XEDHXTVXKPWUAQ-UHFFFAOYSA-N 0.000 claims description 4
- UMCDBZJVDNZBCY-UHFFFAOYSA-N n-[3-[4-[(3-methoxyphenyl)methoxymethyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound COC1=CC=CC(COCC=2C=CC(=CC=2)C=2C(=NC=CN=2)NS(=O)(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 UMCDBZJVDNZBCY-UHFFFAOYSA-N 0.000 claims description 4
- BDLFEHOTOACPIS-UHFFFAOYSA-N n-[3-[4-[(4-chloro-n-methylanilino)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C=C(Cl)C=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F BDLFEHOTOACPIS-UHFFFAOYSA-N 0.000 claims description 4
- DSGSUUPWAPBDII-UHFFFAOYSA-N n-[3-[4-[(4-chloro-n-methylanilino)methyl]phenyl]pyrazin-2-yl]thiophene-2-sulfonamide Chemical compound C=1C=C(Cl)C=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CS1 DSGSUUPWAPBDII-UHFFFAOYSA-N 0.000 claims description 4
- XEWHZMFYZZLOMW-UHFFFAOYSA-N n-[3-[4-[(4-cyano-n-methylanilino)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C=C(C#N)C=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F XEWHZMFYZZLOMW-UHFFFAOYSA-N 0.000 claims description 4
- SFBSSYWBZPFBJO-UHFFFAOYSA-N n-[3-[4-[(4-cyanophenoxy)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1COC1=CC=C(C#N)C=C1 SFBSSYWBZPFBJO-UHFFFAOYSA-N 0.000 claims description 4
- BJINUHXRLLDZQJ-UHFFFAOYSA-N n-[3-[4-[(4-fluoro-n-methylanilino)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C=C(F)C=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F BJINUHXRLLDZQJ-UHFFFAOYSA-N 0.000 claims description 4
- IIQAEIKLTAJTNG-UHFFFAOYSA-N n-[3-[4-[(4-fluorophenoxy)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C1=CC(F)=CC=C1OCC1=CC=C(C=2C(=NC=CN=2)NS(=O)(=O)C=2C(=CC=CC=2)C(F)(F)F)C=C1 IIQAEIKLTAJTNG-UHFFFAOYSA-N 0.000 claims description 4
- RXXBTTGCFYIOAT-UHFFFAOYSA-N n-[3-[4-[(5-chloro-2-methylindol-1-yl)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CC2=CC(Cl)=CC=C2N1CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F RXXBTTGCFYIOAT-UHFFFAOYSA-N 0.000 claims description 4
- ROJQOVLILNFYQA-UHFFFAOYSA-N n-[3-[4-[(5-fluoroindol-1-yl)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C1=CC2=CC(F)=CC=C2N1CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F ROJQOVLILNFYQA-UHFFFAOYSA-N 0.000 claims description 4
- WVNXFUOTDDMKDD-UHFFFAOYSA-N n-[3-[4-[(6-chloropyridin-3-yl)oxymethyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1COC1=CC=C(Cl)N=C1 WVNXFUOTDDMKDD-UHFFFAOYSA-N 0.000 claims description 4
- YSOFERFBJRXWPH-UHFFFAOYSA-N n-[3-[4-[(6-fluoroindol-1-yl)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C12=CC(F)=CC=C2C=CN1CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F YSOFERFBJRXWPH-UHFFFAOYSA-N 0.000 claims description 4
- SEZIHNWPKZJZAK-UHFFFAOYSA-N n-[3-[4-[(n-ethylanilino)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C=CC=CC=1N(CC)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F SEZIHNWPKZJZAK-UHFFFAOYSA-N 0.000 claims description 4
- YPYKQYCRKFEEBJ-UHFFFAOYSA-N n-[3-[4-[(n-methylanilino)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C=CC=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F YPYKQYCRKFEEBJ-UHFFFAOYSA-N 0.000 claims description 4
- RDCBRAVRIZBSMK-UHFFFAOYSA-N n-[3-[4-[[benzyl(pyridin-2-yl)amino]methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1CN(C=1N=CC=CC=1)CC1=CC=CC=C1 RDCBRAVRIZBSMK-UHFFFAOYSA-N 0.000 claims description 4
- ZZEJVEXVDOBXSA-UHFFFAOYSA-N n-[3-[4-[[benzyl(pyridin-2-yl)amino]methyl]phenyl]pyrazin-2-yl]-2-chlorobenzenesulfonamide Chemical compound ClC1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1CN(C=1N=CC=CC=1)CC1=CC=CC=C1 ZZEJVEXVDOBXSA-UHFFFAOYSA-N 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- OPWCXLBGIUCEAS-UHFFFAOYSA-N 2-chloro-n-[3-[4-[(5-methoxy-2-methylindol-1-yl)methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound CC1=CC2=CC(OC)=CC=C2N1CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl OPWCXLBGIUCEAS-UHFFFAOYSA-N 0.000 claims 3
- IHRNXEOEOQZLDB-UHFFFAOYSA-N 2-chloro-n-[3-[4-[[(2-fluorophenyl)methylamino]methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound FC1=CC=CC=C1CNCC1=CC=C(C=2C(=NC=CN=2)NS(=O)(=O)C=2C(=CC=CC=2)Cl)C=C1 IHRNXEOEOQZLDB-UHFFFAOYSA-N 0.000 claims 3
- HZZXPSNVHXKOFL-UHFFFAOYSA-N 2-chloro-n-[3-[4-[[(4-cyanophenyl)methylamino]methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound ClC1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1CNCC1=CC=C(C#N)C=C1 HZZXPSNVHXKOFL-UHFFFAOYSA-N 0.000 claims 3
- ZUCCCPGBDKQESD-UHFFFAOYSA-N 2-chloro-n-[3-[4-[[n-methyl-4-(trifluoromethoxy)anilino]methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl ZUCCCPGBDKQESD-UHFFFAOYSA-N 0.000 claims 3
- ZDCRVJVTSXJVND-UHFFFAOYSA-N 3-chloro-n-[3-[4-[[n-methyl-4-(trifluoromethoxy)anilino]methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC(Cl)=C1 ZDCRVJVTSXJVND-UHFFFAOYSA-N 0.000 claims 3
- JVMPYBKXCOJXKQ-UHFFFAOYSA-N n-[3-[4-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C(C=C1)=CC=C1CN1C2=CC=CC=C2OCC1 JVMPYBKXCOJXKQ-UHFFFAOYSA-N 0.000 claims 3
- HRBCKLQEWYETLK-UHFFFAOYSA-N n-[3-[4-[(4-methoxyphenoxy)methyl]phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1OCC1=CC=C(C=2C(=NC=CN=2)NS(=O)(=O)C=2C(=CC=CC=2)C(F)(F)F)C=C1 HRBCKLQEWYETLK-UHFFFAOYSA-N 0.000 claims 3
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 2
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 238000004949 mass spectrometry Methods 0.000 description 115
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 103
- 239000000543 intermediate Substances 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
- 238000004128 high performance liquid chromatography Methods 0.000 description 64
- 239000007787 solid Substances 0.000 description 64
- 238000007429 general method Methods 0.000 description 50
- 239000002904 solvent Substances 0.000 description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 29
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 25
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 24
- VLBJRICNFRRIRH-UHFFFAOYSA-N n-[3-[4-(chloromethyl)phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1C1=CC=C(CCl)C=C1 VLBJRICNFRRIRH-UHFFFAOYSA-N 0.000 description 23
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 18
- 229910052717 sulfur Inorganic materials 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 230000009257 reactivity Effects 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 14
- QKDJWRHQYAXOBQ-UHFFFAOYSA-N 2-chloro-n-[3-[4-(chloromethyl)phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C1=CC(CCl)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl QKDJWRHQYAXOBQ-UHFFFAOYSA-N 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 11
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000007822 coupling agent Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000005660 chlorination reaction Methods 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 101150041968 CDC13 gene Proteins 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 7
- AFFPZJFLSDVZBV-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C(F)(F)F AFFPZJFLSDVZBV-UHFFFAOYSA-N 0.000 description 7
- HSLJRWQPNZGVHN-UHFFFAOYSA-N 3-chloropyrazine-2-sulfonamide Chemical class NS(=O)(=O)C1=NC=CN=C1Cl HSLJRWQPNZGVHN-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 238000009833 condensation Methods 0.000 description 7
- 230000005494 condensation Effects 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 125000001624 naphthyl group Chemical group 0.000 description 6
- 239000012038 nucleophile Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000003831 tetrazolyl group Chemical group 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 5
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 208000037765 diseases and disorders Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 125000003386 piperidinyl group Chemical group 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 5
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 4
- 125000005964 1,2,4-oxadiazolidinyl group Chemical group 0.000 description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 4
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 4
- 125000005965 1,3,4-oxadiazolidinyl group Chemical group 0.000 description 4
- MLCNOCRGSBCAGH-UHFFFAOYSA-N 2,3-dichloropyrazine Chemical compound ClC1=NC=CN=C1Cl MLCNOCRGSBCAGH-UHFFFAOYSA-N 0.000 description 4
- OPKNGAVZWMRWNV-UHFFFAOYSA-N 2-chloro-n-(3-chloropyrazin-2-yl)benzenesulfonamide Chemical compound ClC1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1Cl OPKNGAVZWMRWNV-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000005620 boronic acid group Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 125000001786 isothiazolyl group Chemical group 0.000 description 4
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- OZCZMUQGIWGIEM-UHFFFAOYSA-N n-(3-chloropyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)NC1=NC=CN=C1Cl OZCZMUQGIWGIEM-UHFFFAOYSA-N 0.000 description 4
- MGCCWCLGIPNIBP-UHFFFAOYSA-N n-methyl-4-(trifluoromethoxy)aniline Chemical compound CNC1=CC=C(OC(F)(F)F)C=C1 MGCCWCLGIPNIBP-UHFFFAOYSA-N 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 125000005493 quinolyl group Chemical group 0.000 description 4
- 238000003653 radioligand binding assay Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 210000004241 Th2 cell Anatomy 0.000 description 3
- HCBRAEWDLZUPNL-UHFFFAOYSA-N [I+].CCCC[N+](CCCC)(CCCC)CCCC Chemical compound [I+].CCCC[N+](CCCC)(CCCC)CCCC HCBRAEWDLZUPNL-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000009285 allergic inflammation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000001743 benzylic group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 150000001934 cyclohexanes Chemical class 0.000 description 3
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 125000005990 isobenzothienyl group Chemical group 0.000 description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 125000005475 oxolanyl group Chemical group 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- ZIQRIAYNHAKDDU-UHFFFAOYSA-N sodium;hydroiodide Chemical compound [Na].I ZIQRIAYNHAKDDU-UHFFFAOYSA-N 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 150000003530 tetrahydroquinolines Chemical class 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 3
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CXCZOMULEPFGPX-UHFFFAOYSA-N 2-chloro-n-[3-[4-(hydroxymethyl)phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C1=CC(CO)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl CXCZOMULEPFGPX-UHFFFAOYSA-N 0.000 description 2
- QHCCOYAKYCWDOJ-UHFFFAOYSA-N 2-ethyl-1h-benzimidazole Chemical compound C1=CC=C2NC(CC)=NC2=C1 QHCCOYAKYCWDOJ-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- AZHGGDCFQPMANU-UHFFFAOYSA-N 3,4-dihydro-1h-1,4-benzodiazepine-2,5-dione Chemical compound N1C(=O)CNC(=O)C2=CC=CC=C21 AZHGGDCFQPMANU-UHFFFAOYSA-N 0.000 description 2
- JEDXDYXIRZOEKG-UHFFFAOYSA-N 4-(methylamino)benzonitrile Chemical compound CNC1=CC=C(C#N)C=C1 JEDXDYXIRZOEKG-UHFFFAOYSA-N 0.000 description 2
- SIAVMDKGVRXFAX-UHFFFAOYSA-N 4-carboxyphenylboronic acid Chemical compound OB(O)C1=CC=C(C(O)=O)C=C1 SIAVMDKGVRXFAX-UHFFFAOYSA-N 0.000 description 2
- XCEYKKJMLOFDSS-UHFFFAOYSA-N 4-chloro-n-methylaniline Chemical compound CNC1=CC=C(Cl)C=C1 XCEYKKJMLOFDSS-UHFFFAOYSA-N 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101001117314 Homo sapiens Prostaglandin D2 receptor 2 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- PZRPBPMLSSNFOM-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=C(B(O)O)C=C1 PZRPBPMLSSNFOM-UHFFFAOYSA-N 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 229940012017 ethylenediamine Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical class N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- BUQMRQRWFGKSSB-UHFFFAOYSA-N n-[3-(3-hydroxyprop-1-ynyl)pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound OCC#CC1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F BUQMRQRWFGKSSB-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KFTBCJUZVUOWRL-UHFFFAOYSA-N 1-fluoro-2,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1[N+]([O-])=O KFTBCJUZVUOWRL-UHFFFAOYSA-N 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 1
- DDBLVMDBBKQXTA-UHFFFAOYSA-N 2,4-dichloro-n-methylaniline Chemical compound CNC1=CC=C(Cl)C=C1Cl DDBLVMDBBKQXTA-UHFFFAOYSA-N 0.000 description 1
- RPGDVPAENGWKAO-UHFFFAOYSA-N 2,4-difluoro-n-methylaniline Chemical compound CNC1=CC=C(F)C=C1F RPGDVPAENGWKAO-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- WDETYCRYUBGKCE-UHFFFAOYSA-N 2-(chloromethyl)quinolin-1-ium;chloride Chemical compound Cl.C1=CC=CC2=NC(CCl)=CC=C21 WDETYCRYUBGKCE-UHFFFAOYSA-N 0.000 description 1
- ZIZGWNOAHUCACM-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1S(Cl)(=O)=O ZIZGWNOAHUCACM-UHFFFAOYSA-N 0.000 description 1
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- CTWFCRXUEWXSTL-UHFFFAOYSA-N 2-chloro-n-[3-[4-[(2-fluoro-n-methylanilino)methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=CC=C(F)C=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl CTWFCRXUEWXSTL-UHFFFAOYSA-N 0.000 description 1
- KMGXJGSTDDYGEW-UHFFFAOYSA-N 2-chloro-n-[3-[4-[(4-cyano-n-methylanilino)methyl]phenyl]pyrazin-2-yl]benzenesulfonamide Chemical compound C=1C=C(C#N)C=CC=1N(C)CC(C=C1)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1Cl KMGXJGSTDDYGEW-UHFFFAOYSA-N 0.000 description 1
- JCCBZCMSYUSCFM-UHFFFAOYSA-N 2-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1Cl JCCBZCMSYUSCFM-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- LDVAIJZDACHGML-UHFFFAOYSA-N 2-fluoro-n-methylaniline Chemical compound CNC1=CC=CC=C1F LDVAIJZDACHGML-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000005979 2-naphthyloxy group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OLGGLCIDAMICTA-UHFFFAOYSA-N 2-pyridin-2-yl-1h-indole Chemical compound N1C2=CC=CC=C2C=C1C1=CC=CC=N1 OLGGLCIDAMICTA-UHFFFAOYSA-N 0.000 description 1
- DUSNCFKVMGTTFK-UHFFFAOYSA-N 3,4-dichloro-n-methylaniline Chemical compound CNC1=CC=C(Cl)C(Cl)=C1 DUSNCFKVMGTTFK-UHFFFAOYSA-N 0.000 description 1
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 description 1
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 description 1
- IIGNZLVHOZEOPV-UHFFFAOYSA-N 3-Methoxybenzyl alcohol Chemical compound COC1=CC=CC(CO)=C1 IIGNZLVHOZEOPV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 1
- FHYDHJXZZQCXOX-UHFFFAOYSA-N 3-fluoro-n-methylaniline Chemical compound CNC1=CC=CC(F)=C1 FHYDHJXZZQCXOX-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
- VLWRKVBQUANIGI-UHFFFAOYSA-N 4-fluoro-n-methylaniline Chemical compound CNC1=CC=C(F)C=C1 VLWRKVBQUANIGI-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- QTWNVDXEEXERMH-UHFFFAOYSA-N 4-phenoxy-n-(3-piperazin-1-ylpyrazin-2-yl)benzenesulfonamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)NC1=NC=CN=C1N1CCNCC1 QTWNVDXEEXERMH-UHFFFAOYSA-N 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- UMKXSOXZAXIOPJ-UHFFFAOYSA-N 5,6,7,8-tetrahydro-2-naphthol Chemical compound C1CCCC2=CC(O)=CC=C21 UMKXSOXZAXIOPJ-UHFFFAOYSA-N 0.000 description 1
- WUVWAXJXPRYUME-UHFFFAOYSA-N 5-chloro-2-methyl-1h-indole Chemical compound ClC1=CC=C2NC(C)=CC2=C1 WUVWAXJXPRYUME-UHFFFAOYSA-N 0.000 description 1
- VSWGLJOQFUMFOQ-UHFFFAOYSA-N 5-methoxy-2-methyl-1h-indole Chemical compound COC1=CC=C2NC(C)=CC2=C1 VSWGLJOQFUMFOQ-UHFFFAOYSA-N 0.000 description 1
- KVCOOWROABTXDJ-UHFFFAOYSA-N 6-chloropyridin-3-ol Chemical compound OC1=CC=C(Cl)N=C1 KVCOOWROABTXDJ-UHFFFAOYSA-N 0.000 description 1
- YYFFEPUCAKVRJX-UHFFFAOYSA-N 6-fluoro-1h-indole Chemical compound FC1=CC=C2C=CNC2=C1 YYFFEPUCAKVRJX-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 101100025412 Arabidopsis thaliana XI-A gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 101000805140 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase II large subunit Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- GFZPUGCMGGUPHH-UHFFFAOYSA-N [I].[Na] Chemical compound [I].[Na] GFZPUGCMGGUPHH-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 150000007854 aminals Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical compound OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 125000005253 heteroarylacyl group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- QEXCSBBYZTYBHQ-UHFFFAOYSA-N n-[3-[4-(chloromethyl)phenyl]pyrazin-2-yl]-4-cyanobenzenesulfonamide Chemical compound C1=CC(CCl)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=C(C#N)C=C1 QEXCSBBYZTYBHQ-UHFFFAOYSA-N 0.000 description 1
- FQDPCTCZQFLPAH-UHFFFAOYSA-N n-[3-[4-(chloromethyl)phenyl]pyrazin-2-yl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC=CN=C1C1=CC=C(CCl)C=C1 FQDPCTCZQFLPAH-UHFFFAOYSA-N 0.000 description 1
- XIKRPMKMPSQBQR-UHFFFAOYSA-N n-[3-[4-(chloromethyl)phenyl]pyrazin-2-yl]thiophene-2-sulfonamide Chemical compound C1=CC(CCl)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CS1 XIKRPMKMPSQBQR-UHFFFAOYSA-N 0.000 description 1
- IUBOTLQPKXCPSC-UHFFFAOYSA-N n-[3-[4-(hydroxymethyl)phenyl]pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C1=CC(CO)=CC=C1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F IUBOTLQPKXCPSC-UHFFFAOYSA-N 0.000 description 1
- WYHXNQXDQQMTQI-UHFFFAOYSA-N n-benzylpyridin-2-amine Chemical compound C=1C=CC=CC=1CNC1=CC=CC=N1 WYHXNQXDQQMTQI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CXGFWBPQQXZELI-UHFFFAOYSA-N n-ethylpyridin-2-amine Chemical compound CCNC1=CC=CC=N1 CXGFWBPQQXZELI-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- KSIVWRIUVFHYMO-UHFFFAOYSA-N tert-butyl 4-[3-[[2-(trifluoromethyl)phenyl]sulfonylamino]pyrazin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=NC=CN=C1NS(=O)(=O)C1=CC=CC=C1C(F)(F)F KSIVWRIUVFHYMO-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 150000003555 thioacetals Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical class CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention is related to the use of 2,3 substituted pyrazine sulfonamides of formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of 2,3 substituted pyrazine sulfonamides for the modulation, notably the inhibition, of CRTH2 activity.
Description
2,3 SUBSTITUTED PYRAZINE SULFONAMIDES
FIELD OF THE INVENTION
The present invention relates to 2,3 substituted pyrazine sulfonamides for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing such 2,3 substituted pyrazine sulfonamides. Said derivatives are useful for the treatment and/or prevention of allergic diseases and inflammatory dermatoses. Specifically, the present invention is related to the use of 2,3 substituted pyrazine sulfonamides for the modulation, notably the inhibition of CRTH2 activity. The present invention furthermore relates to nove12,3 substituted pyrazine sulfonamides as well as methods of their preparation.
BACKGROUND OF THE INVENTION
Prostaglandin D2 (PGD2) has long been associated with inflammatory and atopic conditions, specifically allergic diseases such as asthma, rhinitis and atopic dermatitis (Lewis et al. (1982) J. Immunol. 129, 1627). PGD2 belongs to a class of compounds derived from the 20-carbon fatty acid skeleton of arachidonic acid. In response to an antigen challenge, PGD2 is released in large amounts into the airway as well as to the skin during an acute allergic response. The DP receptor, which is a member of the G-protein coupled receptor (GPCR) subfamily, has long been thought to be the only receptor of PGD2. DP's role in allergic asthma has been demonstrated with DP deficient mice (Matsuoka et al. (2000) Science 287, 2013-2017). However, despite intense interest in the role of PGD2 in the inflammatory response, a direct link between DP receptor activation and PGD2-stimulated eosinophil migration has not been established (Woodward et al.
(1990) Invest. Ophthalomol Vis. Sci. 31, 138-146; Woodward et al. (1993) Eur.
J.
Pharmacol. 230, 327-333).
More recently, another G-protein coupled receptor, referred to as "Chemoattractant Receptor-Homologous molecule expressed on T-Helper 2 cells" (CRTH2) (Nagata et al.
(1999) J. Immunol. 162, 1278-1286, Hirai et al. (2001) J Exp. Med. 193, 255-261) has recently been identified as a receptor for PGD2 and this discovery has begun to shed light on the mechanism of action of PGD2. CRTH2, which is also referred to as DP2, GPR44 or DLIR, shows little structural similarity with the DP receptor and other prostanoid receptors.
However, CRTH2 possesses similar affmity for PGD2. Among peripheral blood T
lymphocytes, human CRTH2 is selectively expressed on Th2 cells and is highly expressed on cell types associated with allergic inflammation such as eosinophils, basophiles and Th2 cells. In addition, CRTH2 mediates PGD2 dependent cell migration of blood eosinophils and basophiles. Furthermore, increased numbers of circulating T cells expressing CRTH2 have been correlated with the severity of atopic dermatitis (Cosmi et al.
(2000) Eur. J.
Immunol. 30, 2972-2979). The interaction of CRTH2 with PGD2 plays a critical role in the allergen-induced recruitment of Th2 cells in the target tissues of allergic inflammation.
Compounds that inhibit the binding of CRTH2 and PGD2 should therefore be useful for the treatment of allergic diseases.
Allergic disease, like asthma, and inflammatory dermatoses represent a major class of complex, and typically chronic, inflammatory diseases that currently affect about 10% of the population and that number appears to be increasing (Bush, R.K., Georgitis J.W., Handbook of asthma and rhinitis. 1st ed. (1997), Abingdon: Blackwell Science.
270).
Atopic dermatitis is a chronic skin disease, wherein the skin becomes extremely itchy. It accounts for 10 to 20 percent of all visits to dermatologists. The increasing incidence of allergic diseases and inflammatory dermatoses worldwide underscores the need for new therapies to effectively treat or prevent these diseases. Currently, numerous classes of pharmaceutical agents are widely used to treat these diseases, for example, antihistamines, decongestants, anticholinergics, methylxanthines, cromolyns, corticosteroids, and leukotriene modulators. However, the usefulness of these agents is offten limited by side effects and low efficacy.
FIELD OF THE INVENTION
The present invention relates to 2,3 substituted pyrazine sulfonamides for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing such 2,3 substituted pyrazine sulfonamides. Said derivatives are useful for the treatment and/or prevention of allergic diseases and inflammatory dermatoses. Specifically, the present invention is related to the use of 2,3 substituted pyrazine sulfonamides for the modulation, notably the inhibition of CRTH2 activity. The present invention furthermore relates to nove12,3 substituted pyrazine sulfonamides as well as methods of their preparation.
BACKGROUND OF THE INVENTION
Prostaglandin D2 (PGD2) has long been associated with inflammatory and atopic conditions, specifically allergic diseases such as asthma, rhinitis and atopic dermatitis (Lewis et al. (1982) J. Immunol. 129, 1627). PGD2 belongs to a class of compounds derived from the 20-carbon fatty acid skeleton of arachidonic acid. In response to an antigen challenge, PGD2 is released in large amounts into the airway as well as to the skin during an acute allergic response. The DP receptor, which is a member of the G-protein coupled receptor (GPCR) subfamily, has long been thought to be the only receptor of PGD2. DP's role in allergic asthma has been demonstrated with DP deficient mice (Matsuoka et al. (2000) Science 287, 2013-2017). However, despite intense interest in the role of PGD2 in the inflammatory response, a direct link between DP receptor activation and PGD2-stimulated eosinophil migration has not been established (Woodward et al.
(1990) Invest. Ophthalomol Vis. Sci. 31, 138-146; Woodward et al. (1993) Eur.
J.
Pharmacol. 230, 327-333).
More recently, another G-protein coupled receptor, referred to as "Chemoattractant Receptor-Homologous molecule expressed on T-Helper 2 cells" (CRTH2) (Nagata et al.
(1999) J. Immunol. 162, 1278-1286, Hirai et al. (2001) J Exp. Med. 193, 255-261) has recently been identified as a receptor for PGD2 and this discovery has begun to shed light on the mechanism of action of PGD2. CRTH2, which is also referred to as DP2, GPR44 or DLIR, shows little structural similarity with the DP receptor and other prostanoid receptors.
However, CRTH2 possesses similar affmity for PGD2. Among peripheral blood T
lymphocytes, human CRTH2 is selectively expressed on Th2 cells and is highly expressed on cell types associated with allergic inflammation such as eosinophils, basophiles and Th2 cells. In addition, CRTH2 mediates PGD2 dependent cell migration of blood eosinophils and basophiles. Furthermore, increased numbers of circulating T cells expressing CRTH2 have been correlated with the severity of atopic dermatitis (Cosmi et al.
(2000) Eur. J.
Immunol. 30, 2972-2979). The interaction of CRTH2 with PGD2 plays a critical role in the allergen-induced recruitment of Th2 cells in the target tissues of allergic inflammation.
Compounds that inhibit the binding of CRTH2 and PGD2 should therefore be useful for the treatment of allergic diseases.
Allergic disease, like asthma, and inflammatory dermatoses represent a major class of complex, and typically chronic, inflammatory diseases that currently affect about 10% of the population and that number appears to be increasing (Bush, R.K., Georgitis J.W., Handbook of asthma and rhinitis. 1st ed. (1997), Abingdon: Blackwell Science.
270).
Atopic dermatitis is a chronic skin disease, wherein the skin becomes extremely itchy. It accounts for 10 to 20 percent of all visits to dermatologists. The increasing incidence of allergic diseases and inflammatory dermatoses worldwide underscores the need for new therapies to effectively treat or prevent these diseases. Currently, numerous classes of pharmaceutical agents are widely used to treat these diseases, for example, antihistamines, decongestants, anticholinergics, methylxanthines, cromolyns, corticosteroids, and leukotriene modulators. However, the usefulness of these agents is offten limited by side effects and low efficacy.
It has been reported recently that 3-sulphur-substituted indole derivatives (A) exhibit CRTH2 activity (WO 04/106302, AstraZeneca AB) and are potentially useful for the treatment of various respiratory diseases.
N
R (A) R
S-R
WO 04/096777 (Bayer Healthcare AG) relates to pyrimidine derivatives, which are useful for the treatment of diseases mediated by CRTH2.
R
R I R (B) N iN
R N /R
\ R
WO 04/035543 and WO 05/102338 (Wamer-Lambert Company LLC) disclose tetrahydrochinoline derivatives as CRTH2 antagonists (C), which are also described to be effective in the treatment of neuropatic pain.
O
R-'~N11 R
R
R ~
(C) R / N R
R 0 j" R
N
R (A) R
S-R
WO 04/096777 (Bayer Healthcare AG) relates to pyrimidine derivatives, which are useful for the treatment of diseases mediated by CRTH2.
R
R I R (B) N iN
R N /R
\ R
WO 04/035543 and WO 05/102338 (Wamer-Lambert Company LLC) disclose tetrahydrochinoline derivatives as CRTH2 antagonists (C), which are also described to be effective in the treatment of neuropatic pain.
O
R-'~N11 R
R
R ~
(C) R / N R
R 0 j" R
Specific tetrahydrochinoline derivatives as CRTH2 modulators are also provided by WO
04/032848 (Millennium Pharmaceutical Inc.) and WO 05/007094 (Tularik Inc.).
These tetrahydrochinoline derivatives are said to be useful for treating disorders associated with allergic inflammation processes.
Other subfamilies of G protein-coupled receptor, namely CCR's and CXCR's, have been discussed as potential drug targets for the treatment of allergic diseases and autoimmune pathologies. WO 04/108692 and WO 04/108717 (AstraZeneca AB) disclose pyrazine sulfonamide compounds that modulate specifically CCR4.
R
S ~~ ~~ N I I (D) R S"' N -y N
H
CI CI 0-Me Pyrazine sulfonamide compounds have also been disclosed in WO 04/058265 as compounds that interact with G protein-coupled receptors.
ox C N NH
N NH
OSO O 5R-\O
R
(E) N'-Z R I N
CN:'~ R IIII
N NH
N NH
O'R
O'SI --O
R
SUMMARY OF THE INVENTION
One aspect of the present invention consists in the use of 2,3 substituted pyrazine sulfonamides represented by the general formula (I) as pharmaceutical active compounds.
Such compounds are suitable for the treatment and/or prevention of allergic disease and 5 inflammatory dermatoses. Said compounds modulate a specific member of the G
protein-coupled family, namely CRTH2. Specifically, the invention relates to 2,3 substituted pyrazine sulfonamides of Formula (I):
N B-A-R
(R1)m (~) N NH
O
wherein A, B, R', R2, R3 and m are defined as described in the detailed description below, for use as a medicament.
The invention further provides a pharmaceutical composition comprising a compound of Formula (I), together with a pharmaceutically acceptable excipient or carrier.
The invention further relates to the use of compounds of Formula I for the preparation of a medicament for the treatment and/or prevention of diseases selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases or disorders associated with CTRH2 activity. Specifically the present invention is related to the use of compounds of Formula I for the modulation, notably the inhibition of CRTH2 activity.
The invention further relates to a method for treating and/or preventing a patient suffering from a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity, by administering a compound according to Formula (I).
The invention further relates to the use of compounds of Formula I for the preparation of a pharmaceutical composition.
The invention finally relates to novel compounds of Formula I as well as to methods to synthesize these molecules.
DESCRIPTION OF THE INVENTION
The following paragraphs provide definitions of various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly through-out the specification and claims unless an otherwise expressly set out defmition provides a broader defmition.
"C1-C6 -alkyl" refers to monovalent alkyl groups having 1 to 6 carbon atoms.
This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl and the like.
"Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g. phenyl) or multiple condensed rings (e.g.
naphthyl). Preferred aryl include phenyl, naphthyl, phenantrenyl and the like. The aryl ring may be also fused to a heterocycloalkyl group. Such fused aryls include dihydrobenzimidazole-2-0ne, benzo[1,3]dioxole and the like.
"C1-C6-alkyl aryP" refers to C1-C6-alkyl groups having an aryl substituent, such as, for example, benzyl, phenethyl and the like.
"Heteroaryl" refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Particular examples of heteroaromatic groups include optionally substituted pyridyl, pyrrolyl, pyrimidinyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazoly1,1,3,4-triazinyl, 1,2,3-triazinyl, 1,3,4-thiadiazolyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnnolinyl, napthyridinyl, pyridazinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl or benzoquinolyl and the like.
"C1-C6-alkyl heteroaryl" refers to C1-C6-alkyl groups having a heteroaryl substituent, such as, for example, 2-furylmethyl, 2-thienylmethyl, 2-(1H-indol-3-yl)ethyl and the like.
"C3-C8-cycloalkyl" refers to a saturated carbocyclic group of from 3 to 8 carbon atoms having a single ring (e.g., cyclohexyl) or multiple condensed rings (e.g., norbornyl).
Preferred cycloalkyl include cyclopentyl, cyclohexyl, norbornyl and the like.
"C3-C8-heterocycloalkyl" refers to a C3-C8-cycloalkyl group according to the definition above, in which up to 3 carbon atoms are replaced by heteroatoms chosen from the group consisting of 0, S, NR, R being defined as hydrogen or methyl. Preferred heterocycloalkyl include pyrrolidine, piperidine, piperazine, 1-methylpiperazine, morpholine, and the like.
04/032848 (Millennium Pharmaceutical Inc.) and WO 05/007094 (Tularik Inc.).
These tetrahydrochinoline derivatives are said to be useful for treating disorders associated with allergic inflammation processes.
Other subfamilies of G protein-coupled receptor, namely CCR's and CXCR's, have been discussed as potential drug targets for the treatment of allergic diseases and autoimmune pathologies. WO 04/108692 and WO 04/108717 (AstraZeneca AB) disclose pyrazine sulfonamide compounds that modulate specifically CCR4.
R
S ~~ ~~ N I I (D) R S"' N -y N
H
CI CI 0-Me Pyrazine sulfonamide compounds have also been disclosed in WO 04/058265 as compounds that interact with G protein-coupled receptors.
ox C N NH
N NH
OSO O 5R-\O
R
(E) N'-Z R I N
CN:'~ R IIII
N NH
N NH
O'R
O'SI --O
R
SUMMARY OF THE INVENTION
One aspect of the present invention consists in the use of 2,3 substituted pyrazine sulfonamides represented by the general formula (I) as pharmaceutical active compounds.
Such compounds are suitable for the treatment and/or prevention of allergic disease and 5 inflammatory dermatoses. Said compounds modulate a specific member of the G
protein-coupled family, namely CRTH2. Specifically, the invention relates to 2,3 substituted pyrazine sulfonamides of Formula (I):
N B-A-R
(R1)m (~) N NH
O
wherein A, B, R', R2, R3 and m are defined as described in the detailed description below, for use as a medicament.
The invention further provides a pharmaceutical composition comprising a compound of Formula (I), together with a pharmaceutically acceptable excipient or carrier.
The invention further relates to the use of compounds of Formula I for the preparation of a medicament for the treatment and/or prevention of diseases selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases or disorders associated with CTRH2 activity. Specifically the present invention is related to the use of compounds of Formula I for the modulation, notably the inhibition of CRTH2 activity.
The invention further relates to a method for treating and/or preventing a patient suffering from a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity, by administering a compound according to Formula (I).
The invention further relates to the use of compounds of Formula I for the preparation of a pharmaceutical composition.
The invention finally relates to novel compounds of Formula I as well as to methods to synthesize these molecules.
DESCRIPTION OF THE INVENTION
The following paragraphs provide definitions of various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly through-out the specification and claims unless an otherwise expressly set out defmition provides a broader defmition.
"C1-C6 -alkyl" refers to monovalent alkyl groups having 1 to 6 carbon atoms.
This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl and the like.
"Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g. phenyl) or multiple condensed rings (e.g.
naphthyl). Preferred aryl include phenyl, naphthyl, phenantrenyl and the like. The aryl ring may be also fused to a heterocycloalkyl group. Such fused aryls include dihydrobenzimidazole-2-0ne, benzo[1,3]dioxole and the like.
"C1-C6-alkyl aryP" refers to C1-C6-alkyl groups having an aryl substituent, such as, for example, benzyl, phenethyl and the like.
"Heteroaryl" refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Particular examples of heteroaromatic groups include optionally substituted pyridyl, pyrrolyl, pyrimidinyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazoly1,1,3,4-triazinyl, 1,2,3-triazinyl, 1,3,4-thiadiazolyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnnolinyl, napthyridinyl, pyridazinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl or benzoquinolyl and the like.
"C1-C6-alkyl heteroaryl" refers to C1-C6-alkyl groups having a heteroaryl substituent, such as, for example, 2-furylmethyl, 2-thienylmethyl, 2-(1H-indol-3-yl)ethyl and the like.
"C3-C8-cycloalkyl" refers to a saturated carbocyclic group of from 3 to 8 carbon atoms having a single ring (e.g., cyclohexyl) or multiple condensed rings (e.g., norbornyl).
Preferred cycloalkyl include cyclopentyl, cyclohexyl, norbornyl and the like.
"C3-C8-heterocycloalkyl" refers to a C3-C8-cycloalkyl group according to the definition above, in which up to 3 carbon atoms are replaced by heteroatoms chosen from the group consisting of 0, S, NR, R being defined as hydrogen or methyl. Preferred heterocycloalkyl include pyrrolidine, piperidine, piperazine, 1-methylpiperazine, morpholine, and the like.
"C1-C6-alkyl cycloalkyl" refers to C1-C6-alkyl groups having a cycloalkyl substituent, including cyclohexylmethyl, cyclopentylpropyl, and the like.
"C1-C6-alkyl heterocycloalkyl" refers to C1-C6-alkyl groups having a heterocycloalkyl substituent, including 2-(1-pyrrolidinyl)ethyl, 4-morpholinylmethyl, (1-methyl-piperidinyl)methyl and the like.
"C2-C6-alkenyl" refers to alkenyl groups preferably having from 2 to 6 carbon atoms and having one or more sites of alkenyl unsaturation. Preferred alkenyl groups include ethenyl (-CH=CH2), n-2-propenyl (allyl, -CH2CH=CH2) and the like.
"C2-C6-alkynyl" refers to alkynyl groups preferably having from 2 to 6 carbon atoms and having one or more sites of alkynyl unsaturation. Preferred alkynyl groups include ethynyl (-C=CH), propynyl (-CH2C=CH), and the like.
"Carboxy refers to the group -C(O)OR, where R includes hydrogen or "C1-C6-a1kyP".
"Acyl" refers to the group -C(O)R where R includes "C1-C6-a1kyP", "aryP', "heteroaryl", "C3-C8-cycloalkyl", "C3-C8-heterocycloalkyl", "C1-C6-alkyl aryl" or "C1-C6-alkyl heteroaryl".
"Acyloxy" refers to the group -OC(O)R where R includes "C1-C6-alkyl", "aryl", "hetero-aryl", "C1-C6-alkyl aryP"or "C1-C6-alkyl heteroaryl".
"Aryl acyl" refers to aryl groups having an acyl substituent, including 2-acetylphenyl and the like.
"Heteroaryl acyl" refers to heteroaryl groups having an acyl substituent, including 2-acetylpyridyl and the like.
"Alkoxy" refers to the group -O-R where R includes "C1-C6-a1kyP", "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryP", "C1-C6-alkyl aryl" or "Cl-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "Cl-C6-alkyl cycloalkyl", "Cl-C6-alkyl heterocycloalkyl". Preferred alkoxy groups include by way of example, methoxy, ethoxy, phenoxy and the like.
"Cl-C6-alkyl alkoxy" refers to C1-C6-alkyl groups having an alkoxy substituent, including 2-ethoxyethyl and the like.
"Alkoxycarbonyl" refers to the group -C(O)OR where R includes "C1-C6-alkyl" or "aryl"
or "heteroaryl" or "C1-C6-alkyl aryl" or "C1-C6-alkyl heteroaryl".
"Aminocarbonyl" refers to the group -C(O)NRR' where each R, R' includes independently hydrogen or C1-C6-alkyl or aryl or heteroaryl or "C1-C6-alkyl aryl" or "C1-C6-alkyl hetero-aryl".
"Acylamino" refers to the group -NR(CO)R' where each R, R' is independently hydrogen or "C1-C6-alkyl" or "aryl" or "heteroaryl" or "C1-C6-alkyl aryl" or "C1-C6-alkyl heteroaryl".
"Halogen" refers to fluoro, chloro, bromo and iodo atoms.
"Sulfonyloxy" refers to a group -OS02-R wherein R is selected from H, "C1-C6-alkyl", "C1-C6-alkyl" substituted with halogens, e.g., an -OS02-CF3 group, "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl"e "heteroaryl"e "C1-C6-a 1 aryl" or "Cl-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "Cl-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
"Sulfonyl" refers to group "-S02-R" wherein R is selected from H, "aryl", "heteroaryl", "C1-C6-alkyl", "C1-C6-alkyl" substituted with halogens, e.g., an -S02-CF3 group, "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "Cl-C6-alkyl aryl" or "Cl-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
"Sulfinyl" refers to a group "-S(O)-R" wherein R is selected from H, "C1-C6-alkyl", "C1-C6-alkyl" substituted with halogens, e.g., an -SO-CF3 group, "C2-C6-alkenyl", "C2-C6-5 alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "C1-C6-alkyl aryl"
or "C1-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
"Sulfanyl" refers to groups -S-R where R includes H, "C1-C6-alkyl", "C1-C6-alkyl"
"C1-C6-alkyl heterocycloalkyl" refers to C1-C6-alkyl groups having a heterocycloalkyl substituent, including 2-(1-pyrrolidinyl)ethyl, 4-morpholinylmethyl, (1-methyl-piperidinyl)methyl and the like.
"C2-C6-alkenyl" refers to alkenyl groups preferably having from 2 to 6 carbon atoms and having one or more sites of alkenyl unsaturation. Preferred alkenyl groups include ethenyl (-CH=CH2), n-2-propenyl (allyl, -CH2CH=CH2) and the like.
"C2-C6-alkynyl" refers to alkynyl groups preferably having from 2 to 6 carbon atoms and having one or more sites of alkynyl unsaturation. Preferred alkynyl groups include ethynyl (-C=CH), propynyl (-CH2C=CH), and the like.
"Carboxy refers to the group -C(O)OR, where R includes hydrogen or "C1-C6-a1kyP".
"Acyl" refers to the group -C(O)R where R includes "C1-C6-a1kyP", "aryP', "heteroaryl", "C3-C8-cycloalkyl", "C3-C8-heterocycloalkyl", "C1-C6-alkyl aryl" or "C1-C6-alkyl heteroaryl".
"Acyloxy" refers to the group -OC(O)R where R includes "C1-C6-alkyl", "aryl", "hetero-aryl", "C1-C6-alkyl aryP"or "C1-C6-alkyl heteroaryl".
"Aryl acyl" refers to aryl groups having an acyl substituent, including 2-acetylphenyl and the like.
"Heteroaryl acyl" refers to heteroaryl groups having an acyl substituent, including 2-acetylpyridyl and the like.
"Alkoxy" refers to the group -O-R where R includes "C1-C6-a1kyP", "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryP", "C1-C6-alkyl aryl" or "Cl-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "Cl-C6-alkyl cycloalkyl", "Cl-C6-alkyl heterocycloalkyl". Preferred alkoxy groups include by way of example, methoxy, ethoxy, phenoxy and the like.
"Cl-C6-alkyl alkoxy" refers to C1-C6-alkyl groups having an alkoxy substituent, including 2-ethoxyethyl and the like.
"Alkoxycarbonyl" refers to the group -C(O)OR where R includes "C1-C6-alkyl" or "aryl"
or "heteroaryl" or "C1-C6-alkyl aryl" or "C1-C6-alkyl heteroaryl".
"Aminocarbonyl" refers to the group -C(O)NRR' where each R, R' includes independently hydrogen or C1-C6-alkyl or aryl or heteroaryl or "C1-C6-alkyl aryl" or "C1-C6-alkyl hetero-aryl".
"Acylamino" refers to the group -NR(CO)R' where each R, R' is independently hydrogen or "C1-C6-alkyl" or "aryl" or "heteroaryl" or "C1-C6-alkyl aryl" or "C1-C6-alkyl heteroaryl".
"Halogen" refers to fluoro, chloro, bromo and iodo atoms.
"Sulfonyloxy" refers to a group -OS02-R wherein R is selected from H, "C1-C6-alkyl", "C1-C6-alkyl" substituted with halogens, e.g., an -OS02-CF3 group, "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl"e "heteroaryl"e "C1-C6-a 1 aryl" or "Cl-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "Cl-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
"Sulfonyl" refers to group "-S02-R" wherein R is selected from H, "aryl", "heteroaryl", "C1-C6-alkyl", "C1-C6-alkyl" substituted with halogens, e.g., an -S02-CF3 group, "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "Cl-C6-alkyl aryl" or "Cl-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
"Sulfinyl" refers to a group "-S(O)-R" wherein R is selected from H, "C1-C6-alkyl", "C1-C6-alkyl" substituted with halogens, e.g., an -SO-CF3 group, "C2-C6-alkenyl", "C2-C6-5 alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "C1-C6-alkyl aryl"
or "C1-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
"Sulfanyl" refers to groups -S-R where R includes H, "C1-C6-alkyl", "C1-C6-alkyl"
10 optionally substituted with halogens., e.g a -S-CF3 group, "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "C1-C6-alkyl aryl"
or "C1-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl". Preferred sulfanyl groups include methylsulfanyl, ethylsulfanyl, and the like.
"Sulfonylamino" refers to a group -NRSO2-R' where each R, R' includes independently hydrogen, "C1-C6-alkyl", "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "C 1-C6-alkyl aryl" or "C 1 -C6-alkyl heteroaryl"
, "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
"Aminosulfonyl" refers to a group -S02-NRR' where each R, R' includes independently hydrogen, "C1-C6-alkyl", "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl"> "heteroaryl", "C 1-C6-al 1 ary1" or "C 1 -C6-alky1 heteroary1", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
or "C1-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl". Preferred sulfanyl groups include methylsulfanyl, ethylsulfanyl, and the like.
"Sulfonylamino" refers to a group -NRSO2-R' where each R, R' includes independently hydrogen, "C1-C6-alkyl", "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "C 1-C6-alkyl aryl" or "C 1 -C6-alkyl heteroaryl"
, "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
"Aminosulfonyl" refers to a group -S02-NRR' where each R, R' includes independently hydrogen, "C1-C6-alkyl", "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl"> "heteroaryl", "C 1-C6-al 1 ary1" or "C 1 -C6-alky1 heteroary1", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl".
"Amino" refers to the group -NRR' where each R, R' is independently hydrogen, "C1-C6-alkyl", "C2-C6-alkenyl", "C2-C6-alkynyl", "C3-C8-cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", "C1-C6-alkyl aryl" or "C1-C6-alkyl heteroaryl", "C2-C6-alkenyl aryl", "C2-C6-alkenyl heteroaryl", "C2-C6-alkynyl aryl", "C2-C6-alkynylheteroaryl", "C1-C6-alkyl cycloalkyl", "C1-C6-alkyl heterocycloalkyl", and where R and R', together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered hetero-cycloalkyl ring.
"Substituted or unsubstituted": Unless otherwise constrained by the defmition of the individual substituent, the above set out groups, like "alkyl", "alkenyl", "alkynyl", "alkoxy", "aryl" and "heteroaryl" etc. groups can optionally be substituted with from 1 to 5 substituents selected from the group consisting of "C1-C6-alkyl", "C1-C6-alkyl aryl", "C1-C6-alkyl heteroaryl", "C2-C6-alkenyl", "C2-C6-alkynyl", primary, secondary or tertiary amino groups or quatemary ammonium moieties, "acyl", "acyloxy", "acylamino", "aminocarbonyl", "alkoxycarbonyl", "aryl", "aryloxy", "heteroaryl", "heteroaryloxy", carboxyl, cyano, halogen, hydroxy, nitro, sulfanyl, sulphoxy, sulphonyl, sulfonamide, alkoxy, thioalkoxy, trihalomethyl and the like. Within the framework of this invention, said "substitution" is meant to also comprise situations where neighboring substituents undergo ring closure, in particular when vicinal functional substituents are involved, thus forming e.g. lactams, lactons, cyclic anhydrides, but also acetals, thioacetals, aminals formed by ring closure for instance in an effort to obtain a protective group.
"Pharmaceutically acceptable cationic salts or complexes" is intended to define such salts as the alkali metal salts, (e.g. sodium and potassium), alkaline earth metal salts (e.g.
calcium or magnesium), aluminium salts, ammonium salts and salts with organic amines such as with methylamine, dimethylamine, trimethylamine, ethylamine, triethylamine, morpholine, N-Me-D-glucamine, N,N'-bis(phenylmethyl)-1,2-ethanediamine, ethanolamine, diethanolamine, ethylenediamine, N-methylmorpholine, piperidine, benzathine (N,N'-dibenzylethylenediamine), choline, ethylene-diamine, meglumine (N-methylglucamine), benethamine (N-benzylphenethylamine), diethylamine, piperazine, thromethamine (2-amino-2-hydroxymethyl-1,3-propanediol), procaine as well as amines of formula -NR,R',R" wherein R, R', R" is independently hydrogen, alkyl or benzyl.
Especially preferred salts are sodium and potassium salts.
"Pharmaceutically acceptable salts or complexes" refers to salts or complexes of the below-identified compounds of Formula I that retain the desired biological activity.
Examples of such salts include, but are not restricted to, acid addition salts formed with inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disul-fonic acid, and poly-galacturonic acid. Said compounds can also be administered as pharmaceutically acceptable quatemary salts known by a person skilled in the art, which specifically include the quartemary ammonium salt of the Formula -NR,R',R" + Z-, wherein R, R', R" is independently hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, -0-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, fumarate, citrate, tartrate, ascorbate, cinnamoate, mandeloate, and diphenylacetate).
"Pharmaceutically active derivative" refers to any compound that, upon administration to the recipient, is capable of providing directly or indirectly, the activity disclosed herein.
The compounds of the present invention according to Formula I are useful in the treatment and/or prevention of diseases selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD).
"Substituted or unsubstituted": Unless otherwise constrained by the defmition of the individual substituent, the above set out groups, like "alkyl", "alkenyl", "alkynyl", "alkoxy", "aryl" and "heteroaryl" etc. groups can optionally be substituted with from 1 to 5 substituents selected from the group consisting of "C1-C6-alkyl", "C1-C6-alkyl aryl", "C1-C6-alkyl heteroaryl", "C2-C6-alkenyl", "C2-C6-alkynyl", primary, secondary or tertiary amino groups or quatemary ammonium moieties, "acyl", "acyloxy", "acylamino", "aminocarbonyl", "alkoxycarbonyl", "aryl", "aryloxy", "heteroaryl", "heteroaryloxy", carboxyl, cyano, halogen, hydroxy, nitro, sulfanyl, sulphoxy, sulphonyl, sulfonamide, alkoxy, thioalkoxy, trihalomethyl and the like. Within the framework of this invention, said "substitution" is meant to also comprise situations where neighboring substituents undergo ring closure, in particular when vicinal functional substituents are involved, thus forming e.g. lactams, lactons, cyclic anhydrides, but also acetals, thioacetals, aminals formed by ring closure for instance in an effort to obtain a protective group.
"Pharmaceutically acceptable cationic salts or complexes" is intended to define such salts as the alkali metal salts, (e.g. sodium and potassium), alkaline earth metal salts (e.g.
calcium or magnesium), aluminium salts, ammonium salts and salts with organic amines such as with methylamine, dimethylamine, trimethylamine, ethylamine, triethylamine, morpholine, N-Me-D-glucamine, N,N'-bis(phenylmethyl)-1,2-ethanediamine, ethanolamine, diethanolamine, ethylenediamine, N-methylmorpholine, piperidine, benzathine (N,N'-dibenzylethylenediamine), choline, ethylene-diamine, meglumine (N-methylglucamine), benethamine (N-benzylphenethylamine), diethylamine, piperazine, thromethamine (2-amino-2-hydroxymethyl-1,3-propanediol), procaine as well as amines of formula -NR,R',R" wherein R, R', R" is independently hydrogen, alkyl or benzyl.
Especially preferred salts are sodium and potassium salts.
"Pharmaceutically acceptable salts or complexes" refers to salts or complexes of the below-identified compounds of Formula I that retain the desired biological activity.
Examples of such salts include, but are not restricted to, acid addition salts formed with inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disul-fonic acid, and poly-galacturonic acid. Said compounds can also be administered as pharmaceutically acceptable quatemary salts known by a person skilled in the art, which specifically include the quartemary ammonium salt of the Formula -NR,R',R" + Z-, wherein R, R', R" is independently hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, -0-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, fumarate, citrate, tartrate, ascorbate, cinnamoate, mandeloate, and diphenylacetate).
"Pharmaceutically active derivative" refers to any compound that, upon administration to the recipient, is capable of providing directly or indirectly, the activity disclosed herein.
The compounds of the present invention according to Formula I are useful in the treatment and/or prevention of diseases selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD).
(R1)m (~) N NH
R2--S~ 0 O
In one embodiment the compounds according to Formula (I) are suitable as modulators, notably as antagonists, of CRTH2. Therefore, the compounds of the present invention are also particularly useful for the treatment and/or prevention of disorders, which are mediated by CRTH2 activity. Said treatment involves the modulation of CRTH2, notably an inhibition of CRTH2 or an antagonizing effect of CRTH2 in mammals, and in particular in humans. The modulators of CRTH2 are selected from the group consisting of an antagonist, an inverse agonist, a partial agonist and an agonist of CRTH2.
In another embodiment, the modulators of CRTH2 are antagonists of CRTH2.
In one embodiment, the modulators of CRTH2 are inverse agonists of CRTH2.
In another embodiment, the modulators of CRTH2 are partial agonists of CRTH2.
In another embodiment, the modulators of CRTH2 are agonists of CRTH2.
The compounds according to Formula (I) are suitable for use as a medicament.
Compounds of Formula (I) include also their geometrical isomers, their optically active forms as enantiomers, diastereomers, its racemate forms and tautomers, as well as pharmaceutically acceptable salts thereof, wherein:
A is either an amine selected from the group consisting of:
R2--S~ 0 O
In one embodiment the compounds according to Formula (I) are suitable as modulators, notably as antagonists, of CRTH2. Therefore, the compounds of the present invention are also particularly useful for the treatment and/or prevention of disorders, which are mediated by CRTH2 activity. Said treatment involves the modulation of CRTH2, notably an inhibition of CRTH2 or an antagonizing effect of CRTH2 in mammals, and in particular in humans. The modulators of CRTH2 are selected from the group consisting of an antagonist, an inverse agonist, a partial agonist and an agonist of CRTH2.
In another embodiment, the modulators of CRTH2 are antagonists of CRTH2.
In one embodiment, the modulators of CRTH2 are inverse agonists of CRTH2.
In another embodiment, the modulators of CRTH2 are partial agonists of CRTH2.
In another embodiment, the modulators of CRTH2 are agonists of CRTH2.
The compounds according to Formula (I) are suitable for use as a medicament.
Compounds of Formula (I) include also their geometrical isomers, their optically active forms as enantiomers, diastereomers, its racemate forms and tautomers, as well as pharmaceutically acceptable salts thereof, wherein:
A is either an amine selected from the group consisting of:
R3 ~
R3 R3 ~ 3 t r 1 R7 R7 B~N~R' B~N~R
~ N-~ ~ n B B
A1 ,q2 or an alkyl, acyl, amino carbonyl or ether selected from the group consisting of:
$
O O
BF(CH2)n-~R3 BR3 B,11-N~R3 BR3 with each n being an integer independently selected from 0, 1, 2, 3 or 4;
m is either 1 or 2;
wherein, R7 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted C2-C6-alkenyl, substituted or unsubstituted C2-C6-alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or unsubstituted C3-heterocycloalkyl, carboxyl, cyano, amino and hydroxyl.
R8 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
B is selected from the group consisting of a substituted or unsubstituted C2-C6-alkynyl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or unsubstituted C3-heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted monocyclic heteroaryl.
Examples of B include ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pyrrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, pyridyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazolidinyl, 1,3,4-oxadiazolidinyl, isoxazolidinyl, morpholinyl, phenyl, naphthyl, pyrrolyl, pyrimidyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, carbazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 5 tetrazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, oxolanyl, pyrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl.
According to one embodiment, B is selected from the group of a substituted or unsubstituted aryl, a substituted or unsubstituted C3-C8-heterocycloalkyl and a substituted or unsubstituted alkynyl.
10 According to one embodiment, B is a substituted or unsubstituted aryl group (e.g. phenyl).
According to another embodiment said phenyl group is mono-substituted in ortho, meta or para position.
In another embodiment, B is a C3-C8-heterocycloalkyl group (e.g. piperazinyl, furyl or thienyl).
R3 R3 ~ 3 t r 1 R7 R7 B~N~R' B~N~R
~ N-~ ~ n B B
A1 ,q2 or an alkyl, acyl, amino carbonyl or ether selected from the group consisting of:
$
O O
BF(CH2)n-~R3 BR3 B,11-N~R3 BR3 with each n being an integer independently selected from 0, 1, 2, 3 or 4;
m is either 1 or 2;
wherein, R7 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted C2-C6-alkenyl, substituted or unsubstituted C2-C6-alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or unsubstituted C3-heterocycloalkyl, carboxyl, cyano, amino and hydroxyl.
R8 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
B is selected from the group consisting of a substituted or unsubstituted C2-C6-alkynyl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or unsubstituted C3-heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted monocyclic heteroaryl.
Examples of B include ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pyrrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, pyridyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazolidinyl, 1,3,4-oxadiazolidinyl, isoxazolidinyl, morpholinyl, phenyl, naphthyl, pyrrolyl, pyrimidyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, carbazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 5 tetrazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, oxolanyl, pyrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl.
According to one embodiment, B is selected from the group of a substituted or unsubstituted aryl, a substituted or unsubstituted C3-C8-heterocycloalkyl and a substituted or unsubstituted alkynyl.
10 According to one embodiment, B is a substituted or unsubstituted aryl group (e.g. phenyl).
According to another embodiment said phenyl group is mono-substituted in ortho, meta or para position.
In another embodiment, B is a C3-C8-heterocycloalkyl group (e.g. piperazinyl, furyl or thienyl).
15 According to another embodiment, B is an alkynyl group (e.g. ethynyl or propynyl).
R' is either hydrogen or a substituted or unsubstituted C1-C6-alkyl. In a preferred embodiment R' is hydrogen.
R2 is selected from the group consisting of substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, substituted or unsubstituted C3-C8-cycloalkyl and substituted or unsubstituted C3-C8heterocycloalkyl.
Examples of R2 include methyl, ethyl, propyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pyrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, pyridyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazolidinyl, 1,3,4-oxadiazolidinyl, isoxazolidinyl or morpholinyl, phenyl, naphthyl, pyrrolyl, pyrimidyl, quinolizinyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, carbazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-0xadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-0xadiazolyl, tetrazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, oxolanyl, pyrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, pyridyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazolidinyl, 1,3,4-oxadiazolidinyl, isoxazolidinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, xanthenyl or benzoquinolyl.
According to one embodiment, R2 is a substituted or unsubstituted aryl group (e.g. phenyl).
The substituents in a substituted R2 are selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, thioalkoxy and thioalkyl.
In one embodiment R2 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, thioalkoxy and thioalkyl.
According to another embodiment, R2 is substituted in ortho, meta or para position. In one embodiment, R2 is chlorophenyl.
According to another embodiment, R2 is substituted or unsubstituted heteroaryl group (e.g.
pyridinyl or thienyl).
According to another embodiment, R2 is a substituted or unsubstituted C1-C6-alkyl group (e.g. methyl).
R3 is selected from the group consisting of a substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C3-C8-cycloalkyl and substituted or unsubstituted C3-C8-heterocycloalkyl;
R' is either hydrogen or a substituted or unsubstituted C1-C6-alkyl. In a preferred embodiment R' is hydrogen.
R2 is selected from the group consisting of substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, substituted or unsubstituted C3-C8-cycloalkyl and substituted or unsubstituted C3-C8heterocycloalkyl.
Examples of R2 include methyl, ethyl, propyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pyrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, pyridyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazolidinyl, 1,3,4-oxadiazolidinyl, isoxazolidinyl or morpholinyl, phenyl, naphthyl, pyrrolyl, pyrimidyl, quinolizinyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, carbazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-0xadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-0xadiazolyl, tetrazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, oxolanyl, pyrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, pyridyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazolidinyl, 1,3,4-oxadiazolidinyl, isoxazolidinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, xanthenyl or benzoquinolyl.
According to one embodiment, R2 is a substituted or unsubstituted aryl group (e.g. phenyl).
The substituents in a substituted R2 are selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, thioalkoxy and thioalkyl.
In one embodiment R2 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, thioalkoxy and thioalkyl.
According to another embodiment, R2 is substituted in ortho, meta or para position. In one embodiment, R2 is chlorophenyl.
According to another embodiment, R2 is substituted or unsubstituted heteroaryl group (e.g.
pyridinyl or thienyl).
According to another embodiment, R2 is a substituted or unsubstituted C1-C6-alkyl group (e.g. methyl).
R3 is selected from the group consisting of a substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C3-C8-cycloalkyl and substituted or unsubstituted C3-C8-heterocycloalkyl;
wherein said substituted or unsubstituted aryl, heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl may be fused to one or more substituted or unsubstituted aryl, heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl group and may be substituted with one or more substituents selected of the group consisting of C1-C6-alkyl, alkoxy, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, amino, amino carbonyl, nitro, sulfoxy, sulfonyl, sulfonamide and trihalo-C1-C6-alkyl.
Examples of R3 include methyl, ethyl, propyl, butyl, t-butyl, phenyl, naphthyl, phenantrenyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, carbazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-0xadiazolyl, benzo(2,1,3)oxadiazolyl, benzo(1,2,5)oxadiazolyl, benzo[1,3]dioxole, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, tetrazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, 3,4-dihydrolH-benzo[1,4]diazepine-2,5-dione, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, pyridazinyl, pyrimidyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl, benzoquinolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxolanyl, pyrrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, pyridyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazolidinyl, 1,3,4-oxadiazolidinyl, isoxazolidinyl or morpholinyl.
According to one embodiment, R3 is a substituted or unsubstituted aryl group (e.g. phenyl or naphthyl). The substituents in a substituted R3 are selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl.
In one embodiment R3 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl.
Examples of R3 include methyl, ethyl, propyl, butyl, t-butyl, phenyl, naphthyl, phenantrenyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, carbazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-0xadiazolyl, benzo(2,1,3)oxadiazolyl, benzo(1,2,5)oxadiazolyl, benzo[1,3]dioxole, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, tetrazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, 3,4-dihydrolH-benzo[1,4]diazepine-2,5-dione, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, pyridazinyl, pyrimidyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl, benzoquinolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxolanyl, pyrrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, pyridyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazolidinyl, 1,3,4-oxadiazolidinyl, isoxazolidinyl or morpholinyl.
According to one embodiment, R3 is a substituted or unsubstituted aryl group (e.g. phenyl or naphthyl). The substituents in a substituted R3 are selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl.
In one embodiment R3 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl.
Examples for a substituted phenyl moiety are 4-trifluoromethoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl, 3,5-dimethylphenyl, 2-benzamide or 2-benzoic acid.
In another embodiment, R3 is a substituted or unsubstituted heteroaryl group (e.g. pyridyl, quinolyl, benzimidazolyl, indolyl, pyridazinyl, pyrazinyl or 1,3,4-thiadiazolyl). An example for a substituted benzimidazole is 2-ethyl-2H-benzimidazolyl.
In another embodiment, R3 is an aryl group fused to a C3-C8-heterocycloalkyl group (e.g.
1,3-dihydrobenzimidazole-2-0ne, 3,4-dihydro1 H-benzo[ 1,4]diazepine-2,5-dione).
In another embodiment, R3 is a substituted or unsubstituted C3-C8-heterocyclalkyl group fused to a substituted or unsubstituted aryl group (e.g. 1,2,3,4-tetrahydrochinoline, 1,2,3,4-tetrahydrochinoxaline, 2,3-dehydrobenzol,4-oxazine, 2,3-dehydro-indole or dihydrobenzo-pyrrolodiazepine).
In another embodiment, R3 is a substituted or unsubstituted C3-C8-heterocyclalkyl group fused to a substituted or unsubstituted aryl group and to a substituted or unsubstituted heteroaryl group (e.g.dihydrobenzopyrrolodiazepine).
In another embodiment, R3 is a substituted or unsubstituted alkyl group (e.g.
isopropyl).
According to another embodiment, the substituents at R2 or R3 are selected from the group consisting of C1-C6-alkyl, alkoxy, cyano, amino and halogen (e.g. methyl, ethyl, butyl, tert.-butyl, methoxy, ethoxy, tert.-butoxy, phenoxy, chloro, fluoro); wherein alkyl, alkoxy or aryloxy are optionally substituted with halogen (e.g. trifluoromethyl, trifluoromethoxy);
as well as isomers and mixtures of these for use as a medicament.
Another specific sub-group of formula (I) are compounds having formula (I'), whereby A, B, R2 and R3 are defined as above and each R' can be independently hydrogen or substituted or unsubstituted C1-C6-alkyl.
In another embodiment, R3 is a substituted or unsubstituted heteroaryl group (e.g. pyridyl, quinolyl, benzimidazolyl, indolyl, pyridazinyl, pyrazinyl or 1,3,4-thiadiazolyl). An example for a substituted benzimidazole is 2-ethyl-2H-benzimidazolyl.
In another embodiment, R3 is an aryl group fused to a C3-C8-heterocycloalkyl group (e.g.
1,3-dihydrobenzimidazole-2-0ne, 3,4-dihydro1 H-benzo[ 1,4]diazepine-2,5-dione).
In another embodiment, R3 is a substituted or unsubstituted C3-C8-heterocyclalkyl group fused to a substituted or unsubstituted aryl group (e.g. 1,2,3,4-tetrahydrochinoline, 1,2,3,4-tetrahydrochinoxaline, 2,3-dehydrobenzol,4-oxazine, 2,3-dehydro-indole or dihydrobenzo-pyrrolodiazepine).
In another embodiment, R3 is a substituted or unsubstituted C3-C8-heterocyclalkyl group fused to a substituted or unsubstituted aryl group and to a substituted or unsubstituted heteroaryl group (e.g.dihydrobenzopyrrolodiazepine).
In another embodiment, R3 is a substituted or unsubstituted alkyl group (e.g.
isopropyl).
According to another embodiment, the substituents at R2 or R3 are selected from the group consisting of C1-C6-alkyl, alkoxy, cyano, amino and halogen (e.g. methyl, ethyl, butyl, tert.-butyl, methoxy, ethoxy, tert.-butoxy, phenoxy, chloro, fluoro); wherein alkyl, alkoxy or aryloxy are optionally substituted with halogen (e.g. trifluoromethyl, trifluoromethoxy);
as well as isomers and mixtures of these for use as a medicament.
Another specific sub-group of formula (I) are compounds having formula (I'), whereby A, B, R2 and R3 are defined as above and each R' can be independently hydrogen or substituted or unsubstituted C1-C6-alkyl.
In a preferred embodiment, R' is hydrogen.
R N B-A--*~
~
i ( r) N NH
RNN H
R2~S~
O
A specific sub-group of formulae (I ) and (I') are compounds having the formulae (Ia-Id), whereby A, R2 and R3 are defined as above and Z is 0 or S.
Z
N N~
~~ ~
N NH
N NH I
R2~S~ R2~S~
O
(Ia) (Ib) ,A-R3 CN CNXNH
R2'S\__O R2_g\ O
(Ic) (Id) Preferred pharmaceutically acceptable salts of compounds of Formula I, and compounds of sub-groups of Formulae (Ia) - (Id) containing a basic residue such as, for example, a primary, secondary, or tertiary amine or a pyridyl moiety, are acid addition salts formed with pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methane-sulfonate, benzenesulfonate, and para-toluenesulfonate salts.
5 Compounds of the present invention that are particularly suitable for use as a medicament, include in particular those of the group consisting of:
xample ame 4o.
1 -{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-2-trifluoromethyl)benzenesulfonamide -chloro-N- { 3 -[4-( {methyl[4-(trifluoromethoxy)phenyl] amino } -ethyl)phenyl]pyrazin-2-yl } benzenesulfonamide -(3-{4-[(2-ethyl-1 H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)-2-trifluoromethyl)benzenesulfonamide -chloro-N-[3 -(4- { [methyl(phenyl)amino]methyl } phenyl)pyrazin-2-1]benzenesulfonamide e 5 -chloro-N-(3-{4-[(2-naphthyloxy)methyl]phenyl}pyrazin-2-yl)-enzenesulfonamide 6 -chloro-N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-benzenesulfonamide -chloro-N-(3 - { 4-[(5, 6, 7, 8-tetrahydronaphthalen-2-yloxy)methyl]-henyl } pyrazin-2-yl)benzenesulfonamide xample ame 4o.
8 -chloro-N-(3-{4-[(2-ethyl-lH-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-1)benzenesulfonamide -(3 - { 4-[(1,3 -benzodioxol-5 -ylamino)methyl]phenyl } pyrazin-2-yl)-2-trifluoromethyl)benzenesulfonamide T-[3-(4-{[(3-methoxybenzyl)oxy]methyl}phenyl)pyrazin-2-yl]-2-trifluoromethyl)benzenesulfonamide 11 3-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}-ethyl)phenyl]pyrazin-2-yl } benzenesulfonamide 12 -[3-(4-{[(4-chlorophenyl)(methyl)amino]methyl}phenyl)pyrazin-2-yl]-iophene-2-sulfonamide 13 I-phenoxy-N-{3-[4-(quinolin-2-ylmethyl)piperazin-l-yl]pyrazin-2-yl}-enzenesulfonamide 14 I-methyl-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}-ethyl)phenyl]pyrazin-2-yl } benzenesulfonamide I-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]-enzenesulfonamide 16 I-cyano-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]-amino}-ethyl)phenyl]pyrazin-2-yl } benzenesulfonamide 17 T-[3-(4-{[(4-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]--trifluoromethyl-benzenesulfonamide xample ame 4o.
18 -(3-{4-[(Methyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-rifluoromethyl-benzenesulfonamide 19 -[3-(4-{[(4-Cyano-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]--trifluoromethyl-benzenesulfonamide 0 -{3-[4-(4-Fluoro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-enzenesulfonamide 1 -(3-{4-[(Ethyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-rifluoromethyl-benzenesulfonamide 2 1-{3-[4-(2,3-Dihydro-benzo[1,4]oxazin-4-ylmethyl)-phenyl]-pyrazin-2-1} -2-trifluoromethyl-benzenesulfonamide 3 -[3-(4-{[(3-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]--trifluoromethyl-benzenesulfonamide 4 -{3-[4-(6-Chloro-pyridin-3-yloxymethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide T-{3-[4-(2-Pyridin-2-yl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 6 -{3-[4-(5-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 7 -[3-(4-Phenoxymethyl-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-enzenesulfonamide xample ame 4o.
g -[3-(4-{[(4-Chloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]--trifluoromethyl-benzenesulfonamide 9 -Chloro-N-[3-(4-{ [(4-cyano-phenyl)-methyl-amino]-methyl}-phenyl)-yrazin-2-yl]-benzenesulfonamide 0 -[3-(4-{[(3,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin--y1] -2-trifluoromethyl-b enzenesulfonamide 1 T-{3-[4-(4-Cyano-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-enzenesulfonamide 32 1-{3-[4-(6-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 3 -Chloro-N-{3-[4-(5-methoxy-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin--yl} -benzenesulfonamide 4 -{3-[4-(4-Methoxy-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide -(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-hloro benzenesulfonamide 6 -{3-[4-(2,3-Dihydro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 7 -[3-(4-{[(2,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-1]-2-trifluoromethyl-benzenesulfonamide xample ame 4o.
g -{3-[4-(3-Chloro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-enzenesulfonamide 39 -Chloro-N-[3-(4-{ [(2,4-difluoro-phenyl)-methyl-amino]-methyl} -phenyl)-yrazin-2-yl]-benzenesulfonamide p T-{3-[4-(2-Methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 1 -Chloro-N-{3-[4-(5-fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-enzenesulfonamide 12 -Chloro-N-[3-(4-{ [(2-fluoro-phenyl)-methyl-amino]-methyl} -phenyl)-yrazin-2-yl]-benzenesulfonamide 13 -Chloro-N-{3-[4-(2-methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl} -enzenesulfonamide 14 -(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-rifluoromethyl-benzenesulfonamide 15 -Chloro-N-(3-{4-[(ethyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-1)-benzenesulfonamide 16 T-{3-[4-(5-Chloro-2-methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide In a second aspect, the invention provides a pharmaceutical composition comprising a 2,3 substituted pyrazine sulfonamide according to Formula (I), together with a pharmaceutically acceptable excipient or carrier.
In a third aspect, the invention provides the use of a 2,3 substituted pyrazine sulfonamide according to formulae (I) for the preparation of a medicament for the treatment and/or prevention of a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and 5 inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis and other diseases with an inflammatory component such as rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity.
In a forth aspect, the invention provides a method for treating and/or preventing a patient 10 suffering from a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and 15 inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity, by administering a 2,3 substituted pyrazine sulfonamide according to Formula (I).
The term "preventing", as used herein, should be understood as partially or totally preventing, inhibiting, alleviating, or reversing one or more symptoms or cause(s) of 20 allergic disease or inflammatory dermatitis.
In a fifth aspect, the invention provides the use of a 2,3 substituted pyrazine sulfonamide of Formula (I) for the preparation of a pharmaceutical composition useful for a variety of therapies, including preventing and/or treating a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or 25 hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity.
The invention provides further the use of a 2,3 substituted pyrazine sulfonamide of Formula (I) for preventing and/or treating a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity.
The compounds of the invention, together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous use). Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
The compounds according to Formula (I) of the present invention are typically administered in form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. Generally, the compounds of this invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
The pharmaceutical compositions of these inventions can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms"
refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the substituted methylene amide derivative according to the invention is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatine;
an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as pepper-mint, methyl salicylate, or orange flavoring.
Injectable compositions are typically based upon injectable sterile saline or phosphate buffered saline or other injectable carriers known in the art. As above mentioned, substituted methylene amide derivatives of Formula (I) in such compositions is typically a minor component, frequently ranging between 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
The above-described components for orally administered or injectable compositions are merely representative. Further materials as well as processing techniques and the like are set out in Part 5 of Remington's Pharmaceutical Sciences, 20t' Edition, 2000, Marck Publishing Company, Easton, Pennsylvania, which is incorporated herein be reference.
The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can also be found in the incorporated materials in Remington's Pharmaceutical Sciences.
In a sixth aspect, the invention provides novel 2,3-substituted pyrazine sulfonamides of Formulae (Ia) - (Id) wherein A, R2, and R3 are defined as described above.
Novel compounds of Formulae (Ia) - (Id) are in particular those of the group consisting of:
N- { 3 - [4 -(1 H-indol-1-ylmethyl)phenyl]pyrazin-2-yl } -2-(trifluoromethyl)benzenesulfonamide, 2-chloro-N- { 3 -[4-( {methyl[4-(trifluoromethoxy)phenyl] amino } -methyl)phenyl]pyrazin-2-yl } benzene sulfonamide, N-(3- {4-[(2-ethyl-1 H-benzimidazol-l-yl)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, 2-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]benzenesulfonamide, 2-chloro-N-(3 - { 4-[(2-naphthyloxy)methyl]phenyl } pyrazin-2-yl)-benzenesulfonamide, 2-chloro-N- { 3-[4-(1 H-indol-1-ylmethyl)phenyl]pyrazin-2-yl} -+benzenesulfonamide, 2-chloro-N-(3 - { 4-[(5,6,7,8 -tetrahydronaphthalen-2-yloxy)methyl]-phenyl }
pyrazin-2-yl)benzenesulfonamide, 2-chloro-N-(3-{4-[(2-ethyl-1 H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)benzenesulfonamide, N-(3-{4-[(1,3-benzodioxol-5-ylamino)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, N-[3-(4-{ [(3-methoxybenzyl)oxy]methyl}phenyl)pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide, 3-chloro-N- { 3-[4-( {methyl[4-(trifluoromethoxy)phenyl]amino } -methyl)phenyl]pyrazin-2-1o yl}benzenesulfonamide, N-[3-(4-{ [(4-chlorophenyl)(methyl)amino]methyl}phenyl)pyrazin-2-yl]-thiophene-sulfonamide, 4-phenoxy-N- { 3-[4-(quinolin-2-ylmethyl)piperazin-1-yl]pyrazin-2-yl} -benzenesulfonamide, 4-methyl-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}-methyl)phenyl]pyrazin-2-yl } benzenesulfonamide, 4-chloro-N-[3 -(4- { [methyl(phenyl)amino]methyl } phenyl)pyrazin-2-yl] -benzenesulfonamide, 4-cyano-N- {3-[4-( {methyl[4-(trifluoromethoxy)phenyl]-amino} -methyl)phenyl]pyrazin-2-yl}benzenesulfonamide, N-[3-(4-{ [(4-Fluoro-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-(3- {4-[(Methyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{ [(4-Cyano-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, 5 N-{3-[4-(4-Fluoro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-(3- {4-[(Ethyl-phenyl-amino)-methyl]-phenyl } -pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N- { 3-[4-(2,3-Dihydro-benzo[ 1,4]oxazin-4-ylmethyl)-phenyl]-pyrazin-2-yl} -2-10 trifluoromethyl-benzenesulfonamide, N-[3-(4-{ [(3-Fluoro-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N- {3-[4-(6-Chloro-pyridin-3-yloxymethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, 15 N-{3-[4-(2-Pyridin-2-yl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N- { 3-[4-(5-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, N-[3-(4-Phenoxymethyl-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, 20 N-[3-(4-{ [(4-Chloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{ [(4-cyano-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-benzenesulfonamide, N-[3 -(4- { [(3,4-Dichloro-phenyl)-methyl-amino]-methyl } -phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(4-Cyano-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N- { 3-[4-(6-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-methoxy-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -1 o benzenesulfonamide, N- {3-[4-(4-Methoxy-phenoxymethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, N-(3 - { 4-[(B enzyl-pyridin-2-yl-amino)-methyl]-phenyl } -pyrazin-2-yl)-2-chloro-benzenesulfonamide, N-{3-[4-(2,3-Dihydro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{ [(2,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N- {3-[4-(3-Chloro-phenoxymethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{ [(2,4-difluoro-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-benzenesulfonamide, N- { 3-[4-(2-Methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -benzenesulfonamide, 2-Chloro-N-[3-(4-{ [(2-fluoro-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-benzenesulfonamide, 2-Chloro-N-{3-[4-(2-methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl} -benzenesulfonamide, N-(3 - { 4-[(B enzyl-pyridin-2-yl-amino)-methyl]-phenyl } -pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-(3 - {4-[(ethyl-pyridin-2-yl-amino)-methyl]-phenyl } -pyrazin-2-yl)-benzenesulfonamide, and N- { 3-[4-(5-Chloro-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide.
In a seventh aspect, the invention provides a method of synthesis of a compound according to formula (Ia)-(Id).
The 2,3 substituted sulfonamides exemplified in this invention may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimisation procedures.
A general description of methods for preparing compounds of Formula (I) is given in WO
04/058265 (PCT/GB03/005668).
The general synthetic approach for obtaining compounds of Formulae (Ia)-(Id) is depicted in Scheme 1. Therein, 2,3-substituted pyrazine sulfonamide derivatives according to the general formula I, may be prepared in 4 to 5 chemical steps, from commercially available 2,3-dichloropyrazine. Synthetic protocols are outlined in Schemes 1 to 10.
Scheme 1 NHZ A = CH21 C(O) R? O 0 CIN L = Cl, Br, coupling agent Cl N X = H, Me, Et, tBu HN
I -) CI N Alkylation R? S=0 R3 = R H or R6-OH
O or as described I I I I I here above L a R R\
B OH H~A (COhCl2or A\ I N R H A N
N coupling agent or X
0-q ~ or SOCI2 ~ R6-OH HN N
HN~~~N HN N R? S=0 R? S=0 R? S=0 1/Suzuki Coupling õ Activation 0 Alkylation 0 21 Deprotection (if needed) 0 or Chlorination or acylation IV V Ia A -z z B, ( )2 A z R a H i A z N CO CI2 or I
OH coupling agent N or ~ _ X~O~A 3 or SOCIz R6-OH N
HN N HN N HN N
1/Suzuki Coupling R? S=0 Activation R 2 -S=0 Alkylation R 2 -S=0 Cl ~ N 21 Deprotection (if needed) 0 or Chlorination p or acylation O
) VI VII lb HN N
R? S=0 III A (CO)zClz or A Ra H A
O N coupling agent N\ or N
X' q or SOCI2 HN N HN N
1/Sonogashira Coupling R? S=0 Activation R? S=0 Alkylation R? S=0 21 Deprotection (if needed) O or Chlorination 0 or acylation 0 VIII IX Ic O~ R3 HN~~ O ~~ N H~~ N A N~ 0 HNIN~ Add HNIN) R3 A L ~NIN
Alkylation R? S=0 Deprotection R? S=0 Alkylation R? S=0 O O or acylation 0 X XI Id In a more specific method, the sulfonamide derivatives XXI, wherein R2 is defined as above is reacted with the 2,3-dichloropyrazine II to give the corresponding 3-chloropyrazine sulfonamide compounds III. Several reaction conditions may be utilized for performing this first reaction step, e.g. by the use of sulfonamide derivative XXI in presence of a base such as cesium carbonate, potassium carbonate or the like.
This reaction may be performed in solvents like NMP, DMF or DMA at various temperature depending on the intrinsic reactivity of compounds XXI and II, by traditional thermic or microwawe method, using standard conditions well known to the person skilled in the art or shown in Scheme 2, below:
Scheme 2 CI N
CI N\ 2 NH2 Cs2CO3, NMP
~ + R-S=0 HN N
CI N 0 1300C R? S=0 II XXI III
The sulfonamide derivatives XXI are obtained from commercial sources or can be prepared by treatment of the corresponding sulfonyl chlorides XX, using standard conditions well known to the person skilled in the art, with a solution of 2M ammonia in EtOH
or dioxane at room temperature for lhour or using can be performed at various temperature depending on the intrinsic reactivity of compounds XXI, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art or shown in the Scheme 3, below.
Scheme 3 i R2 S C=0 NH EtOH R? S=O
ii = 3 30 ii O O
xx xxi The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ia, may be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. A synthetic route is shown in Scheme 4. In a first step, the 2,3-substituted 5 pyrazine sulfonamide derivatives IVa are isolated after condensation of the chloropyrazine sulfonamide compounds III with the boronic acids XXII. This reaction may be performed in presence of appropriated palladium catalysts such as palladium diacetate and in solvents like Dioxane, methanol or solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic 10 reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives Va, whereby the substituent R2 is as above defined, are isolated after chlorination of intermediate compounds IVa in presence of thionyl chloride. This reaction is usually performed at room 15 temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art.
In a following step, as shown in Scheme 4, the 2,3-substituted pyrazine sulfonamide derivatives Va, may be treated with various nucleophiles, e.g. an amine XXIV
or alcohol XXV, wherein R4, R5, R6 are independently selected from the group of hydrogen, alkyl, 20 aryl, heteroaryl, cycloalkyl, heterocycloalkyl or fused ring systems of the mentioned to give the expected 2,3-substituted pyrazine sulfonamide derivative Ia. The nucleophilic displacement of the chlorine atom of the benzylic moiety by the amine XXIV or the alcohol XXV, is accomplished by treatment with an appropriated based such as sodium hydride or potassium tert-butoxide in anhydrous conditions, in presence or absence of e.g. sodium iodine or tetrabutylammonium iodine as catalyst in solvents such as DMF, THF
or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds Va, XXIV and XXV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 4 HO CI
CI N OH Pd(OAc)Z, PPh3, IN\
B,OH K2COs N~ SOCIZ
HN N + H HN N ZHN N
RZ S=0 O Dioxane:MeOH, Rz S-_O DCM, r.t. R S=0 0 110 C ~ 0 I I I xxI I IVa Va R5 A = CH2 R4 Ij XXIV
H R\ 3 CI
NaH, DMF
HN N HN N R3 = or RZ S=O ~ RZ S=O
0 R6-OH ~ R6-O
Va tBuOK, THF la The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ia, may also be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. Another synthetic route is shown in Scheme 5. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives Nb are isolated after condensation of the 3-chloropyrazine sulfonamide compounds III with the boronic acids XXIII. This reaction may be performed in presence of appropriate palladium catalysts such as palladium diacetate and in solvents like Dioxane, methanol or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives Vb, whereby the substituent R2 is as above defined, are isolated either after chlorination of intermediate compounds Nb in presence of oxalyl chloride or after treatment of compounds IVb with an appropriate coupling reagent such as DCC, HATU or Mukayama reagent in presence of a base like DIPEA or triethylamine. These reactions are usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art.
In a fmal step, as shown in Scheme 5, the 2,3-substituted pyrazine sulfonamide derivative Vb, may be treated with various nucleophiles, e.g. an amine XXIV, to give the expected 2,3-substituted pyrazine sulfonamide derivative Ia. The formation of the amide bond is accomplished by treatment with an appropriate base such as DIPEA or triethylamine, in solvents such as DMF, THF or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds Vb and XXIV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 5 L
N
OH Pd(OAc)2, PPh3, p HO I
CII N
B OH K2C03 0 N (CO)ZCl2or ~'-O Jl -) coupling agent HN N
HN N + H HN N R2 S=O
R2 S=O pP Dioxane:MeOH, R2 S-O DMF or DCM, r.t.
~ 0 110 C 0 0 I I I XXI I I IVb Vb A = C(O) L = CI, interemdiate coupling agent L R N R
p N H XXIV ACI N Re I
HN I N HN N R3 =
R2 S=O DMF or DCM, r.t. R2 S=O
Vb la The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ib, may be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. A synthetic route is shown in Scheme 6. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives VIa are isolated after condensation of the 3-chloropyrazine sulfonamide compounds III with the boronic acids XXVI. This reaction may be performed in presence of appropriate palladium catalysts such as palladium diacetate and in solvents like Dioxane, methanol or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives VIIa, whereby the substituent R2 is as above defined, are isolated after chlorination of intermediate compounds VIa in presence of thionyl chloride. This reaction is usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art.
In a following step, as shown in Scheme 6, the 2,3-substituted pyrazine sulfonamide derivatives VIIa, may treated with various nucleophiles, e.g. an amine XXIV or alcohol XXV, to give the expected 2,3-substituted pyrazine sulfonamide derivative lb.
The nucleophilic displacement of the chlorine atom of the benzylic moiety by the amine XXIV
or the alcohol XXV, is accomplished by treatment with an appropriate base such as sodium hydride or potassium tert-butoxide under anhydrous conditions, in presence or absence of e.g. sodium iodine or tetrabutylammonium iodine as catalyst in solvents such as DMF, THF
or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds VIIa, XXIV and XXV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 6 OH L
I ,_z CI N OH Pd(OAc)21 PPh3, N IN_ HNIN\ ~ + H~O~ z ~ OH HN N HN N
? S=O Dioxane:MeOH, R2 S=0 R ~ S=O
11 R 0 1100C 0 DCM, r.t. 0 III XXVI Via Vlla 5 A=CH2 R L=CI
R N XXIV H z = O,S
z NaH, DMF A
Z
N Ra HR N
N
HNN~ R3= or HN N~
R2 S=O xxv R? S=O R6-O
11 p R6-OH 0 Vlla lb tBuOK, THF
The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ib, may also be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. Another synthetic route is shown in Scheme 7. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives VIb are isolated after condensation of the 3-5 chloropyrazine sulfonamide compounds III with the boronic acids XXVII. This reaction may be performed in presence of appropriate palladium catalysts such as palladium diacetate and in solvents like Dioxane, methanol or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave 10 technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives VIIb, whereby the substituent R2 is as above defined, are isolated either after chlorination of intermediate compounds VIb in presence of oxalyl chloride or after treatment of compounds VIb with an appropriate coupling reagent such as DCC, HATU or Mukayama reagent in presence of a 15 base like DIPEA or triethylamine. These reactions are usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art.
In a final step, as shown in Scheme 7, the 2,3-substituted pyrazine sulfonamide derivatives VIIb, may be treated with various nucleophiles, e.g. an amine XXIV, to give the expected 20 2,3-substituted pyrazine sulfonamide derivatives lb. The formation of the amide bond is accomplished by treatment with an appropriate base such as DIPEA or triethylamine, in solvents such as DMF, THF or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds VIIb and XXIV, by traditional thermal method or using microwave technology, using standard conditions well 25 known to the person skilled in the art.
Scheme 7 OH L
CI N OH Pd(OAc)2, PPh3, O N (CO)2CI2 or O z ' ~ 'Jl B OH K2C03 coupling agent N
z ~Jl ~
HN N
RZ S=O + H' O Dioxane:MeOH, RZ HS=O N DMF or DCM, r.t. RZ HS-O N
O
III xxVll Vib Vllb A = C(O) L = CI, intermediate coupling agent RS z = O, S
L R -N R z N
i I ' I H
XXIV A LR_51 \Jl ~ R3 =
~
HN N DMF or DCM, r.t. 2 HN N
R2 S=0 R-S=0 Vllb lb The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ic, may be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. A synthetic route is shown in Scheme 8. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives VIIIa are isolated after condensation of the chloropyrazine sulfonamide compounds III with the acetylene XXVIII. This reaction may be performed in the presence of appropriate palladium catalysts such as palladium triphenyl phosphine tetrakis or Pd(Ph3)2C12 in presence of cupper iodine and potassium acetate, in solvents like Dioxane, DMF or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives IXa, whereby the substituent R2 is as above defined, are isolated after chlorination of intermediate compounds VIIIa in presence of thionyl chloride. This reaction is usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art In a following step, as shown in Scheme 8, the 2,3-substituted pyrazine sulfonamide derivatives IXa, may be treated with various nucleophiles, e.g. an amine XXIV
or alcohol XXV, to give the expected 2,3-substituted pyrazine sulfonamide derivatives Ic.
The nucleophilic displacement of the chlorine atom of the benzylic moiety by the amine XXIV
or the alcohol XXV, is accomplished by treatment with an appropriate base such as sodium hydride or potassium tert-butoxide under anhydrous conditions, in presence or absence of e.g. sodium iodine or tetrabutylammonium iodine as catalyst in solvents such as DMF, THF
or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds IXa, XXIV and XXV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 8 OH L
CH3COOK, DMF l CI N 100 C, Cul N N
SOCIZ HNN
HN ~ N~ + H"O/ I
HN N
R? S=O Pd(Ph3)2CI2or Pd(Ph3)a R? S-O DCM, r.t. R? S=O
III XXVIII Villa IXa A = CH2 R5 XXIV L = CI
Ra-N
NaH, DMF
HN N A, R5 IN_ HNNN
~ R3 R or S=0 xxV R? S=O R6-O
p R6-OH p IXa Ic tBuOK, THF
The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ic, may also be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. Another synthetic route is shown in Scheme 9. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives VIIIb are isolated after condensation of the 3-chloropyrazine sulfonamide compounds III with the acetylene XXIX. This reaction may be performed in the presence of appropriate palladium catalysts such as palladium triphenyl phosphine tetrakis or Pd(Ph3)2C12 in presence of cupper iodine and potassium acetate, in solvents like Dioxane, DMF or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives IXb, whereby the substituent R2 is as above defined, are isolated either after chlorination of intermediate compounds VIIIb in the presence of oxalyl chloride or after treatment of compounds VIIIb with an appropriate coupling reagent such as DCC, HATU or Mukayama reagent in presence of a base like DIPEA or triethylamine. These reactions are usually performed at room temperature in solvent like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art In a fmal step, as shown in Scheme 9, the 2,3-substituted pyrazine sulfonamide derivatives IXb, may be treated with various nucleophiles, e.g. an amine XXIV, to give the expected 2,3-substituted pyrazine sulfonamide derivative Ic. The formation of the amide bond is accomplished by treatment with an appropriate base such as DIPEA or triethylamine, in solvents such as DMF, THF or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds IXb and XXIV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 9 OH L
CI N CH3COOK, DMF O N (CO)2CI2 or O ~ N
~ H,O' 100 C, Cul I 1 coupling agent ~
' + HN N HN N
HN N
I
2 O R? S=O DMF or DCM, r.t. R-S=O
R-S=0 Pd(Ph3)2CI2 or Pd(Ph3)4 0 0 0 xxix III Vlllb IXb A = C(O) L = CI, coupling agent R5 Ra z=O,S
L
R4 N A s O N H XXIV R
xN:] N R3 =
R? S=O DMF or DCM, r.t. R? S=0 u i IXb Ic The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Id, may be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. A synthetic route is shown in Scheme 10. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives X are isolated after condensation of the 3-chloropyrazine sulfonamide compounds III with the piperazine-l-carboxylic acid tert-butyl ester XXX.
This reaction may be performed in presence of an appropriate base such as DIPEA or triethylamine, in solvents like NMP, DMF or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives XI, whereby the substituent R2 is deprotected under acidic conditions using either TFA or HC1 solution at different concentrations. This reaction is usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art. In a following step, as shown in Scheme 10, the 2,3-substituted pyrazine sulfonamide derivatives X, may be treated either with various electrophiles, e.g.
an alkyl halide XXXIa in the presence of an appropriate base such as Cs2CO3, DIPEA or triethylamine, or also with an acyl chloride or a carboxylic acid XXXIb initially 5 preactivated by treatment with an appropriate coupling reagent such as DCC, Mukayama reagent, PyBrop, in order to give the expected 2,3-substituted pyrazine sulfonamide derivative Id. The nucleophilic displacement of the halide atom or the formation of the amide bond respectively, with the alkyl halide XXXIa or acyl chloride or carboxylic acid XXXIb can be performed at various temperatures depending on the intrinsic reactivity of 10 compounds XI, XXXIa or XXXIb, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 10 0, HN~
O ONIN, ~N N
IIICIN' ~ 0 DIPEA, DMF
'Jl N~O or NMP, 1400C TFA or HCI ~
~ HN N
HN N + HN J~ HN N 2' i =0 R2 S=0 R? S-O DCM, r.t. R-S11 'O' 11 O
O
III xxx x XI
A = CH2 XXXIa I
HN Cs2CO3, DMF '4, 3XN
~N
J
~
N
R? S= 0 R3-A-L 2' HN=0 -S
p A = C(O) XXXIb R
XI DIPEA, THF
Id The following abbreviations refer respectively to the definitions below:
min (minute), hr (hour), g(gram), MHz (Megahertz), ml (milliliter), mmol (millimole), mM (millimolar), RT (room temperature), ATP (Adenoside Triphosphate), BSA
(Bovine Serum Albumin), DCM (dichloromethane), DCC (dicyclohexylcarbodiimide), DIPEA
(di-isopropyl ethylamine), DMSO (Dimethyl Sulfoxide), Mukayama reagent (1-methyl-2-chloropyridinium iodide), DMF (Dimethylformamide), CsCO3 (Cesium carbonate), cHex (Cyclohexanes), Et3N (Triethylamine), EtOAc (Ethyl acetate), EtOH (Ethanol), (potassium carbonate), NaI (Sodium Iodine), NaH (Sodium hydride), NaHCO3 (Sodium bicarbonate), NH4C1 (Ammonium chloride), TEA (Triethyl amine), TFA
(Trifluoroacetic acid), THF (Tetrahydrofuran), Pd(PPh3)4 (Palladium triphenylphosphine tetrakis), CuI
(Copper iodide), Pd(OAc)2(Palladium II acetate), Pd(PPh3)2 C12 (Bis(triphenylphosphine) Palladium II Chloride), CH3COOK (Potassium acetate), PPh3 (Triphenylphosphine), HATU (N,N,N',N'-Tetramethyl-O-(7-Azabenzotriazol-1-yl)uranium hexafluorophosphate, (CO)2C12 (Oxalyl chloride), SOC12 (Thionyl chloride), tBuOK (Potassium tert-butoxide), MeOH (Methanol), MgS04 (Magnesium sulfate), NMP N-Methyl pyrrolidinone, PetEther (Petroleum ether), rt (room temperature). HPLC (High Performance Liquid Chromatography), FC (Flash Chromatography on silica gel), MS (Mass Spectrometry), NMR (Nuclear Magnetic Resonance), PBS (Phosphate Buffered Saline), SPA
(Scintillation Proximity Assay), TLC (Thin Layer Chromatography), UV (Ultraviolet).
If the above set of general synthetic methods is not applicable to obtain compounds according to Formula (I) and/or necessary intermediates for the synthesis of compounds of Formula (I), suitable methods of preparation known by a person skilled in the art should be used. In general, the synthesis pathways for any individual compound of Formula (I) will depend on the specific substituents of each molecule and upon the ready availability of intermediates necessary; again such factors being appreciated by those of ordinary skill in the art. For all the protection and deprotection methods, see Philip J.
Kocienski, in "Protecting Groups", Georg Thieme Verlag Stuttgart, New York, 1994 and, Theodora W.
Greene and Peter G. M. Wuts in "Protective Groups in Organic Synthesis", Wiley Interscience, 3rd Edition 1999.
Compounds of this invention can be isolated in association with solvent molecules by crystallization from evaporation of an appropriate solvent. The pharmaceutically acceptable acid addition salts of the compounds of Formula (I), which contain a basic center, may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of compound of Formula (I) with a suitable base. Both types of salts may be formed or interconverted using ion-exchange resin techniques.
In the following the present invention shall be illustrated by means of some examples, which are not construed to be viewed as limiting the scope of the invention.
EXPERIMENTAL PART
The HPLC, NMR and MS data provided in the examples described below are obtained as followed: HPLC: column Waters Symmetry C8 50 x 4.6 mm, Conditions: MeCN/H2O, 5 to 100% (8 min), max plot 230-400 nm; Mass spectra: PE-SCIEX API 150 EX (APCI and ESI), LC/MS spectra: Waters ZMD (ES); 1H-NMR: Bruker DPX-300MHz.
The preparative HPLC purifications are performed with HPLC Waters Prep LC 4000 System equipped with columns Prep Nova-Pak HR C186 m 60A, 40x30mm (up to 100mg) or with XTerra Prep MS C8, 10 m, 50x300mm (up to lg). All the purifications are performed with a gradient of MeCN/H2O 0.09% TFA. The semi-preparative reverse-phase HPLC are performed with the Biotage Parallex Flex System equipped with columns SupelcosilTM ABZ+Plus (25 cm x 21.2 mm, 12 m); UV detection at 254 nm and 220 nm;
flow 20 mL/min (up to 50 mg). TLC Analysis is performed on Merck Precoated 60 plates. Purifications by flash chromatography are performed on Si02 support, using cyclohexane/EtOAc or DCM/MeOH mixtures as eluents.
Intermediate 1: 2-(trifluoromethyl)benzenesulfonamide (cf. Scheme 3, compound XXI) O F
H2N-S'O F
F
To a solution of 2-(trifluoromethyl)benzenesulfonyl chloride (5g; 20.44 mmol;
1.00 eq.) in anhydrous THF (5.00 ml) was added a solution of 71 ml Ammonia in Ethanol 2M
under nitrogen at room temperature. The reaction mixture was shaken for 20h at room temperature. The solvent was evaporated and the residue redissolved in EtOAc(150mL) and then washed with NH4C1 saturated aqueous solution (50mL) and brine (50mL). The organic layer was dried over MgSO4, filtered and the solvent evaporated to give the pure 2-(trifluoromethyl)benzenesulfonamide as a yellowish solid (4.6g, 89% yield, 98.6% HPLC
purity). This compound was utilized as such for the next reaction.
1H NMR (300MHz, CDC13); 5.0 (m, 2H), 7.6 (m, 2H), 7.8 (m, 1H), 8.3 (m, 1H).
MS(ESt):
224.1.
Intermediate 2: 2-chloro-N-(3-chloropyrazin-2-yl)benzenesulfonamide (cf. Scheme 2, compound III) f~N
N~ I ~
S~O CI EI:CI
2,3-dichloropyrazine (1g; 6.71 mmol; 1.00 eq.) and 2-dichlorobenzenesulfonamide (1.29g;
6.71mmo1; 1.00 eq.) were stirred in NMP (9m1). To this reaction mixture was added cesium carbonate (2g; 6mmol; 0.90 eq.) and the reaction mixture was stirred and heated up to 130 C for 20h. The reaction was cooled down to room temperature, added to water 98m1 and washed with AcOEt (2x30m1). The aqueous phase was acidified with citric acid and extraced with AcOEt (3x60m1). The organic extracts were combined, washed with brine (lOml), dried over MgSO4 and evaporated down. The residue was purified by Flash master using a gradient AcOEt/cHex 2:8 to AcOEt 100% in 45 min, the title compound was isolated, after filtration and evaporation. The solid was recrystallized in a mixture EtOAc:Chex (30:70) to give the pure 2-chloro-N-(3-chloropyrazin-2-yl)benzene sulfonamide as a yellowish solid (lg, 49% yield, 100%HPLC purity).
1H NMR (300MHz, CDC13); 7.3-7.5 (m, 3H), 7.8-8.0 (m, 3H), 8.3 (m, 1H).
MS(ESI+):
304.1; MS(ESI-): 302Ø
Intermediate 3: N-(3-chloropyrazin-2-Xl)-~trifluoromethXl)benzenesulfonamide (cf.
Scheme 2, compound III) f~N
F
N / ~ F
N-S;O
CI H / ~ F
~
Following the general method as outlined for Intermediate 2, starting from 2,3-dichloropyrazine and 2-(trifluoromethyl)benzenesulfonamide, the title compound was isolated, after evaporation and recrystallization, as a yellowish solid in 63%
yield (97 %
purity by HPLC).
1H NMR (300MHz, CDC13); 7.6-7.8 (m, 4H), 7.9-8.1 (m, 2H), 8.5 (m, 1H).
MS(ESI+):
338.0; MS(ESI-): 336Ø
Intermediate 4: 2-chloro-N-{344-(hydroxymethyl phenyl]pyrazin-2-VI} benzene sulfonamide (cf. Scheme 4, compound IVa) ~
N
N~ I 0,, N_S;O H bC' HO
5 2-chloro-N-(3-chloropyrazin-2-yl)benzenesulfonamide (2.2g; 7.23 mmol; 1.00 eq.) and 4-hydroxymethyl benzene boronic acid (1.21g; 7.96 mmol; 1.10 eq.) were dissolved in 48mL
of a 1:1 mixture of Dioxane:MeOH that was previously degassed. Potassium carbonate (2.75g; 19.89 mmol; 2.75 eq.) and triphenylphosphine (284.58 mg; 1.08 mmol;
0.15 eq.) were added to the reaction mixture under nitrogen, followed by palladium II
(81.19 mg;
10 0.36 mmol; 0.05 eq.). The reaction mixture was then heated at 110 C under N2 for 30minutes. The reaction mixture was cooled down to room temperature, diluted with diethyl ether (50mL) and water (25mL) and filtered through celite. The aqueous layer was separated and the organic layer washed with water (50mL). The combined aqueous solutions were washed with diethyl ether (50mL), then acidified aqueous layer with HC1 15 5N and extracted with AcOEt. The organic extracts were combined, washed with brine (lOml), dried over MgS04 and evaporated down to give the pure 2-chloro-N-{3-[4-(hydroxymethyl)phenyl]pyrazin-2-yl} benzene sulfonamide as a yellowish solid (2.5g, 91%
yield, 98% HPLC purity). This compound was used as such for the next reaction.
1H NMR (300MHz, CDC13); 4.68 (m, 2H), 7.5-7.7 (m, 7H), 8.1-8.2 (m, 3H), 8.3 (m, 1H).
20 MS(ESI'): 376.1; MS(ESI-): 374.1.
Intermediate 5: 2-trifluoromethyl-N-{3-f4-(hydroxymethyl -phenyl{pyrazin-2-yl}
benzene sulfonamide (cf. Scheme 4, compound IVa) ~N
~ F
N,S;O
H F
\ ~ ~\
HO
Following the general method as outlined for Intermediate 4, starting from N-(3-chloropyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide and 4-hydroxymethyl benzene boronic acid, the title compound was isolated, after evaporation and recrystallization, as a yellowish solid in 85% yield (97 % purity by HPLC).
1H NMR (300MHz, CDC13); 4.83 (m, 2H), 7.5-7.9 (m, 8H), 8.1 (m, 1H), 8.3 (m, 1H), 8.64 (m, 1H). MS(ESI+): 410.3; MS(ESI-): 408.5.
Intermediate 6: 4-(3-{I(2-chlorophenyl sulfonyllamino}pyrazin-2-yl)benzoic acid (cf. Scheme 5, compound Nb) / N
N~S~O H bC' HO O
Following the general method as outlined for Intermediate 4, starting from 2-chloro-N-(3-chloropyrazin-2-yl)benzenesulfonamide and 4-carboxybenzene boronic acid, the title compound was isolated, after evaporation and recrystallization, as a yellowish solid in 83%
yield (96 % purity by HPLC).
1H NMR (300MHz, CDC13); 7.5-7.7 (m, 4H), 7.9-8.0 (m, 2H), 8.1-8.4 (m, 5H).
MS(ESI+):
390.8; MS(ESI-): 388.9.
Intermediate 7: 4-(3-{j(2-trifluorometh~~phenyl sulfonyllamino}pyrazin-2-yl)benzoic acid (cf. Scheme 5, compound IVb) ~N
N~ ~ ~ F
,S;O
N F
H
/ ~ F
~
HO O
Following the general method as outlined for Intermediate 4, starting from N-(3-chloropyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide and 4-carboxybenzene boronic acid, the title compound was isolated, after evaporation and recrystallization, as a yellowish solid in 80% yield (98 % purity by HPLC).
MS(ESI+): 424.4; MS(ESI-): 422.2.
Intermediate 8: 2-chloro-N-{3-f4-(chloromethyl -phenyl]pyrazin-2-~}benzene-sulfonamide (cf. Scheme 4, compound Vb) ~N
N~ I ~
N_S~O H 6C' CI
2-chloro-N-{3-[4-(hydroxymethyl)phenyl]pyrazin-2-yl} benzene sulfonamide (3.15g; 8.4 mmol; 1.00 eq.) was dissolved in dichloromethane (8OmL) and thionyl chloride (8.5mL, 117mmo1, 14eq.) was added dropwise. The reaction mixture was stirred overnight. The reaction mixture was poured carefully into ice/water (200mL) and stirred until clear layers were formed. The mixture was separated and the organic layer was dried over MgSO4 and evaporated down to give the crude solid which was recrystallsied in AcOEt/cyclohexane to give the pure 2-chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide as a white solid (3.02 g, 95% yield, 99% HPLC purity).
1H NMR (300MHz, CDC13); 4.69 (m, 2H), 7.45-7.6 (m, 3H), 7.65-7.7 (m, 5H), 8.0 (m, 1H), 8.3 (m, 1H), 8.38 (m, 1H). MS(ESI+): 396.1; MS(ESI-): 393.1.
Intermediate 9: N-13-[4-(chloromethyl -phenyl]pyrazin-2-vl}-2-(trifluoromethyl) benzenesulfonamide (cf. Scheme 4, compound Vb) ~N
N~ ~ ~ F
NS;O
H F
\ ~ ~\
CI
Following the general method as outlined for Intermediate 8, starting from 2-trifluoromethyl-N-{3-[4-(hydroxymethyl)phenyl]pyrazin-2-yl} benzene sulfonamide and thionyl chloride, the title compound was isolated, after evaporation and recrystallization, as a white solid in 96% yield (97 % purity by HPLC).
MS(ESI+): 428.9; MS(ESI-): 426.7.
Intermediate 10: N-[3-(3-hydroxyprop-l-yn-1-Xl)pyrazin-2-yll-~trifl uoromethXl) benzenesulfonamide (cf. Scheme 8, compound VIIIa) f~N
N~ 0 F
N,S;o " F
Method A:
N-(3-chloropyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide (1.35g; 4.0 mmol; 1.00 eq.) and 2-propyn-l-ol (336mg; 6.0 mmol; 1.5 eq.) were dissolved in lOmL of DMF under nitrogen atmosphere. To the reaction mixture was added CH3COOK (588mg; 6.0 mmol;
1.5 eq.) and Pd(PPh3)4 (232 mg; 0.2 mmol) under nitrogen. The reaction mixture was then heated at 100 C under nitrogen for 2hours. After removal of the solvent by distillation in vacuo, the residue was triturated with water (40mL) and extracted with diethyl ether (3x3OmL). The organic layer was dried over MgSO4 and evaporated down. The crude product was purified by silica gel column chromatography using a mixture of hexane and AcOEt to give pure N-[3-(3-hydroxyprop-1-yn-1-yl)pyrazin-2-yl]-2-(trifluoromethyl) benzenesulfonamide as a yellowish solid (686mg, 48% yield, 98% HPLC purity).
Method B:
N-(3-chloropyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide (1.35g; 4.0 mmol; 1.00 eq.) and 2-propyn-l-ol (336mg 6.0 mmol; 1.5 eq.) were dissolved in lOmL of DMF
under nitrogen atmosphere. To the reaction mixture was added CH3COOK (588mg; 6.0 mmol;
1.5 eq.) CuI (40mg; 0.2 mmol; 0.05 eq.) and Pd(PPh3)2C12 (28mg; 0.04 mmol) under nitrogen. The reaction mixture was then heated at 100 C under nitrogen for 2hours. After removal of the solvent by distillation in vacuo, the residue was triturated with water (4OmL) and extracted with diethyl ether (3x30mL). The organic layer was dried over MgSO4 and evapored down. The crude product was purified by silica gel column chromatography using a mixture of hexane and AcOEt to give pure N-[3-(3-hydroxyprop-1-yn-1-yl)pyrazin-2-yl]-2-(trifluoromethyl) benzenesulfonamide as a yellowish solid (702mg, 50% yield, 98%
HPLC purity).
MS(ESI'): 358.6; MS(ESI-): 356.5.
Intermediate 11: N-(3--pi-perazin-l-vlpyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide (cf. Scheme 10, compound XI) ~N
;O F
F
CN H F
H
5 tert-butyl 4-[3-({[2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrazin-2-yl]piperazine-l-carboxylate (1.46g, 3mmol) was dissolved in dichloromethane (50mL) and trifluoroacetic acid (4.5g, 40mmo1) was added at 0 C. The reaction mixture was stirred for 2h.
The solvents were evaporated and the residue redissolved in dichloromethane (50m1) and evaporated to dryness to give the expected product N-(3-piperazin-1-ylpyrazin-2-yl)-2-10 (trifluoromethyl)benzenesulfonamide as a yellow solid (1.1g, 95% yield, 95 % purity by HPLC).
MS(ESI'): 388.4; MS(ESI-): 386.3.
Example 1: General procedure for the synthesis of 2,3-substituted pyrazine sulfonamide 15 derivatives of general formula I. with A and Z as above defined (Schemes 1, 4, 5, 6, 7, 8, 9 and 10): N-{3-f4-(1H-indol-1-ylmethyl -phenyl]pyrazin-2-yl}-2-(trifluoromethyl benzene-sulfonamide N N-N
HN pF F
~ S' F
Method A:
To a solution of 1H-Indole (234mg, 2.Ommol, leq) in dimethylformamide (lOmL) was added sodium hydride (80mg, 2mmol, leq). After the evolution of hydrogen ceased, N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (intermediate 26) (854mg, 2mmol, leq) in dimethylformamide (5mL) was added and the reaction mixture heated to 80 degrees over 3hours. The reaction was cooled, diluted with 30mL of water and extracted with diethyl ether. The organic layer was dried over MgSO4, evaporated and purified by flash chromatography on silica gel eluting with AcOEt and cyclohexane to give pure N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl)benzenesulfonamide as a yellow solid (630mg, 1.24mmo1, yield:
62%, 97% HPLC purity).
Method B:
N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzene sulfonamide (intermediate 26) (854mg, 2mmol, leq) and 1H-Indole (234mg, 2.Ommol, leq) were shaken in tetrahydrofuran (20mL) and heated up to 50 degrees for lOminutes. To the reaction mixture was added potassium tert-butoxide (4.5mL of a 1M solution in THF). The reaction mixture was maintained to 50 degrees for 5h, and then cooled down to room temperature. The reaction mixture was treated with 10m1 of an aqueous citric acid solution (20g in lOOmL of water) and extracted with AcOEt. The organic layer was dried over MgSO4 and evaporated. The crude was purified similarly to Method A to give pure N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl)benzenesulfonamide as a yellow solid (691mg, 1.36mmol, yield: 68%, 98% HPLC purity).
N-{3-[4-(1H-indol-l-ylmethyl vhenyl]pyrazin-2-yl}-2-(trifluoromethyl benzene sulfonamide: yellow solid; 'H NMR (300 MHz, CDC13); 5.50 (m, 2H), 6.5 (m, 1H), 7.0-7.2 (m, 2H), 7.4-7.65 (m, 8H), 7.65-7.7 (m, 2H), 8.0 (m, 2H), 8.3 (m,1H), 8.38 (m,1H). MS
(ESI+) 509.5, (ESI-) 507.6.
Example 2: 2-chloro-N-{3-[4-(Imethyl[4-(trifluoromethoxx)phenyllamino}-methXl)-phenyl]pyrazin-2-vl} benzenesulfonamide F F
G ~ F
\ ~ p .NH ~Na N
k~-,N
Following the general methods as outlined in Example 1(Method B), starting from 2-chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and N-methyl-4-(trifluoromethoxy)aniline, the title compound was isolated as a yellow solid in 72% yield (99% purity by HPLC).
MS(ESI'): 550.1; MS(ESI-): 547.8.
Example 3: N-(3-{4-[(2-ethyl-lH-benzimidazol-l-yl methyllphenyl}vyrazin-2-yl)-(trifluoromethyl)benzenesulfonamide N
r N-N \ \ ~
N
HN OF
"S, O F
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-ethylbenzimidazole, the title compound was isolated as a yellow solid in 63%
yield (96% purity by HPLC).
MS(ESI'): 538.6; MS(ESI-): 536.5.
Example 4: 2-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yi1' benzenesulfonamide N
I
~ N
HN N
0=S=0 G
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and N-methyl-aniline, the title compound was isolated as a yellow solid in 83%
yield (99%
purity by HPLC).
MS(ESI'): 465.6; MS(ESI-): 463.8.
Example 5: 2-chloro-N-(3-{4-[(2-naphthyloxy methyllphenyl}yyrazin-2-yl benzene-sulfonamide N
N
G
0 / HN. 0 \ I / O ~
Following the general method as outlined in Example 1(Method A), starting from chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide (Intermediate 8), and 2-hydroxy naphthalene, the title compound was isolated as a yellow solid in 72% yield (99% purity by HPLC).
MS(ESI'): 503.4; MS(ESI-): 501.2.
Example 6: 2-chloro-N-{3-[4-(1H-indol-l-ylmethyl vhenyljvyrazin-2-yl}benzene-sulfonamide N \
N
HN.
O
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 1-H-Indole, the title compound was isolated as a yellow solid in 71% yield (98% purity by HPLC).
MS(ESI'): 475.9; MS(ESI-): 473.5.
Example 7: 2-chloro-N-(3-{4-[(5,6,7,8-tetrahydronaphthalen-2-yloxy methyll-phenyl}-pvrazin-2-Xl)benzenesulfonamide N
N
O I / HN,S
al~ O
Following the general method as outlined in Example 1(Method B), starting from 5 chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide (Intermediate 8), and 6-hydroxy-1,2,3,4-tetrahydronaphtalene, the title compound was isolated as a yellow solid in 69% yield (99% purity by HPLC).
MS(ESI'): 507.6; MS(ESI-): 505.2.
Example 8: 2-chloro-N-(3-{4-[(2-ethyl-lH-benzimidazol-l-Xl)methyllphenyl}pvrazin-2-10 yl)benzenesulfonamide N
N-N ~\
N
HN O
,S" G
O
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 2-ethyl benzimidazole, the title compound was isolated as a yellow solid in 65% yield 15 (96% purity by HPLC).
MS(ESI'): 505.4; MS(ESI-): 503.2.
Example 9: N-(3-{4-[(1,3-benzodioxol-5-ylamino methyl]pheMl}l)yrazin-2-yl)-2-(trifluoromethXl)benzenesulfonamide N~
H \ N F F
~ N I i HN O F
I
~ ~ O
O
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3,4-(methylenedioxy)aniline, the title compound was isolated as a yellow solid in 69% yield (96% purity by HPLC).
MS(ESI'): 529.7; MS(ESI-): 527.5.
Example 10: N-[3-4-{[(3-methoxybenzXl)oxy]methyl}phenXl)p3razin-2-yll-2-(trifluoromethXl)benzenesulfonamide N
0~ N F F
HN O F
~ I O O
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3-anisyl alcohol, the title compound was isolated as a yellow solid in 64% yield (92% purity by HPLC).
MS(ESI'): 530.4; MS(ESI-): 528.8.
Example 11: 3-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyllamino}methyl) phenLIlpyrazin-2-yl} benzenesulfonamide a F'I- F
F
O O
OS.NH
N
~,, N
Following the general method as outlined in Example 1(Method B), starting from chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide, and N-methyl-4-(trifluoromethoxy)aniline, the title compound was isolated as a yellow solid in 69% yield (94% purity by HPLC).
MS(ESI'): 550.2; MS(ESI-): 547.6.
Example 12: N-[3-(4-{ [(4-chlorophenXl)(methXl)amino]methyl}phnXle)~pvrazin-2-~1~
thiophene-2-sulfonamide O
,S.
G ~ I N / I N
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}thiophene-2-sulfonamide, and N-methyl-4-chloro aniline, the title compound was isolated as a yellow solid in 69% yield (94%
purity by HPLC).
MS(ESI'): 472.8; MS(ESI-): 470.7.
Example 13: 4-phenoxy-N-{3-[4-(guinolin-2-ylmethyl)-pi-perazin-l-yl]pyrazin-2-yl}~
benzenesulfonamide i I
N
0'NH ~N
N~Nv ~,, N
To a solution of 4-phenoxy-N-(3-piperazin-1-ylpyrazin-2-yl)benzenesulfonamide (411mg, 1.0mmo1, 1eq) in dimethylformamide (10mL) was added 2-(chloromethyl)quinoline hydrochloride (214mg, lmmol, leq) and DIPEA (322mg, 2.5mmol, 2.5eq). The reaction mixture was heated to 50 degrees over lhour. The reaction was cooled, diluted with 30mL
of water and extracted with diethyl ether. The organic layer was dried over MgSO4, evaporated and purified by flash chromatography on silica gel eluting with AcOEt and cyclohexane to give pure 4-phenoxy-N-{3-[4-(quinolin-2-ylmethyl)piperazin-1-yl]pyrazin-2-yl}benzenesulfonamide as a yellow solid (419mg, 0.76mmo1, yield: 76%, 97%
HPLC
purity).
MS (ESI+) 553.6, (ESI-) 551.2.
Example 14: 4-methyl-N-13-[4-({methyl[4-(trifluoromethoxy)phenyllaminol-methXl)phenyllpyrazin-2-yl}benzenesulfonamide FY- F
O
\ ~ O I ~
~ 'NH N
N
~,, N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-4-methylbenzenesulfonamide, and N-methyl-4-(trifluoromethoxy)aniline, the title compound was isolated as a yellow solid in 69% yield (94% purity by HPLC).
MS(ESI'): 529.5; MS(ESI-): 526.6.
Example 15: 4-chloro-N-[3-(4-{[methyl(phenyl)aminolmethyl}l)henyl ])yrazin-2-yll-benzenesulfonamide ~
G I ~ N ~ , ~
G'NH
N
~,, N
Following the general method as outlined in Example 1(Method B), starting from 1o chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide, and N-methyl-aniline, the title compound was isolated as a yellow solid in 76% yield (96%
purity by HPLC).
MS(ESI'): 465.6; MS(ESI-): 463.7.
Example 16: 4-cyano-N-{3-[4-(Imethyl[4-(trifluoromethoxy)phenyllaminol-methyl -phenyllpyrazin-2-yl}benzenesulfonamide N~
F
F
p ~ O F
N \
N
Following the general method as outlined in Example 1(Method D), N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-4-cyanobenzenesulfonamide, and N-methyl-4-(trifluoromethoxy)aniline, the title compounds were isolated as a yellow solid in 70% yield (92% purity by HPLC).
5 MS(ESI'): 540.6; MS(ESI-): 538.5.
Example 17: N-[3-(4-{j(4-Fluoro-phenyl -methyl-aminol-methyl}--phenyl)--pyrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F
W F
F ~ F
s. N ~ ~
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-10 (chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-Fluoro-N-methylaniline, the title compound was isolated as a yellow solid in 78%
yield (98% purity by HPLC).
MS(ESI'): 517.9; MS(ESI-): 515.8.
Example 18: N-(3- {4-[(Methyl-phenyl-amino)-methyll-phenyl} -pvrazin-2-Xl)-2-15 trifluoromethyl-benzenesulfonamide F
WF F
~
N ~ ~
O NH
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and N-methylaniline, the title compound was isolated as a yellow solid in 75% yield (99% purity by HPLC).
MS(ESI'): 499.9; MS(ESI-): 497.8.
Example 19: N-[3-(4-{j(4-Cyano-phenyl -methyl-aminol-methyl}--phenyl)--pyrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F
W F
F :N s. N
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-(N-methylamino)benzonitrile, the title compound was isolated as a yellow solid in 71 % yield (94% purity by HPLC).
MS(ESI'): 524.6; MS(ESI-): 522.4.
Example 20: N-{3-[4-(4-Fluoro-phenoxymethXl)-phenyl]-pvrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F
j OF ~ F
O \ ~
O NH
N
~\ \ I
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-fluorophenol, the title compound was isolated as a yellow solid in 67% yield (95% purity by HPLC).
MS(ESI'): 504.6; MS(ESI-): 502.6.
Example 21: N-(3-{4-[(Ethyl-phenyl-amino -methyll-phenLl}--pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide F
W F
F
S. N ~ 1 O NH
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and N-ethylaniline, the title compound was isolated as a yellow solid in 70% yield (96%
purity by HPLC).
MS(ESI'): 513.6; MS(ESI-): 511.7.
Example 22: N-{3-[4-(2.3-Dihydro benzo[1.4]oxazin-4-ylmethXl)-pheMll-pvrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F
W F O
/ F O
O NH
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3,4-dihydro-2H-1,4-benzoxazine, the title compound was isolated as a yellow solid in 65% yield (97% purity by HPLC).
MS(ESI'): 527.7; MS(ESI-): 525.5.
Example 23: N-[3-(4-{j(3-Fluoro-phenyl -methyl-aminol-methyl}--phenyl)--pyrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F
F , S, N ~ /
O NH
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3-Fluoro-N-methylaniline, the title compound was isolated as a yellow solid in 69%
yield (92% purity by HPLC).
MS(ESI'): 517.7; MS(ESI-): 515.6.
Example 24: N-{3-[4-(6-Chloro :pyridin-3-yloxymethXl)-phenLll-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F
W F
F N
G
.S, O 4/
O NH
N\
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-chloro-5-hydroxy-pyridine, the title compound was isolated as a yellow solid in 73% yield (98% purity by HPLC).
MS(ESI'): 522.1; MS(ESI-): 520.1.
Example 25: N-{3-[4-(2-Pyridin-2-yl-indol-1-ylmethyl --phenyll-pyrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F
\ ~ 0F
Q QN
S.
O NH ~ I \
N
'\
N
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-pyridine-2-yl-lH-indole, the title compound was isolated as a yellow solid in 56%
yield (92% purity by HPLC).
MS(ESI'): 586.8; MS(ESI-): 584.6.
Example 26: N-{3-[4-(5-Fluoro-indol-1-ylmethXl)-phenLll-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F F
F
pF ONH N
ol ~\ \ I
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 5-fluoro-indole, the title compound was isolated as a yellow solid in 69% yield (99% purity by HPLC).
5 MS(ESI'): 527.6; MS(ESI-): 525.7.
Example 27: N-[3-(4-Phenoxymethyl-phenyl)--pyrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F
S= O
N\
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-10 (chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and phenol, the title compound was isolated as a yellow solid in 75% yield (98% purity by HPLC).
MS(ESI'): 486.8; MS(ESI-): 484.7.
Example 28: N-[3-(4- { [(4-Chloro-phenXl)-methyl-amino]-methyl } -phenXl)-pvrazin-2-yj1~
15 2-trifluoromethyl-benzenesulfonamide F G
F ~ , --.S, N
O NH
N\
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-chloro-N-methylaniline, the title compound was isolated as a yellow solid in 72%
yield (94% purity by HPLC).
MS(ESI'): 534.1; MS(ESI-): 532.1.
Example 29: 2-Chloro-N-[3-(4-{j(4-cyano-phenyl -methyl-aminol-methyl}--phenylL
pyrazin-2-vll-benzenesulfonamide N
G
O
.S, N-N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(chloro) benzenesulfonamide (Intermediate 8), and 4-(N-methylamino)-benzonitrile, the title compound was isolated as a yellow solid in 52%
yield (99% purity by HPLC).
MS(ESI'): 491.0; MS(ESI-): 489Ø
Example 30: N-[3-4-{[(3.4-Dichloro-phenXl)-methyl-amino]-methyl}-phenXl)-pvrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F G G
F
.S, N
O NH
N\
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3,4-dichloro-N-methylaniline, the title compound was isolated as a yellow solid in 63% yield (91% purity by HPLC).
MS(ESI'): 569.6; MS(ESI-): 565.1.
Example 31: N-{3-[4-4-Cyano-phenoxymethXl)-phenyll-pvrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide N
~ F
F W
~ / F
O
\ \ I
~N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-cyanophenol, the title compound was isolated as a yellow solid in 73% yield (93% purity by HPLC).
MS(ESI'): 511.6; MS(ESI-): 509.6.
Example 32: N-{3-[4-(6-Fluoro-indol-1-ylmethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F
c:F-Q1 S N
O NH
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 6-fluoro-lH-indole, the title compound was isolated as a yellow solid in 77% yield (97% purity by HPLC).
MS(ESI'): 527.8; MS(ESI-): 525.6.
Example 33: 2-Chloro-N-{3-[4-(5-methoxy-2-methyl-indol-1-ylmethXl)-phen1l-pvrazin-2-yl} -benzenesulfonamide a G
O
/ I ~ O~
.S, N ~
ONH H
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(chloro) benzenesulfonamide (Intermediate 8), and 2-methyl-5-methoxyindole, the title compound was isolated as a yellow solid in 72% yield (98% purity by HPLC).
MS(ESI'): 520.2; MS(ESI-): 518.3.
Example 34: N-{3-[4-(4-Methoxy-phenoxymethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F C ~ OF I ~ O"
S, O
O NH
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-hydroxyanisole, the title compound was isolated as a yellow solid in 48% yield (91% purity by HPLC).
MS(ESI'): 516.6; MS(ESI-): 514.5.
Example 35: N-(3- {4-[(Benzyl-pyridin-2-yl-amino)-methyll-phenyl} -pyrazin-2-Xl)-2-1 o chloro-benzenesulfonamide G
.o nI
.S, N /
_\
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(chloro) benzenesulfonamide (Intermediate 8), and 2-benzylaminopyridine, the title compound was isolated as a yellow solid in 35% yield (94% purity by HPLC).
MS(ESI'): 543.3; MS(ESI-): 541.3.
Example 36: N-{3-[4-(2,3-Dihydro-indol-1-ylmethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F F
.S, O NH N
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-5 (chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2,3-dihydro-lH-indole, the title compound was isolated as a yellow solid in 66%
yield (94% purity by HPLC).
MS(ESI'): 511.6; MS(ESI-): 509.4.
Example 37: N-[3-4-{[(2,4-Dichloro-phenXl)-methyl-amino]-methyl}-phenXl)-pvrazin-2-10 yll-2-trifluoromethyl-benzenesulfonamide F CI
F _ F ~ ~ G
~
N~
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2,4-dichloro-N-methylaniline, the title compound was isolated as a yellow solid in 15 69% yield (96% purity by HPLC).
MS(ESI'): 569.6; MS(ESI-): 566.8.
Example 38: N-{3-[4-(3-Chloro-phenoxymethyl -I)henyll-p,yrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F a F _ G~~
F
O
S, N
'\
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3-chlorophenol, the title compound was isolated as a yellow solid in 70% yield (98% purity by HPLC).
MS(ESI'): 521.0; MS(ESI-): 519Ø
Example 39: 2-Chloro-N-[3-(4-{j(2,4-difluoro-phenyl -methyl-aminol-methyI}--phenylL
pyrazin-2-vll-benzenesulfonamide F
aa - p ~ ~ F
.S, N-N\
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(chloro) benzenesulfonamide (Intermediate 8), and 2,4-difluoro-N-methylaniline, the title compound was isolated as a yellow solid in 77%
yield (92% purity by HPLC).
MS(ESI'): 502.0; MS(ESI-): 500Ø
Example 40: N-{3-[4-(2-Methyl-indol-1-ylmethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F F
~ F
o N
~\ \ I
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-methyl-l-H-indole, the title compound was isolated as a yellow solid in 70%
yield (98% purity by HPLC).
MS(ESI'): 523.5; MS(ESI-): 521.5.
Example 41: 2-Chloro-N-{3-[4-(5-fluoro-indol-1-ylmethXl)-pheMll-pyrazin-2-yl}-benzenesulfonamide F C~/ ~ N N
\ /
N
.S' a O
\ ~
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 5-fluoroindole, the title compound was isolated as a yellow solid in 72%
yield (96%
purity by HPLC).
MS(ESI'): 493.9; MS(ESI-): 491.9 Example 42: 2-Chloro-N-[3-(4-{j(2-fluoro-phenyl -methyl-aminol-methyl}-phenyl)-pyrazin-2-vll-benzenesulfonamide N
N
F
HN O
O
Following the general method as outlined in Example 1(Method B), starting from chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide (Intermediate 8), and 2-fluoro-N-methyl-aniline, the title compound was isolated as a yellow solid in 79%
yield (99% purity by HPLC).
MS(ESI'): 484.1; MS(ESI-): 482.1 Example 43: 2-Chloro-N-13-[4-(2-methyl-indol-1-ylmethyl -phenyll-pyrazin-2-I}~
benzenesulfonamide N=) ' N \ \ N
,S' a O
\ ~
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 2-methyl-l-H-indole, the title compound was isolated as a yellow solid in 81% yield (96% purity by HPLC).
MS(ESI'): 490.0; MS(ESI-): 488.1 Example 44: N-(3-{4-[Benzyl-p,yridin-2-yl-amino -methyll-phenLl}--pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide ~ F F y .S O F ~
N
~\
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and N-(2-pyridine)-benzylamine, the title compound was isolated as a yellow solid in 79% yield (98% purity by HPLC).
MS(ESI'): 576.6; MS(ESI-): 574.6.
Example 45: 2-Chloro-N-(3-{4-[(ethyl-pyridin-2-yl-amino)-methyll-phenyl}-pyrazin-2-Xl)-benzenesulfonamide QNiQp HN O
O
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 2-(ethylamino)-pyridine, the title compound was isolated as a yellow solid in 64%
yield (96% purity by HPLC).
MS(ESI'): 481.0; MS(ESI-): 478.1 Example 46: N-{3-[4-(5-Chloro-2-methyl-indol-l-ylmethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F F
wo F G
/ ~ ~
.S, N ~
N\
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-5 (chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-methyl-5-chloroindole, the title compound was isolated as a yellow solid in 71%
yield (95% purity by HPLC).
MS(ESI'): 558.3; MS(ESI-): 556.4.
Example 47: Preparation of a pharmaceutical formulation 10 The following formulation examples illustrate representative pharmaceutical compositions according to the present invention being not restricted thereto.
Formulation 1- Tablets A 2,3-substituted pyrazine sulfonamide derivative of formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of 15 magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active 2,3-substituted pyrazine sulfonamide compound per tablet) in a tablet press.
Formulation 2 - Capsules A 2,3-substituted pyrazine sulfonamide derivative of formula I is admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active 2,3-substituted pyrazine sulfonamide compound per capsule).
Formulation 3 - Liquid A 2,3-substituted pyrazine sulfonamide derivative of formula I(1250 mg), sucrose (1.75 g) and xanthan gum (4 mg) are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously prepared solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water. Sodium benzoate (10 mg), flavor, and color are diluted with water and added with stirring. Sufficient water is then added to produce a total volume of 5 ml.
Formulation 4 - Tablets A 2,3-substituted pyrazine sulfonamide derivative of formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active 2,3-substituted pyrazine sulfonamide compound) in a tablet press.
Formulation 5 - Injection A 2,3-substituted pyrazine sulfonamide derivative of formula (I) is dissolved in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/ml.
BIOLOGICAL ASSAYS
Example 48: Construction of pCEP4-hCRTH2 mammalian expression vector Human CRTH2 cDNA was amplified by PCR using a human urinary bladder cDNA
library as a template and specific primers containing HindIII and BamHI restriction sites for cloning into the pCEP4 vector (Invitrogen). The vector construction is described in detail in Sawyer et al., Br. J. Pharmoco12002, 137, 1163-72. The nucleotide sequence of the cloned cDNA was identical the previously reported hCRTH2 sequence (Nagata et al, 1999, J.
Immunol. 162, 1278-1286).
Example 49: Establishment of a pCEP4-hCRTH2-HEK293 (EBNA) line HEK293 (EBNA) cells were transfected with the pCEP4-hCRTH2 construct using the calcium phosphate technique. Cells were maintained in culture at 37 C in an atmosphere of 5% CO2 in Dulbecco's modified Eagle's F12 medium (Invitrogen), containing 10%
heat-inactivated foetal calf serum (TerraCell International, Canada), 2mM
Glutamine, 100units/ml of penicillin and 100 g/m1 streptomycin (Invitrogen). 48 hours after the transfection, cells were grown in presence of 300 g/ml of Hygromycin B(Invitrogen) for 4 weeks and antibiotic resistant cells were amplified for cell membrane preparation.
Example 50: Preparation of hCRTH2-expressing membranes Adherent HEK293 (EBNA) cells expressing hCRTH2 were cultured in 225 cm2 cell culture flasks (Coming, USA) in 30m1 of medium. After two rinses of phosphate buffered saline (PBS), cells were harvested in lOml of PBS containing 1mM EDTA, centrifuged at 500 x g for 5 min at 4 C and frozen at -80 C. The pellet was re-suspended in 50 mM
Tris-HC1, pH
7.4, 2mM EDTA, 250mM Sucrose, containing protease inhibitor cocktail tablets, (Complete EDTA-free, Roche, Germany) and incubated 30 min at 4 C. Cells were disrupted by nitrogen cavitation (Parr Instruments, USA) at 4 C (800 p.s.i.
for 30 min), and centrifuged at 500 x g for lOmin at 4 C. Pellet containing nuclei and cellular debris was discarded and supematant was centrifuged 60 min at 4 C at 45000 x g. Membrane pellet was re-suspended in storage buffer (10mM HEPES/KOH pH 7.4, 1mM EDTA, 250mM
sucrose, protease inhibitor cocktail tablets) using Dounce homogenization and frozen in liquid nitrogen, and stored at -80 C.
Example 51: Radioligand binding assay The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligand binding assay (Sawyer et al., Br. J. Pharmoco12002, 137, 1163-72). The radioligand binding assay was performed at room temperature in binding buffer (10mM HEPES/KOH pH 7.4, 10mM MnC12, with protease inhibitor cocktail tablets), containing 1.5nM [3H]PGD2 (Amersham, 156 Cie/mmol), and 10 g of hCRTH2 HEK293 (EBNA) cell membrane protein in a fmal volume of l00 1 in 96 well plates (Coming, USA). Non-specific binding was determined in the presence of 1 M PGD2 (Cayman, USA). Competing pyrazine sulfonamides were diluted in dimethylsulphoxide so that the totale volume of dimethylsulfoxide was kept constant at 1% dimethylsulphoxide (Me2S0). 10 1 of the pyrazine sulfonamides were added. Incubation (60min at room temperature) was terminated by rapid filtration through 96 wells hydrophobic GF/C Unifilter plates (Whatman, USA). Filters were washed twice with 250 1 of Tris-HC1 pH 7.4, 10mM MnC12, and residual radioligand bound to the filters was mixed to 100 1 of liquid scintillation cocktail (Optiphase Supermix, Perkin Elmer, USA) and binding activity was determined by counting residual radioligand using a 1450 Micro-beta scintillation counter (Wallac, UK). Results of the binding assay are shown in Table 1.
Table 1 Compound No. Name Structure Inhibition hCRTH2 [%J
1 4-{3-[4-(1H-indol-l- 94.5 -lmethyl)phenyl]pyrazin-2-yl}- N N
- N
HN F
trifluoromethyl)benzenesulfona 61S F
ide Compound No. Name Structure Inhibition hCRTH2 [%J
2 -chloro-N-{3-[4-({methyl[4- , F~F 91.5 trifluoromethoxy)phenyl]amino Ci } -methyl)phenyl]pyrazin-2- 5\NH
N
1} benzenesulfonamide 3 -(3-{4-[(2-ethyl-lH- 86.5 enZimidaz01-1- "
1)methyl]phenyl}pyrazin-2- F N 1)-2-(trifluoromethyl)benzene- o-5 ~ F
sulfonamide ~ i 4 84.5 -chloro-N-[3-(4-{ [methyl(phenyl)amino]methyl}
henyl)pyrazin-2- "~
o-s_o 1]benzenesulfonamide i ~
82.0 -chloro-N-(3-{4-[(2-aphthyloxy)methyl]phenyl}pyr N
zin-2-yl)-benzenesulfonamide HN N_ -s-- - .p ll 6 81.5 -chloro-N-{3-[4-(1H-indol-l-lmethyl)phenyl]-pyrazin-2-yl}- - "
enzenesulfonamide "'s ~o -t Compound No. Name Structure Inhibition hCRTH2 [%J
7 80.0 -chloro-N-(3-{4-[(5,6,7,8-etrahydronaphthalen-2- 0 N
loxy)methyl]-phenyl}pyrazin--y1)benzenesulfonamide HN N
-s-6c, 8 N~ ~ 79.0 -chloro-N-(3-{4-[(2-ethyl-lH- N
enzimidazol-l- ~ ~~
1)methyl]phenyl}pyrazin-2- oso c, 1)benzenesulfonamide 9 < 72.5 ~ /
4-(3-{4-[(1,3-benzodioxol-5- NH
lamino)methyl]-henyl } pyrazin-2-yl)-2-N
trifluoromethyl)benzenesulfona HN
ide 10 , 72.0 -[3-(4-{[(3-ethoxybenzyl)oxy]methyl}phe Yl)pyrazin-2-yl]-2- N~
trifluoromethyl)benzenesulfona o "~-~" F
ide F
11 3-chloro-N-{3-[4-({methyl[4- ' FF F 65.0 trifluoromethoxy)phenyl]-mino}-methyl)phenyl]pyrazin- " i -yl}benzenesulfonamide \
Compound No. Name Structure Inhibition hCRTH2 [%J
12 -[3-(4-1[(4- 65.0 hlorophenyl)(methyl)amino]- ethyl}phenyl)pyrazin-2-yl]-hiophene-2-sulfonamide 13 64.5 I-phenoxy-N-{3-[4-(quinolin-2- ~
lmethyl)piperazin-l-1]pyrazin-2-yl} - s=
N ""
enzenesulfonamide -"x N- I \ \
14 I-methyl-N-{3-[4-({methyl[4- F+F 53.0 trifluoromethoxy)phenyl]-mino}-methyl)phenyl]pyrazin- ~ ""
-yl} benzenesulfonamide N
15 r~NO 51.0 I-chloro-N-[3-(4- " Ho { [methyl(phenyl)amino]methyl}
henyl)pyrazin-2-yl]-enzenesulfonamide "/
16 N'i N 47.0 _ I-cyano-N-{3-[4-({methyl[4- H o -"
trifluoromethoxy)phenyl]-mino}methyl)phenyl]pyrazin- "--yl}benzenesulfonamide o XF
F F
Example 52: Determination of K;(Radioligand bindin agssay) Ki values were determined by equilibrium competition binding experiments against[3H]PGD2. Kl values were calculated from the formula below and represent the average of at least three independent dose response experiments. The Kl values give the ligand concentrations necessary to inhibit 50% of the binding of 3[H]PGD2 to CRTH2.
Ki= IC50/(1+[Concentration of Ligand]/Kd)]
All experiments were performed in 96 well plates, in a final volume of l00 1 according to the above described filtration assay. The concentration of membranes and 3[H]PGD2, as well as the positive and negative controls were identical to the conditions described above.
In one embodiment, the pyrazine sulfonamides of the present invention inhibit CRTH2 at a concentration of <100 M. In another embodiment, the pyrazine sulfonamides of the present invention inhibit CRTH2 at a concentration of <10 M. In a preferred embodiment, the pyrazine sulfonamides of the present invention inhibit CRTH2 at a concentration of <5 M. In a further preferred embodiment, the pyrazine sulfonamides of the present invention inhibit CRTH2 at a concentration of <1 M.
Kl values are shown in Table 2. It can be derived that said compounds according to Formula I showed a significant inhibition of the binding of PGD2 to CRTH2.
Table 2 Compound %,[ MJ Compoun %, [ MJ Compound %, [ MJ
No. No. No.
1 1.01 17 0.38 33 2.21 2 1.26 18 0.40 34 2.60 3 0.45 19 0.47 35 2.64 4 1.57 20 0.48 36 2.69 2.32 21 0.59 37 2.82 6 2.12 22 0.62 38 2.90 7 2.59 23 0.70 39 2.95 8 1.42 24 0.72 40 3.06 9 2.98 25 0.85 41 3.90 1.40 26 0.95 42 3.90 11 5.16 27 1.32 43 4.11 12 8.43 28 1.47 44 4.44 13 4.03 29 1.49 45 4.51 14 5.85 30 1.58 46 4.65 5.38 31 1.59 16 5.71 32 1.93 Example 53: [35S]GTPyS binding assaX
The [35S]GTPyS assay measures the increase in guanine nucleotide exchange at G-proteins in cell membranes, resulting from agonist (PGD2) binding to CRTH2. This process can be monitored in vitro by incubating cell membranes containing G-proteins and CRTH2 with GDP and [35S]GTPyS, a radiolabeled, hydrolysis-resistant analogue of GTP (see, Harrison et al., Life Sciences 74, 489-508, 2003). The addition of a pyrazine sulfonamide results in binding to CRTH2 and thus in an inhibition of agonist binding, which can be monitered as inhibition of the stimulation of GTP/GDP exchange.
Assay conditions were identical to conditions of radioligand binding assay as described in Example 21. The [35S]GTPyS binding assay was performed at 30 C with gentle agitation in 96-well scintillating white polystyrene plates (Perkin Elmer, USA), in a final volume of 200 1, containing 2% of dimethylsulphoxide (Me2SO). The 2,3 substituted pyrazine sulfonamides were incubated in 20mM HEPES/KOH pH 7.4, 10mM MgC12, 10 g/ml Saponin, 3 M GDP, 150mM NaC1 containing 10 g of membranes expressing the hCRTH2 receptor (Euroscreen, Belgium) for 10 min. Non-specific binding was determined in the presence of 10 M of GTPyS. Samples were incubated for 30 min in the presence of increasing concentrations of PGD2 for the determination of agonist activity, or with 8OnM
of PGD2 for determination of antagonist activity, respectively. 0.15nM of [35S]GTPyS were subsequently added to each sample and after incubation of 30min reactions were stopped by centrifugation at 1000 x g, at 4 C for 10 min. Supernatant was removed and [35S]GTPyS
binding was determined using a 1450 Micro-beta scintillation counter. Data were analysed using "Prism" (GraphPad Software, Inc. San Diego, USA). The determination of the IC50 values (i.e. the amount necessary to achieve 50% inhibition of binding (in M)) were performed in 96 well plates, in a final volume of l00 1 according to the above described filtration assay. The concentration of membranes and radioactive ligand, as well as the positive and negative controls were identical to the conditions used and described aboveExamples 21 and 22.
The compound of Example 1 showed an IC50 value of 1.9 M. The compound of Example 2 showed an IC50 value of 4.6 M and the compound of Example 3 showed an IC50 value of 1.4 M.
Example 54: CHS model 5 The contact hypersensitivity model can be used to evaluate the therapeutic efficacy of 2, 3-substituted pyrazine sulfonamides on skin inflammation mediated by T cells.
The model is well established for characterization of compound for dermatological indications like psoriasis and allergic contact dermatitis (Xu et al. J Exp Med. 183, 1001-12, 1996). It involves a sensitization phase and a subsequent challenge with an antigen (DNFB, 2,4-10 dinitrofluorbenzene). This results in skin inflammation with formation of edema and cellular infiltrates in the skin. The edema can be measured by caliper at the challenged site (ear of the mice). Intravenous administration of the compounds of the invention 30 min before challenge with DNFB results in a decrease of the swelling and therefore reduces inflammation in the skin compared to positive controls treated with vehicle only before 15 challenge with the antigen. Negative control mice are not sensitized, but challenged with DNFB, therefore no T cell dependent inflammation occurs and no edema is formed. Balb/c mice are obtained from CharlesRiver (Calcco, Italy). Animals are housed in a conventional animal facility. Treatment starts at an average age of 8 - 12 weeks.
DNFB (2,4-dinitrofluorbenzene) is purchased from Sigma-Aldrich (St.Louis, MO
USA) 20 Sensitization and challenge of CHS by DNFB
Mice are sensitized and challenged to elicit CHS to DNFB. The sensitization phase is followed by a challenge phase. DNFB is diluted in acetone/olive oil (4/1) immediately before use. Mice are sensitized to DNFB by applying 25 1 of 0.5%DNFB solution onto the shaved dorsal skin. Five days later, 10 1 of 0.2% DNFB are applied onto both sides of the 25 right ear (challenge). Ear thickness is monitored on day 6 (1 day affter challenge) using a caliper (Mitutoyo, Milan, Italy). Ear swelling is calculated as ((Tn-T5)right ear - (Tn-T5)left ear), wherein Tn and T5 represent values of ear thickness at day n of investigation and day 5 prior to challenge, respectively.
REFERENCE LIST
Cosmi et al. (2000) Eur. J. Immunol. 30, 2972-2979 Bush, R.K., Georgitis J.W., Handbook of asthma and rhinitis. 1st ed. (1997), Abingdon:
Blackwell Science. 270 Harrison et al.(2003) Life Sciences 74, 489-508 Hirai et al. (2001) J Exp. Med. 193, 255-261 Lewis et al. (1982) J. Immunol. 129, 1627 Matsuoka et al. (2000) Science 287, 2013-2017 Nagata et al. (1999) J. Immunol. 162, 1278-1286 Sawyer et al. (2002) Br. J. Pharmacol. 137, 1163-1172 Woodward et al. (1990) Invest. Ophthalomol Vis. Sci. 31, 138-146 Woodward et al. (1993) Eur. J. Pharmacol. 230, 327-333 Xu et al. (1996) J Exp Med. 183, 1001-12
R N B-A--*~
~
i ( r) N NH
RNN H
R2~S~
O
A specific sub-group of formulae (I ) and (I') are compounds having the formulae (Ia-Id), whereby A, R2 and R3 are defined as above and Z is 0 or S.
Z
N N~
~~ ~
N NH
N NH I
R2~S~ R2~S~
O
(Ia) (Ib) ,A-R3 CN CNXNH
R2'S\__O R2_g\ O
(Ic) (Id) Preferred pharmaceutically acceptable salts of compounds of Formula I, and compounds of sub-groups of Formulae (Ia) - (Id) containing a basic residue such as, for example, a primary, secondary, or tertiary amine or a pyridyl moiety, are acid addition salts formed with pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methane-sulfonate, benzenesulfonate, and para-toluenesulfonate salts.
5 Compounds of the present invention that are particularly suitable for use as a medicament, include in particular those of the group consisting of:
xample ame 4o.
1 -{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-2-trifluoromethyl)benzenesulfonamide -chloro-N- { 3 -[4-( {methyl[4-(trifluoromethoxy)phenyl] amino } -ethyl)phenyl]pyrazin-2-yl } benzenesulfonamide -(3-{4-[(2-ethyl-1 H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)-2-trifluoromethyl)benzenesulfonamide -chloro-N-[3 -(4- { [methyl(phenyl)amino]methyl } phenyl)pyrazin-2-1]benzenesulfonamide e 5 -chloro-N-(3-{4-[(2-naphthyloxy)methyl]phenyl}pyrazin-2-yl)-enzenesulfonamide 6 -chloro-N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-benzenesulfonamide -chloro-N-(3 - { 4-[(5, 6, 7, 8-tetrahydronaphthalen-2-yloxy)methyl]-henyl } pyrazin-2-yl)benzenesulfonamide xample ame 4o.
8 -chloro-N-(3-{4-[(2-ethyl-lH-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-1)benzenesulfonamide -(3 - { 4-[(1,3 -benzodioxol-5 -ylamino)methyl]phenyl } pyrazin-2-yl)-2-trifluoromethyl)benzenesulfonamide T-[3-(4-{[(3-methoxybenzyl)oxy]methyl}phenyl)pyrazin-2-yl]-2-trifluoromethyl)benzenesulfonamide 11 3-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}-ethyl)phenyl]pyrazin-2-yl } benzenesulfonamide 12 -[3-(4-{[(4-chlorophenyl)(methyl)amino]methyl}phenyl)pyrazin-2-yl]-iophene-2-sulfonamide 13 I-phenoxy-N-{3-[4-(quinolin-2-ylmethyl)piperazin-l-yl]pyrazin-2-yl}-enzenesulfonamide 14 I-methyl-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}-ethyl)phenyl]pyrazin-2-yl } benzenesulfonamide I-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]-enzenesulfonamide 16 I-cyano-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]-amino}-ethyl)phenyl]pyrazin-2-yl } benzenesulfonamide 17 T-[3-(4-{[(4-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]--trifluoromethyl-benzenesulfonamide xample ame 4o.
18 -(3-{4-[(Methyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-rifluoromethyl-benzenesulfonamide 19 -[3-(4-{[(4-Cyano-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]--trifluoromethyl-benzenesulfonamide 0 -{3-[4-(4-Fluoro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-enzenesulfonamide 1 -(3-{4-[(Ethyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-rifluoromethyl-benzenesulfonamide 2 1-{3-[4-(2,3-Dihydro-benzo[1,4]oxazin-4-ylmethyl)-phenyl]-pyrazin-2-1} -2-trifluoromethyl-benzenesulfonamide 3 -[3-(4-{[(3-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]--trifluoromethyl-benzenesulfonamide 4 -{3-[4-(6-Chloro-pyridin-3-yloxymethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide T-{3-[4-(2-Pyridin-2-yl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 6 -{3-[4-(5-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 7 -[3-(4-Phenoxymethyl-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-enzenesulfonamide xample ame 4o.
g -[3-(4-{[(4-Chloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]--trifluoromethyl-benzenesulfonamide 9 -Chloro-N-[3-(4-{ [(4-cyano-phenyl)-methyl-amino]-methyl}-phenyl)-yrazin-2-yl]-benzenesulfonamide 0 -[3-(4-{[(3,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin--y1] -2-trifluoromethyl-b enzenesulfonamide 1 T-{3-[4-(4-Cyano-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-enzenesulfonamide 32 1-{3-[4-(6-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 3 -Chloro-N-{3-[4-(5-methoxy-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin--yl} -benzenesulfonamide 4 -{3-[4-(4-Methoxy-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide -(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-hloro benzenesulfonamide 6 -{3-[4-(2,3-Dihydro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 7 -[3-(4-{[(2,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-1]-2-trifluoromethyl-benzenesulfonamide xample ame 4o.
g -{3-[4-(3-Chloro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-enzenesulfonamide 39 -Chloro-N-[3-(4-{ [(2,4-difluoro-phenyl)-methyl-amino]-methyl} -phenyl)-yrazin-2-yl]-benzenesulfonamide p T-{3-[4-(2-Methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide 1 -Chloro-N-{3-[4-(5-fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-enzenesulfonamide 12 -Chloro-N-[3-(4-{ [(2-fluoro-phenyl)-methyl-amino]-methyl} -phenyl)-yrazin-2-yl]-benzenesulfonamide 13 -Chloro-N-{3-[4-(2-methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl} -enzenesulfonamide 14 -(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-rifluoromethyl-benzenesulfonamide 15 -Chloro-N-(3-{4-[(ethyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-1)-benzenesulfonamide 16 T-{3-[4-(5-Chloro-2-methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl}-2-rifluoromethyl-benzenesulfonamide In a second aspect, the invention provides a pharmaceutical composition comprising a 2,3 substituted pyrazine sulfonamide according to Formula (I), together with a pharmaceutically acceptable excipient or carrier.
In a third aspect, the invention provides the use of a 2,3 substituted pyrazine sulfonamide according to formulae (I) for the preparation of a medicament for the treatment and/or prevention of a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and 5 inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis and other diseases with an inflammatory component such as rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity.
In a forth aspect, the invention provides a method for treating and/or preventing a patient 10 suffering from a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and 15 inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity, by administering a 2,3 substituted pyrazine sulfonamide according to Formula (I).
The term "preventing", as used herein, should be understood as partially or totally preventing, inhibiting, alleviating, or reversing one or more symptoms or cause(s) of 20 allergic disease or inflammatory dermatitis.
In a fifth aspect, the invention provides the use of a 2,3 substituted pyrazine sulfonamide of Formula (I) for the preparation of a pharmaceutical composition useful for a variety of therapies, including preventing and/or treating a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or 25 hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity.
The invention provides further the use of a 2,3 substituted pyrazine sulfonamide of Formula (I) for preventing and/or treating a disease selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses, and inflammatory dermatoses such as atopic dermatitis, eczema, allergic contact dermatitis, and urticaria, myositis, neurodegenerative disorders such as neuropatic pain, and other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD) and other diseases and disorders associated with CTRH2 activity.
The compounds of the invention, together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous use). Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
The compounds according to Formula (I) of the present invention are typically administered in form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. Generally, the compounds of this invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
The pharmaceutical compositions of these inventions can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms"
refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the substituted methylene amide derivative according to the invention is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatine;
an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as pepper-mint, methyl salicylate, or orange flavoring.
Injectable compositions are typically based upon injectable sterile saline or phosphate buffered saline or other injectable carriers known in the art. As above mentioned, substituted methylene amide derivatives of Formula (I) in such compositions is typically a minor component, frequently ranging between 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
The above-described components for orally administered or injectable compositions are merely representative. Further materials as well as processing techniques and the like are set out in Part 5 of Remington's Pharmaceutical Sciences, 20t' Edition, 2000, Marck Publishing Company, Easton, Pennsylvania, which is incorporated herein be reference.
The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can also be found in the incorporated materials in Remington's Pharmaceutical Sciences.
In a sixth aspect, the invention provides novel 2,3-substituted pyrazine sulfonamides of Formulae (Ia) - (Id) wherein A, R2, and R3 are defined as described above.
Novel compounds of Formulae (Ia) - (Id) are in particular those of the group consisting of:
N- { 3 - [4 -(1 H-indol-1-ylmethyl)phenyl]pyrazin-2-yl } -2-(trifluoromethyl)benzenesulfonamide, 2-chloro-N- { 3 -[4-( {methyl[4-(trifluoromethoxy)phenyl] amino } -methyl)phenyl]pyrazin-2-yl } benzene sulfonamide, N-(3- {4-[(2-ethyl-1 H-benzimidazol-l-yl)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, 2-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]benzenesulfonamide, 2-chloro-N-(3 - { 4-[(2-naphthyloxy)methyl]phenyl } pyrazin-2-yl)-benzenesulfonamide, 2-chloro-N- { 3-[4-(1 H-indol-1-ylmethyl)phenyl]pyrazin-2-yl} -+benzenesulfonamide, 2-chloro-N-(3 - { 4-[(5,6,7,8 -tetrahydronaphthalen-2-yloxy)methyl]-phenyl }
pyrazin-2-yl)benzenesulfonamide, 2-chloro-N-(3-{4-[(2-ethyl-1 H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)benzenesulfonamide, N-(3-{4-[(1,3-benzodioxol-5-ylamino)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, N-[3-(4-{ [(3-methoxybenzyl)oxy]methyl}phenyl)pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide, 3-chloro-N- { 3-[4-( {methyl[4-(trifluoromethoxy)phenyl]amino } -methyl)phenyl]pyrazin-2-1o yl}benzenesulfonamide, N-[3-(4-{ [(4-chlorophenyl)(methyl)amino]methyl}phenyl)pyrazin-2-yl]-thiophene-sulfonamide, 4-phenoxy-N- { 3-[4-(quinolin-2-ylmethyl)piperazin-1-yl]pyrazin-2-yl} -benzenesulfonamide, 4-methyl-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}-methyl)phenyl]pyrazin-2-yl } benzenesulfonamide, 4-chloro-N-[3 -(4- { [methyl(phenyl)amino]methyl } phenyl)pyrazin-2-yl] -benzenesulfonamide, 4-cyano-N- {3-[4-( {methyl[4-(trifluoromethoxy)phenyl]-amino} -methyl)phenyl]pyrazin-2-yl}benzenesulfonamide, N-[3-(4-{ [(4-Fluoro-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-(3- {4-[(Methyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{ [(4-Cyano-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, 5 N-{3-[4-(4-Fluoro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-(3- {4-[(Ethyl-phenyl-amino)-methyl]-phenyl } -pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N- { 3-[4-(2,3-Dihydro-benzo[ 1,4]oxazin-4-ylmethyl)-phenyl]-pyrazin-2-yl} -2-10 trifluoromethyl-benzenesulfonamide, N-[3-(4-{ [(3-Fluoro-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N- {3-[4-(6-Chloro-pyridin-3-yloxymethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, 15 N-{3-[4-(2-Pyridin-2-yl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N- { 3-[4-(5-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, N-[3-(4-Phenoxymethyl-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, 20 N-[3-(4-{ [(4-Chloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{ [(4-cyano-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-benzenesulfonamide, N-[3 -(4- { [(3,4-Dichloro-phenyl)-methyl-amino]-methyl } -phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(4-Cyano-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N- { 3-[4-(6-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-methoxy-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -1 o benzenesulfonamide, N- {3-[4-(4-Methoxy-phenoxymethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, N-(3 - { 4-[(B enzyl-pyridin-2-yl-amino)-methyl]-phenyl } -pyrazin-2-yl)-2-chloro-benzenesulfonamide, N-{3-[4-(2,3-Dihydro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{ [(2,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N- {3-[4-(3-Chloro-phenoxymethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{ [(2,4-difluoro-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-benzenesulfonamide, N- { 3-[4-(2-Methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -benzenesulfonamide, 2-Chloro-N-[3-(4-{ [(2-fluoro-phenyl)-methyl-amino]-methyl} -phenyl)-pyrazin-2-yl]-benzenesulfonamide, 2-Chloro-N-{3-[4-(2-methyl-indol-l-ylmethyl)-phenyl]-pyrazin-2-yl} -benzenesulfonamide, N-(3 - { 4-[(B enzyl-pyridin-2-yl-amino)-methyl]-phenyl } -pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-(3 - {4-[(ethyl-pyridin-2-yl-amino)-methyl]-phenyl } -pyrazin-2-yl)-benzenesulfonamide, and N- { 3-[4-(5-Chloro-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl} -2-trifluoromethyl-benzenesulfonamide.
In a seventh aspect, the invention provides a method of synthesis of a compound according to formula (Ia)-(Id).
The 2,3 substituted sulfonamides exemplified in this invention may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimisation procedures.
A general description of methods for preparing compounds of Formula (I) is given in WO
04/058265 (PCT/GB03/005668).
The general synthetic approach for obtaining compounds of Formulae (Ia)-(Id) is depicted in Scheme 1. Therein, 2,3-substituted pyrazine sulfonamide derivatives according to the general formula I, may be prepared in 4 to 5 chemical steps, from commercially available 2,3-dichloropyrazine. Synthetic protocols are outlined in Schemes 1 to 10.
Scheme 1 NHZ A = CH21 C(O) R? O 0 CIN L = Cl, Br, coupling agent Cl N X = H, Me, Et, tBu HN
I -) CI N Alkylation R? S=0 R3 = R H or R6-OH
O or as described I I I I I here above L a R R\
B OH H~A (COhCl2or A\ I N R H A N
N coupling agent or X
0-q ~ or SOCI2 ~ R6-OH HN N
HN~~~N HN N R? S=0 R? S=0 R? S=0 1/Suzuki Coupling õ Activation 0 Alkylation 0 21 Deprotection (if needed) 0 or Chlorination or acylation IV V Ia A -z z B, ( )2 A z R a H i A z N CO CI2 or I
OH coupling agent N or ~ _ X~O~A 3 or SOCIz R6-OH N
HN N HN N HN N
1/Suzuki Coupling R? S=0 Activation R 2 -S=0 Alkylation R 2 -S=0 Cl ~ N 21 Deprotection (if needed) 0 or Chlorination p or acylation O
) VI VII lb HN N
R? S=0 III A (CO)zClz or A Ra H A
O N coupling agent N\ or N
X' q or SOCI2 HN N HN N
1/Sonogashira Coupling R? S=0 Activation R? S=0 Alkylation R? S=0 21 Deprotection (if needed) O or Chlorination 0 or acylation 0 VIII IX Ic O~ R3 HN~~ O ~~ N H~~ N A N~ 0 HNIN~ Add HNIN) R3 A L ~NIN
Alkylation R? S=0 Deprotection R? S=0 Alkylation R? S=0 O O or acylation 0 X XI Id In a more specific method, the sulfonamide derivatives XXI, wherein R2 is defined as above is reacted with the 2,3-dichloropyrazine II to give the corresponding 3-chloropyrazine sulfonamide compounds III. Several reaction conditions may be utilized for performing this first reaction step, e.g. by the use of sulfonamide derivative XXI in presence of a base such as cesium carbonate, potassium carbonate or the like.
This reaction may be performed in solvents like NMP, DMF or DMA at various temperature depending on the intrinsic reactivity of compounds XXI and II, by traditional thermic or microwawe method, using standard conditions well known to the person skilled in the art or shown in Scheme 2, below:
Scheme 2 CI N
CI N\ 2 NH2 Cs2CO3, NMP
~ + R-S=0 HN N
CI N 0 1300C R? S=0 II XXI III
The sulfonamide derivatives XXI are obtained from commercial sources or can be prepared by treatment of the corresponding sulfonyl chlorides XX, using standard conditions well known to the person skilled in the art, with a solution of 2M ammonia in EtOH
or dioxane at room temperature for lhour or using can be performed at various temperature depending on the intrinsic reactivity of compounds XXI, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art or shown in the Scheme 3, below.
Scheme 3 i R2 S C=0 NH EtOH R? S=O
ii = 3 30 ii O O
xx xxi The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ia, may be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. A synthetic route is shown in Scheme 4. In a first step, the 2,3-substituted 5 pyrazine sulfonamide derivatives IVa are isolated after condensation of the chloropyrazine sulfonamide compounds III with the boronic acids XXII. This reaction may be performed in presence of appropriated palladium catalysts such as palladium diacetate and in solvents like Dioxane, methanol or solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic 10 reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives Va, whereby the substituent R2 is as above defined, are isolated after chlorination of intermediate compounds IVa in presence of thionyl chloride. This reaction is usually performed at room 15 temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art.
In a following step, as shown in Scheme 4, the 2,3-substituted pyrazine sulfonamide derivatives Va, may be treated with various nucleophiles, e.g. an amine XXIV
or alcohol XXV, wherein R4, R5, R6 are independently selected from the group of hydrogen, alkyl, 20 aryl, heteroaryl, cycloalkyl, heterocycloalkyl or fused ring systems of the mentioned to give the expected 2,3-substituted pyrazine sulfonamide derivative Ia. The nucleophilic displacement of the chlorine atom of the benzylic moiety by the amine XXIV or the alcohol XXV, is accomplished by treatment with an appropriated based such as sodium hydride or potassium tert-butoxide in anhydrous conditions, in presence or absence of e.g. sodium iodine or tetrabutylammonium iodine as catalyst in solvents such as DMF, THF
or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds Va, XXIV and XXV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 4 HO CI
CI N OH Pd(OAc)Z, PPh3, IN\
B,OH K2COs N~ SOCIZ
HN N + H HN N ZHN N
RZ S=0 O Dioxane:MeOH, Rz S-_O DCM, r.t. R S=0 0 110 C ~ 0 I I I xxI I IVa Va R5 A = CH2 R4 Ij XXIV
H R\ 3 CI
NaH, DMF
HN N HN N R3 = or RZ S=O ~ RZ S=O
0 R6-OH ~ R6-O
Va tBuOK, THF la The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ia, may also be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. Another synthetic route is shown in Scheme 5. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives Nb are isolated after condensation of the 3-chloropyrazine sulfonamide compounds III with the boronic acids XXIII. This reaction may be performed in presence of appropriate palladium catalysts such as palladium diacetate and in solvents like Dioxane, methanol or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives Vb, whereby the substituent R2 is as above defined, are isolated either after chlorination of intermediate compounds Nb in presence of oxalyl chloride or after treatment of compounds IVb with an appropriate coupling reagent such as DCC, HATU or Mukayama reagent in presence of a base like DIPEA or triethylamine. These reactions are usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art.
In a fmal step, as shown in Scheme 5, the 2,3-substituted pyrazine sulfonamide derivative Vb, may be treated with various nucleophiles, e.g. an amine XXIV, to give the expected 2,3-substituted pyrazine sulfonamide derivative Ia. The formation of the amide bond is accomplished by treatment with an appropriate base such as DIPEA or triethylamine, in solvents such as DMF, THF or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds Vb and XXIV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 5 L
N
OH Pd(OAc)2, PPh3, p HO I
CII N
B OH K2C03 0 N (CO)ZCl2or ~'-O Jl -) coupling agent HN N
HN N + H HN N R2 S=O
R2 S=O pP Dioxane:MeOH, R2 S-O DMF or DCM, r.t.
~ 0 110 C 0 0 I I I XXI I I IVb Vb A = C(O) L = CI, interemdiate coupling agent L R N R
p N H XXIV ACI N Re I
HN I N HN N R3 =
R2 S=O DMF or DCM, r.t. R2 S=O
Vb la The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ib, may be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. A synthetic route is shown in Scheme 6. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives VIa are isolated after condensation of the 3-chloropyrazine sulfonamide compounds III with the boronic acids XXVI. This reaction may be performed in presence of appropriate palladium catalysts such as palladium diacetate and in solvents like Dioxane, methanol or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives VIIa, whereby the substituent R2 is as above defined, are isolated after chlorination of intermediate compounds VIa in presence of thionyl chloride. This reaction is usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art.
In a following step, as shown in Scheme 6, the 2,3-substituted pyrazine sulfonamide derivatives VIIa, may treated with various nucleophiles, e.g. an amine XXIV or alcohol XXV, to give the expected 2,3-substituted pyrazine sulfonamide derivative lb.
The nucleophilic displacement of the chlorine atom of the benzylic moiety by the amine XXIV
or the alcohol XXV, is accomplished by treatment with an appropriate base such as sodium hydride or potassium tert-butoxide under anhydrous conditions, in presence or absence of e.g. sodium iodine or tetrabutylammonium iodine as catalyst in solvents such as DMF, THF
or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds VIIa, XXIV and XXV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 6 OH L
I ,_z CI N OH Pd(OAc)21 PPh3, N IN_ HNIN\ ~ + H~O~ z ~ OH HN N HN N
? S=O Dioxane:MeOH, R2 S=0 R ~ S=O
11 R 0 1100C 0 DCM, r.t. 0 III XXVI Via Vlla 5 A=CH2 R L=CI
R N XXIV H z = O,S
z NaH, DMF A
Z
N Ra HR N
N
HNN~ R3= or HN N~
R2 S=O xxv R? S=O R6-O
11 p R6-OH 0 Vlla lb tBuOK, THF
The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ib, may also be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. Another synthetic route is shown in Scheme 7. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives VIb are isolated after condensation of the 3-5 chloropyrazine sulfonamide compounds III with the boronic acids XXVII. This reaction may be performed in presence of appropriate palladium catalysts such as palladium diacetate and in solvents like Dioxane, methanol or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave 10 technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives VIIb, whereby the substituent R2 is as above defined, are isolated either after chlorination of intermediate compounds VIb in presence of oxalyl chloride or after treatment of compounds VIb with an appropriate coupling reagent such as DCC, HATU or Mukayama reagent in presence of a 15 base like DIPEA or triethylamine. These reactions are usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art.
In a final step, as shown in Scheme 7, the 2,3-substituted pyrazine sulfonamide derivatives VIIb, may be treated with various nucleophiles, e.g. an amine XXIV, to give the expected 20 2,3-substituted pyrazine sulfonamide derivatives lb. The formation of the amide bond is accomplished by treatment with an appropriate base such as DIPEA or triethylamine, in solvents such as DMF, THF or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds VIIb and XXIV, by traditional thermal method or using microwave technology, using standard conditions well 25 known to the person skilled in the art.
Scheme 7 OH L
CI N OH Pd(OAc)2, PPh3, O N (CO)2CI2 or O z ' ~ 'Jl B OH K2C03 coupling agent N
z ~Jl ~
HN N
RZ S=O + H' O Dioxane:MeOH, RZ HS=O N DMF or DCM, r.t. RZ HS-O N
O
III xxVll Vib Vllb A = C(O) L = CI, intermediate coupling agent RS z = O, S
L R -N R z N
i I ' I H
XXIV A LR_51 \Jl ~ R3 =
~
HN N DMF or DCM, r.t. 2 HN N
R2 S=0 R-S=0 Vllb lb The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ic, may be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. A synthetic route is shown in Scheme 8. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives VIIIa are isolated after condensation of the chloropyrazine sulfonamide compounds III with the acetylene XXVIII. This reaction may be performed in the presence of appropriate palladium catalysts such as palladium triphenyl phosphine tetrakis or Pd(Ph3)2C12 in presence of cupper iodine and potassium acetate, in solvents like Dioxane, DMF or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives IXa, whereby the substituent R2 is as above defined, are isolated after chlorination of intermediate compounds VIIIa in presence of thionyl chloride. This reaction is usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art In a following step, as shown in Scheme 8, the 2,3-substituted pyrazine sulfonamide derivatives IXa, may be treated with various nucleophiles, e.g. an amine XXIV
or alcohol XXV, to give the expected 2,3-substituted pyrazine sulfonamide derivatives Ic.
The nucleophilic displacement of the chlorine atom of the benzylic moiety by the amine XXIV
or the alcohol XXV, is accomplished by treatment with an appropriate base such as sodium hydride or potassium tert-butoxide under anhydrous conditions, in presence or absence of e.g. sodium iodine or tetrabutylammonium iodine as catalyst in solvents such as DMF, THF
or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds IXa, XXIV and XXV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 8 OH L
CH3COOK, DMF l CI N 100 C, Cul N N
SOCIZ HNN
HN ~ N~ + H"O/ I
HN N
R? S=O Pd(Ph3)2CI2or Pd(Ph3)a R? S-O DCM, r.t. R? S=O
III XXVIII Villa IXa A = CH2 R5 XXIV L = CI
Ra-N
NaH, DMF
HN N A, R5 IN_ HNNN
~ R3 R or S=0 xxV R? S=O R6-O
p R6-OH p IXa Ic tBuOK, THF
The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Ic, may also be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. Another synthetic route is shown in Scheme 9. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives VIIIb are isolated after condensation of the 3-chloropyrazine sulfonamide compounds III with the acetylene XXIX. This reaction may be performed in the presence of appropriate palladium catalysts such as palladium triphenyl phosphine tetrakis or Pd(Ph3)2C12 in presence of cupper iodine and potassium acetate, in solvents like Dioxane, DMF or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives IXb, whereby the substituent R2 is as above defined, are isolated either after chlorination of intermediate compounds VIIIb in the presence of oxalyl chloride or after treatment of compounds VIIIb with an appropriate coupling reagent such as DCC, HATU or Mukayama reagent in presence of a base like DIPEA or triethylamine. These reactions are usually performed at room temperature in solvent like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art In a fmal step, as shown in Scheme 9, the 2,3-substituted pyrazine sulfonamide derivatives IXb, may be treated with various nucleophiles, e.g. an amine XXIV, to give the expected 2,3-substituted pyrazine sulfonamide derivative Ic. The formation of the amide bond is accomplished by treatment with an appropriate base such as DIPEA or triethylamine, in solvents such as DMF, THF or similar solvents. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds IXb and XXIV, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 9 OH L
CI N CH3COOK, DMF O N (CO)2CI2 or O ~ N
~ H,O' 100 C, Cul I 1 coupling agent ~
' + HN N HN N
HN N
I
2 O R? S=O DMF or DCM, r.t. R-S=O
R-S=0 Pd(Ph3)2CI2 or Pd(Ph3)4 0 0 0 xxix III Vlllb IXb A = C(O) L = CI, coupling agent R5 Ra z=O,S
L
R4 N A s O N H XXIV R
xN:] N R3 =
R? S=O DMF or DCM, r.t. R? S=0 u i IXb Ic The 2,3-substituted pyrazine sulfonamide derivatives according to the general formula Id, may be obtained in 3 subsequent steps depending the availability of starting materials and building blocks. A synthetic route is shown in Scheme 10. In a first step, the 2,3-substituted pyrazine sulfonamide derivatives X are isolated after condensation of the 3-chloropyrazine sulfonamide compounds III with the piperazine-l-carboxylic acid tert-butyl ester XXX.
This reaction may be performed in presence of an appropriate base such as DIPEA or triethylamine, in solvents like NMP, DMF or a solution containing both solvents in various ratios. This reaction can be performed at various temperatures depending on the intrinsic reactivity of compounds III, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
In a subsequent step, the 2,3-substituted pyrazine sulfonamide derivatives XI, whereby the substituent R2 is deprotected under acidic conditions using either TFA or HC1 solution at different concentrations. This reaction is usually performed at room temperature in solvents like dichloromethane, dichloroethane or DMF, using standard conditions well known to the person skilled in the art. In a following step, as shown in Scheme 10, the 2,3-substituted pyrazine sulfonamide derivatives X, may be treated either with various electrophiles, e.g.
an alkyl halide XXXIa in the presence of an appropriate base such as Cs2CO3, DIPEA or triethylamine, or also with an acyl chloride or a carboxylic acid XXXIb initially 5 preactivated by treatment with an appropriate coupling reagent such as DCC, Mukayama reagent, PyBrop, in order to give the expected 2,3-substituted pyrazine sulfonamide derivative Id. The nucleophilic displacement of the halide atom or the formation of the amide bond respectively, with the alkyl halide XXXIa or acyl chloride or carboxylic acid XXXIb can be performed at various temperatures depending on the intrinsic reactivity of 10 compounds XI, XXXIa or XXXIb, by traditional thermal method or using microwave technology, using standard conditions well known to the person skilled in the art.
Scheme 10 0, HN~
O ONIN, ~N N
IIICIN' ~ 0 DIPEA, DMF
'Jl N~O or NMP, 1400C TFA or HCI ~
~ HN N
HN N + HN J~ HN N 2' i =0 R2 S=0 R? S-O DCM, r.t. R-S11 'O' 11 O
O
III xxx x XI
A = CH2 XXXIa I
HN Cs2CO3, DMF '4, 3XN
~N
J
~
N
R? S= 0 R3-A-L 2' HN=0 -S
p A = C(O) XXXIb R
XI DIPEA, THF
Id The following abbreviations refer respectively to the definitions below:
min (minute), hr (hour), g(gram), MHz (Megahertz), ml (milliliter), mmol (millimole), mM (millimolar), RT (room temperature), ATP (Adenoside Triphosphate), BSA
(Bovine Serum Albumin), DCM (dichloromethane), DCC (dicyclohexylcarbodiimide), DIPEA
(di-isopropyl ethylamine), DMSO (Dimethyl Sulfoxide), Mukayama reagent (1-methyl-2-chloropyridinium iodide), DMF (Dimethylformamide), CsCO3 (Cesium carbonate), cHex (Cyclohexanes), Et3N (Triethylamine), EtOAc (Ethyl acetate), EtOH (Ethanol), (potassium carbonate), NaI (Sodium Iodine), NaH (Sodium hydride), NaHCO3 (Sodium bicarbonate), NH4C1 (Ammonium chloride), TEA (Triethyl amine), TFA
(Trifluoroacetic acid), THF (Tetrahydrofuran), Pd(PPh3)4 (Palladium triphenylphosphine tetrakis), CuI
(Copper iodide), Pd(OAc)2(Palladium II acetate), Pd(PPh3)2 C12 (Bis(triphenylphosphine) Palladium II Chloride), CH3COOK (Potassium acetate), PPh3 (Triphenylphosphine), HATU (N,N,N',N'-Tetramethyl-O-(7-Azabenzotriazol-1-yl)uranium hexafluorophosphate, (CO)2C12 (Oxalyl chloride), SOC12 (Thionyl chloride), tBuOK (Potassium tert-butoxide), MeOH (Methanol), MgS04 (Magnesium sulfate), NMP N-Methyl pyrrolidinone, PetEther (Petroleum ether), rt (room temperature). HPLC (High Performance Liquid Chromatography), FC (Flash Chromatography on silica gel), MS (Mass Spectrometry), NMR (Nuclear Magnetic Resonance), PBS (Phosphate Buffered Saline), SPA
(Scintillation Proximity Assay), TLC (Thin Layer Chromatography), UV (Ultraviolet).
If the above set of general synthetic methods is not applicable to obtain compounds according to Formula (I) and/or necessary intermediates for the synthesis of compounds of Formula (I), suitable methods of preparation known by a person skilled in the art should be used. In general, the synthesis pathways for any individual compound of Formula (I) will depend on the specific substituents of each molecule and upon the ready availability of intermediates necessary; again such factors being appreciated by those of ordinary skill in the art. For all the protection and deprotection methods, see Philip J.
Kocienski, in "Protecting Groups", Georg Thieme Verlag Stuttgart, New York, 1994 and, Theodora W.
Greene and Peter G. M. Wuts in "Protective Groups in Organic Synthesis", Wiley Interscience, 3rd Edition 1999.
Compounds of this invention can be isolated in association with solvent molecules by crystallization from evaporation of an appropriate solvent. The pharmaceutically acceptable acid addition salts of the compounds of Formula (I), which contain a basic center, may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of compound of Formula (I) with a suitable base. Both types of salts may be formed or interconverted using ion-exchange resin techniques.
In the following the present invention shall be illustrated by means of some examples, which are not construed to be viewed as limiting the scope of the invention.
EXPERIMENTAL PART
The HPLC, NMR and MS data provided in the examples described below are obtained as followed: HPLC: column Waters Symmetry C8 50 x 4.6 mm, Conditions: MeCN/H2O, 5 to 100% (8 min), max plot 230-400 nm; Mass spectra: PE-SCIEX API 150 EX (APCI and ESI), LC/MS spectra: Waters ZMD (ES); 1H-NMR: Bruker DPX-300MHz.
The preparative HPLC purifications are performed with HPLC Waters Prep LC 4000 System equipped with columns Prep Nova-Pak HR C186 m 60A, 40x30mm (up to 100mg) or with XTerra Prep MS C8, 10 m, 50x300mm (up to lg). All the purifications are performed with a gradient of MeCN/H2O 0.09% TFA. The semi-preparative reverse-phase HPLC are performed with the Biotage Parallex Flex System equipped with columns SupelcosilTM ABZ+Plus (25 cm x 21.2 mm, 12 m); UV detection at 254 nm and 220 nm;
flow 20 mL/min (up to 50 mg). TLC Analysis is performed on Merck Precoated 60 plates. Purifications by flash chromatography are performed on Si02 support, using cyclohexane/EtOAc or DCM/MeOH mixtures as eluents.
Intermediate 1: 2-(trifluoromethyl)benzenesulfonamide (cf. Scheme 3, compound XXI) O F
H2N-S'O F
F
To a solution of 2-(trifluoromethyl)benzenesulfonyl chloride (5g; 20.44 mmol;
1.00 eq.) in anhydrous THF (5.00 ml) was added a solution of 71 ml Ammonia in Ethanol 2M
under nitrogen at room temperature. The reaction mixture was shaken for 20h at room temperature. The solvent was evaporated and the residue redissolved in EtOAc(150mL) and then washed with NH4C1 saturated aqueous solution (50mL) and brine (50mL). The organic layer was dried over MgSO4, filtered and the solvent evaporated to give the pure 2-(trifluoromethyl)benzenesulfonamide as a yellowish solid (4.6g, 89% yield, 98.6% HPLC
purity). This compound was utilized as such for the next reaction.
1H NMR (300MHz, CDC13); 5.0 (m, 2H), 7.6 (m, 2H), 7.8 (m, 1H), 8.3 (m, 1H).
MS(ESt):
224.1.
Intermediate 2: 2-chloro-N-(3-chloropyrazin-2-yl)benzenesulfonamide (cf. Scheme 2, compound III) f~N
N~ I ~
S~O CI EI:CI
2,3-dichloropyrazine (1g; 6.71 mmol; 1.00 eq.) and 2-dichlorobenzenesulfonamide (1.29g;
6.71mmo1; 1.00 eq.) were stirred in NMP (9m1). To this reaction mixture was added cesium carbonate (2g; 6mmol; 0.90 eq.) and the reaction mixture was stirred and heated up to 130 C for 20h. The reaction was cooled down to room temperature, added to water 98m1 and washed with AcOEt (2x30m1). The aqueous phase was acidified with citric acid and extraced with AcOEt (3x60m1). The organic extracts were combined, washed with brine (lOml), dried over MgSO4 and evaporated down. The residue was purified by Flash master using a gradient AcOEt/cHex 2:8 to AcOEt 100% in 45 min, the title compound was isolated, after filtration and evaporation. The solid was recrystallized in a mixture EtOAc:Chex (30:70) to give the pure 2-chloro-N-(3-chloropyrazin-2-yl)benzene sulfonamide as a yellowish solid (lg, 49% yield, 100%HPLC purity).
1H NMR (300MHz, CDC13); 7.3-7.5 (m, 3H), 7.8-8.0 (m, 3H), 8.3 (m, 1H).
MS(ESI+):
304.1; MS(ESI-): 302Ø
Intermediate 3: N-(3-chloropyrazin-2-Xl)-~trifluoromethXl)benzenesulfonamide (cf.
Scheme 2, compound III) f~N
F
N / ~ F
N-S;O
CI H / ~ F
~
Following the general method as outlined for Intermediate 2, starting from 2,3-dichloropyrazine and 2-(trifluoromethyl)benzenesulfonamide, the title compound was isolated, after evaporation and recrystallization, as a yellowish solid in 63%
yield (97 %
purity by HPLC).
1H NMR (300MHz, CDC13); 7.6-7.8 (m, 4H), 7.9-8.1 (m, 2H), 8.5 (m, 1H).
MS(ESI+):
338.0; MS(ESI-): 336Ø
Intermediate 4: 2-chloro-N-{344-(hydroxymethyl phenyl]pyrazin-2-VI} benzene sulfonamide (cf. Scheme 4, compound IVa) ~
N
N~ I 0,, N_S;O H bC' HO
5 2-chloro-N-(3-chloropyrazin-2-yl)benzenesulfonamide (2.2g; 7.23 mmol; 1.00 eq.) and 4-hydroxymethyl benzene boronic acid (1.21g; 7.96 mmol; 1.10 eq.) were dissolved in 48mL
of a 1:1 mixture of Dioxane:MeOH that was previously degassed. Potassium carbonate (2.75g; 19.89 mmol; 2.75 eq.) and triphenylphosphine (284.58 mg; 1.08 mmol;
0.15 eq.) were added to the reaction mixture under nitrogen, followed by palladium II
(81.19 mg;
10 0.36 mmol; 0.05 eq.). The reaction mixture was then heated at 110 C under N2 for 30minutes. The reaction mixture was cooled down to room temperature, diluted with diethyl ether (50mL) and water (25mL) and filtered through celite. The aqueous layer was separated and the organic layer washed with water (50mL). The combined aqueous solutions were washed with diethyl ether (50mL), then acidified aqueous layer with HC1 15 5N and extracted with AcOEt. The organic extracts were combined, washed with brine (lOml), dried over MgS04 and evaporated down to give the pure 2-chloro-N-{3-[4-(hydroxymethyl)phenyl]pyrazin-2-yl} benzene sulfonamide as a yellowish solid (2.5g, 91%
yield, 98% HPLC purity). This compound was used as such for the next reaction.
1H NMR (300MHz, CDC13); 4.68 (m, 2H), 7.5-7.7 (m, 7H), 8.1-8.2 (m, 3H), 8.3 (m, 1H).
20 MS(ESI'): 376.1; MS(ESI-): 374.1.
Intermediate 5: 2-trifluoromethyl-N-{3-f4-(hydroxymethyl -phenyl{pyrazin-2-yl}
benzene sulfonamide (cf. Scheme 4, compound IVa) ~N
~ F
N,S;O
H F
\ ~ ~\
HO
Following the general method as outlined for Intermediate 4, starting from N-(3-chloropyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide and 4-hydroxymethyl benzene boronic acid, the title compound was isolated, after evaporation and recrystallization, as a yellowish solid in 85% yield (97 % purity by HPLC).
1H NMR (300MHz, CDC13); 4.83 (m, 2H), 7.5-7.9 (m, 8H), 8.1 (m, 1H), 8.3 (m, 1H), 8.64 (m, 1H). MS(ESI+): 410.3; MS(ESI-): 408.5.
Intermediate 6: 4-(3-{I(2-chlorophenyl sulfonyllamino}pyrazin-2-yl)benzoic acid (cf. Scheme 5, compound Nb) / N
N~S~O H bC' HO O
Following the general method as outlined for Intermediate 4, starting from 2-chloro-N-(3-chloropyrazin-2-yl)benzenesulfonamide and 4-carboxybenzene boronic acid, the title compound was isolated, after evaporation and recrystallization, as a yellowish solid in 83%
yield (96 % purity by HPLC).
1H NMR (300MHz, CDC13); 7.5-7.7 (m, 4H), 7.9-8.0 (m, 2H), 8.1-8.4 (m, 5H).
MS(ESI+):
390.8; MS(ESI-): 388.9.
Intermediate 7: 4-(3-{j(2-trifluorometh~~phenyl sulfonyllamino}pyrazin-2-yl)benzoic acid (cf. Scheme 5, compound IVb) ~N
N~ ~ ~ F
,S;O
N F
H
/ ~ F
~
HO O
Following the general method as outlined for Intermediate 4, starting from N-(3-chloropyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide and 4-carboxybenzene boronic acid, the title compound was isolated, after evaporation and recrystallization, as a yellowish solid in 80% yield (98 % purity by HPLC).
MS(ESI+): 424.4; MS(ESI-): 422.2.
Intermediate 8: 2-chloro-N-{3-f4-(chloromethyl -phenyl]pyrazin-2-~}benzene-sulfonamide (cf. Scheme 4, compound Vb) ~N
N~ I ~
N_S~O H 6C' CI
2-chloro-N-{3-[4-(hydroxymethyl)phenyl]pyrazin-2-yl} benzene sulfonamide (3.15g; 8.4 mmol; 1.00 eq.) was dissolved in dichloromethane (8OmL) and thionyl chloride (8.5mL, 117mmo1, 14eq.) was added dropwise. The reaction mixture was stirred overnight. The reaction mixture was poured carefully into ice/water (200mL) and stirred until clear layers were formed. The mixture was separated and the organic layer was dried over MgSO4 and evaporated down to give the crude solid which was recrystallsied in AcOEt/cyclohexane to give the pure 2-chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide as a white solid (3.02 g, 95% yield, 99% HPLC purity).
1H NMR (300MHz, CDC13); 4.69 (m, 2H), 7.45-7.6 (m, 3H), 7.65-7.7 (m, 5H), 8.0 (m, 1H), 8.3 (m, 1H), 8.38 (m, 1H). MS(ESI+): 396.1; MS(ESI-): 393.1.
Intermediate 9: N-13-[4-(chloromethyl -phenyl]pyrazin-2-vl}-2-(trifluoromethyl) benzenesulfonamide (cf. Scheme 4, compound Vb) ~N
N~ ~ ~ F
NS;O
H F
\ ~ ~\
CI
Following the general method as outlined for Intermediate 8, starting from 2-trifluoromethyl-N-{3-[4-(hydroxymethyl)phenyl]pyrazin-2-yl} benzene sulfonamide and thionyl chloride, the title compound was isolated, after evaporation and recrystallization, as a white solid in 96% yield (97 % purity by HPLC).
MS(ESI+): 428.9; MS(ESI-): 426.7.
Intermediate 10: N-[3-(3-hydroxyprop-l-yn-1-Xl)pyrazin-2-yll-~trifl uoromethXl) benzenesulfonamide (cf. Scheme 8, compound VIIIa) f~N
N~ 0 F
N,S;o " F
Method A:
N-(3-chloropyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide (1.35g; 4.0 mmol; 1.00 eq.) and 2-propyn-l-ol (336mg; 6.0 mmol; 1.5 eq.) were dissolved in lOmL of DMF under nitrogen atmosphere. To the reaction mixture was added CH3COOK (588mg; 6.0 mmol;
1.5 eq.) and Pd(PPh3)4 (232 mg; 0.2 mmol) under nitrogen. The reaction mixture was then heated at 100 C under nitrogen for 2hours. After removal of the solvent by distillation in vacuo, the residue was triturated with water (40mL) and extracted with diethyl ether (3x3OmL). The organic layer was dried over MgSO4 and evaporated down. The crude product was purified by silica gel column chromatography using a mixture of hexane and AcOEt to give pure N-[3-(3-hydroxyprop-1-yn-1-yl)pyrazin-2-yl]-2-(trifluoromethyl) benzenesulfonamide as a yellowish solid (686mg, 48% yield, 98% HPLC purity).
Method B:
N-(3-chloropyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide (1.35g; 4.0 mmol; 1.00 eq.) and 2-propyn-l-ol (336mg 6.0 mmol; 1.5 eq.) were dissolved in lOmL of DMF
under nitrogen atmosphere. To the reaction mixture was added CH3COOK (588mg; 6.0 mmol;
1.5 eq.) CuI (40mg; 0.2 mmol; 0.05 eq.) and Pd(PPh3)2C12 (28mg; 0.04 mmol) under nitrogen. The reaction mixture was then heated at 100 C under nitrogen for 2hours. After removal of the solvent by distillation in vacuo, the residue was triturated with water (4OmL) and extracted with diethyl ether (3x30mL). The organic layer was dried over MgSO4 and evapored down. The crude product was purified by silica gel column chromatography using a mixture of hexane and AcOEt to give pure N-[3-(3-hydroxyprop-1-yn-1-yl)pyrazin-2-yl]-2-(trifluoromethyl) benzenesulfonamide as a yellowish solid (702mg, 50% yield, 98%
HPLC purity).
MS(ESI'): 358.6; MS(ESI-): 356.5.
Intermediate 11: N-(3--pi-perazin-l-vlpyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide (cf. Scheme 10, compound XI) ~N
;O F
F
CN H F
H
5 tert-butyl 4-[3-({[2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrazin-2-yl]piperazine-l-carboxylate (1.46g, 3mmol) was dissolved in dichloromethane (50mL) and trifluoroacetic acid (4.5g, 40mmo1) was added at 0 C. The reaction mixture was stirred for 2h.
The solvents were evaporated and the residue redissolved in dichloromethane (50m1) and evaporated to dryness to give the expected product N-(3-piperazin-1-ylpyrazin-2-yl)-2-10 (trifluoromethyl)benzenesulfonamide as a yellow solid (1.1g, 95% yield, 95 % purity by HPLC).
MS(ESI'): 388.4; MS(ESI-): 386.3.
Example 1: General procedure for the synthesis of 2,3-substituted pyrazine sulfonamide 15 derivatives of general formula I. with A and Z as above defined (Schemes 1, 4, 5, 6, 7, 8, 9 and 10): N-{3-f4-(1H-indol-1-ylmethyl -phenyl]pyrazin-2-yl}-2-(trifluoromethyl benzene-sulfonamide N N-N
HN pF F
~ S' F
Method A:
To a solution of 1H-Indole (234mg, 2.Ommol, leq) in dimethylformamide (lOmL) was added sodium hydride (80mg, 2mmol, leq). After the evolution of hydrogen ceased, N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (intermediate 26) (854mg, 2mmol, leq) in dimethylformamide (5mL) was added and the reaction mixture heated to 80 degrees over 3hours. The reaction was cooled, diluted with 30mL of water and extracted with diethyl ether. The organic layer was dried over MgSO4, evaporated and purified by flash chromatography on silica gel eluting with AcOEt and cyclohexane to give pure N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl)benzenesulfonamide as a yellow solid (630mg, 1.24mmo1, yield:
62%, 97% HPLC purity).
Method B:
N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzene sulfonamide (intermediate 26) (854mg, 2mmol, leq) and 1H-Indole (234mg, 2.Ommol, leq) were shaken in tetrahydrofuran (20mL) and heated up to 50 degrees for lOminutes. To the reaction mixture was added potassium tert-butoxide (4.5mL of a 1M solution in THF). The reaction mixture was maintained to 50 degrees for 5h, and then cooled down to room temperature. The reaction mixture was treated with 10m1 of an aqueous citric acid solution (20g in lOOmL of water) and extracted with AcOEt. The organic layer was dried over MgSO4 and evaporated. The crude was purified similarly to Method A to give pure N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl)benzenesulfonamide as a yellow solid (691mg, 1.36mmol, yield: 68%, 98% HPLC purity).
N-{3-[4-(1H-indol-l-ylmethyl vhenyl]pyrazin-2-yl}-2-(trifluoromethyl benzene sulfonamide: yellow solid; 'H NMR (300 MHz, CDC13); 5.50 (m, 2H), 6.5 (m, 1H), 7.0-7.2 (m, 2H), 7.4-7.65 (m, 8H), 7.65-7.7 (m, 2H), 8.0 (m, 2H), 8.3 (m,1H), 8.38 (m,1H). MS
(ESI+) 509.5, (ESI-) 507.6.
Example 2: 2-chloro-N-{3-[4-(Imethyl[4-(trifluoromethoxx)phenyllamino}-methXl)-phenyl]pyrazin-2-vl} benzenesulfonamide F F
G ~ F
\ ~ p .NH ~Na N
k~-,N
Following the general methods as outlined in Example 1(Method B), starting from 2-chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and N-methyl-4-(trifluoromethoxy)aniline, the title compound was isolated as a yellow solid in 72% yield (99% purity by HPLC).
MS(ESI'): 550.1; MS(ESI-): 547.8.
Example 3: N-(3-{4-[(2-ethyl-lH-benzimidazol-l-yl methyllphenyl}vyrazin-2-yl)-(trifluoromethyl)benzenesulfonamide N
r N-N \ \ ~
N
HN OF
"S, O F
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-ethylbenzimidazole, the title compound was isolated as a yellow solid in 63%
yield (96% purity by HPLC).
MS(ESI'): 538.6; MS(ESI-): 536.5.
Example 4: 2-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yi1' benzenesulfonamide N
I
~ N
HN N
0=S=0 G
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and N-methyl-aniline, the title compound was isolated as a yellow solid in 83%
yield (99%
purity by HPLC).
MS(ESI'): 465.6; MS(ESI-): 463.8.
Example 5: 2-chloro-N-(3-{4-[(2-naphthyloxy methyllphenyl}yyrazin-2-yl benzene-sulfonamide N
N
G
0 / HN. 0 \ I / O ~
Following the general method as outlined in Example 1(Method A), starting from chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide (Intermediate 8), and 2-hydroxy naphthalene, the title compound was isolated as a yellow solid in 72% yield (99% purity by HPLC).
MS(ESI'): 503.4; MS(ESI-): 501.2.
Example 6: 2-chloro-N-{3-[4-(1H-indol-l-ylmethyl vhenyljvyrazin-2-yl}benzene-sulfonamide N \
N
HN.
O
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 1-H-Indole, the title compound was isolated as a yellow solid in 71% yield (98% purity by HPLC).
MS(ESI'): 475.9; MS(ESI-): 473.5.
Example 7: 2-chloro-N-(3-{4-[(5,6,7,8-tetrahydronaphthalen-2-yloxy methyll-phenyl}-pvrazin-2-Xl)benzenesulfonamide N
N
O I / HN,S
al~ O
Following the general method as outlined in Example 1(Method B), starting from 5 chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide (Intermediate 8), and 6-hydroxy-1,2,3,4-tetrahydronaphtalene, the title compound was isolated as a yellow solid in 69% yield (99% purity by HPLC).
MS(ESI'): 507.6; MS(ESI-): 505.2.
Example 8: 2-chloro-N-(3-{4-[(2-ethyl-lH-benzimidazol-l-Xl)methyllphenyl}pvrazin-2-10 yl)benzenesulfonamide N
N-N ~\
N
HN O
,S" G
O
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 2-ethyl benzimidazole, the title compound was isolated as a yellow solid in 65% yield 15 (96% purity by HPLC).
MS(ESI'): 505.4; MS(ESI-): 503.2.
Example 9: N-(3-{4-[(1,3-benzodioxol-5-ylamino methyl]pheMl}l)yrazin-2-yl)-2-(trifluoromethXl)benzenesulfonamide N~
H \ N F F
~ N I i HN O F
I
~ ~ O
O
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3,4-(methylenedioxy)aniline, the title compound was isolated as a yellow solid in 69% yield (96% purity by HPLC).
MS(ESI'): 529.7; MS(ESI-): 527.5.
Example 10: N-[3-4-{[(3-methoxybenzXl)oxy]methyl}phenXl)p3razin-2-yll-2-(trifluoromethXl)benzenesulfonamide N
0~ N F F
HN O F
~ I O O
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3-anisyl alcohol, the title compound was isolated as a yellow solid in 64% yield (92% purity by HPLC).
MS(ESI'): 530.4; MS(ESI-): 528.8.
Example 11: 3-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyllamino}methyl) phenLIlpyrazin-2-yl} benzenesulfonamide a F'I- F
F
O O
OS.NH
N
~,, N
Following the general method as outlined in Example 1(Method B), starting from chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide, and N-methyl-4-(trifluoromethoxy)aniline, the title compound was isolated as a yellow solid in 69% yield (94% purity by HPLC).
MS(ESI'): 550.2; MS(ESI-): 547.6.
Example 12: N-[3-(4-{ [(4-chlorophenXl)(methXl)amino]methyl}phnXle)~pvrazin-2-~1~
thiophene-2-sulfonamide O
,S.
G ~ I N / I N
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}thiophene-2-sulfonamide, and N-methyl-4-chloro aniline, the title compound was isolated as a yellow solid in 69% yield (94%
purity by HPLC).
MS(ESI'): 472.8; MS(ESI-): 470.7.
Example 13: 4-phenoxy-N-{3-[4-(guinolin-2-ylmethyl)-pi-perazin-l-yl]pyrazin-2-yl}~
benzenesulfonamide i I
N
0'NH ~N
N~Nv ~,, N
To a solution of 4-phenoxy-N-(3-piperazin-1-ylpyrazin-2-yl)benzenesulfonamide (411mg, 1.0mmo1, 1eq) in dimethylformamide (10mL) was added 2-(chloromethyl)quinoline hydrochloride (214mg, lmmol, leq) and DIPEA (322mg, 2.5mmol, 2.5eq). The reaction mixture was heated to 50 degrees over lhour. The reaction was cooled, diluted with 30mL
of water and extracted with diethyl ether. The organic layer was dried over MgSO4, evaporated and purified by flash chromatography on silica gel eluting with AcOEt and cyclohexane to give pure 4-phenoxy-N-{3-[4-(quinolin-2-ylmethyl)piperazin-1-yl]pyrazin-2-yl}benzenesulfonamide as a yellow solid (419mg, 0.76mmo1, yield: 76%, 97%
HPLC
purity).
MS (ESI+) 553.6, (ESI-) 551.2.
Example 14: 4-methyl-N-13-[4-({methyl[4-(trifluoromethoxy)phenyllaminol-methXl)phenyllpyrazin-2-yl}benzenesulfonamide FY- F
O
\ ~ O I ~
~ 'NH N
N
~,, N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-4-methylbenzenesulfonamide, and N-methyl-4-(trifluoromethoxy)aniline, the title compound was isolated as a yellow solid in 69% yield (94% purity by HPLC).
MS(ESI'): 529.5; MS(ESI-): 526.6.
Example 15: 4-chloro-N-[3-(4-{[methyl(phenyl)aminolmethyl}l)henyl ])yrazin-2-yll-benzenesulfonamide ~
G I ~ N ~ , ~
G'NH
N
~,, N
Following the general method as outlined in Example 1(Method B), starting from 1o chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide, and N-methyl-aniline, the title compound was isolated as a yellow solid in 76% yield (96%
purity by HPLC).
MS(ESI'): 465.6; MS(ESI-): 463.7.
Example 16: 4-cyano-N-{3-[4-(Imethyl[4-(trifluoromethoxy)phenyllaminol-methyl -phenyllpyrazin-2-yl}benzenesulfonamide N~
F
F
p ~ O F
N \
N
Following the general method as outlined in Example 1(Method D), N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-4-cyanobenzenesulfonamide, and N-methyl-4-(trifluoromethoxy)aniline, the title compounds were isolated as a yellow solid in 70% yield (92% purity by HPLC).
5 MS(ESI'): 540.6; MS(ESI-): 538.5.
Example 17: N-[3-(4-{j(4-Fluoro-phenyl -methyl-aminol-methyl}--phenyl)--pyrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F
W F
F ~ F
s. N ~ ~
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-10 (chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-Fluoro-N-methylaniline, the title compound was isolated as a yellow solid in 78%
yield (98% purity by HPLC).
MS(ESI'): 517.9; MS(ESI-): 515.8.
Example 18: N-(3- {4-[(Methyl-phenyl-amino)-methyll-phenyl} -pvrazin-2-Xl)-2-15 trifluoromethyl-benzenesulfonamide F
WF F
~
N ~ ~
O NH
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and N-methylaniline, the title compound was isolated as a yellow solid in 75% yield (99% purity by HPLC).
MS(ESI'): 499.9; MS(ESI-): 497.8.
Example 19: N-[3-(4-{j(4-Cyano-phenyl -methyl-aminol-methyl}--phenyl)--pyrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F
W F
F :N s. N
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-(N-methylamino)benzonitrile, the title compound was isolated as a yellow solid in 71 % yield (94% purity by HPLC).
MS(ESI'): 524.6; MS(ESI-): 522.4.
Example 20: N-{3-[4-(4-Fluoro-phenoxymethXl)-phenyl]-pvrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F
j OF ~ F
O \ ~
O NH
N
~\ \ I
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-fluorophenol, the title compound was isolated as a yellow solid in 67% yield (95% purity by HPLC).
MS(ESI'): 504.6; MS(ESI-): 502.6.
Example 21: N-(3-{4-[(Ethyl-phenyl-amino -methyll-phenLl}--pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide F
W F
F
S. N ~ 1 O NH
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and N-ethylaniline, the title compound was isolated as a yellow solid in 70% yield (96%
purity by HPLC).
MS(ESI'): 513.6; MS(ESI-): 511.7.
Example 22: N-{3-[4-(2.3-Dihydro benzo[1.4]oxazin-4-ylmethXl)-pheMll-pvrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F
W F O
/ F O
O NH
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3,4-dihydro-2H-1,4-benzoxazine, the title compound was isolated as a yellow solid in 65% yield (97% purity by HPLC).
MS(ESI'): 527.7; MS(ESI-): 525.5.
Example 23: N-[3-(4-{j(3-Fluoro-phenyl -methyl-aminol-methyl}--phenyl)--pyrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F
F , S, N ~ /
O NH
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3-Fluoro-N-methylaniline, the title compound was isolated as a yellow solid in 69%
yield (92% purity by HPLC).
MS(ESI'): 517.7; MS(ESI-): 515.6.
Example 24: N-{3-[4-(6-Chloro :pyridin-3-yloxymethXl)-phenLll-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F
W F
F N
G
.S, O 4/
O NH
N\
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-chloro-5-hydroxy-pyridine, the title compound was isolated as a yellow solid in 73% yield (98% purity by HPLC).
MS(ESI'): 522.1; MS(ESI-): 520.1.
Example 25: N-{3-[4-(2-Pyridin-2-yl-indol-1-ylmethyl --phenyll-pyrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F
\ ~ 0F
Q QN
S.
O NH ~ I \
N
'\
N
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-pyridine-2-yl-lH-indole, the title compound was isolated as a yellow solid in 56%
yield (92% purity by HPLC).
MS(ESI'): 586.8; MS(ESI-): 584.6.
Example 26: N-{3-[4-(5-Fluoro-indol-1-ylmethXl)-phenLll-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F F
F
pF ONH N
ol ~\ \ I
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 5-fluoro-indole, the title compound was isolated as a yellow solid in 69% yield (99% purity by HPLC).
5 MS(ESI'): 527.6; MS(ESI-): 525.7.
Example 27: N-[3-(4-Phenoxymethyl-phenyl)--pyrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F
S= O
N\
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-10 (chloromethyl)phenyl]pyrazin-2-yl} -2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and phenol, the title compound was isolated as a yellow solid in 75% yield (98% purity by HPLC).
MS(ESI'): 486.8; MS(ESI-): 484.7.
Example 28: N-[3-(4- { [(4-Chloro-phenXl)-methyl-amino]-methyl } -phenXl)-pvrazin-2-yj1~
15 2-trifluoromethyl-benzenesulfonamide F G
F ~ , --.S, N
O NH
N\
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-chloro-N-methylaniline, the title compound was isolated as a yellow solid in 72%
yield (94% purity by HPLC).
MS(ESI'): 534.1; MS(ESI-): 532.1.
Example 29: 2-Chloro-N-[3-(4-{j(4-cyano-phenyl -methyl-aminol-methyl}--phenylL
pyrazin-2-vll-benzenesulfonamide N
G
O
.S, N-N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl} -2-(chloro) benzenesulfonamide (Intermediate 8), and 4-(N-methylamino)-benzonitrile, the title compound was isolated as a yellow solid in 52%
yield (99% purity by HPLC).
MS(ESI'): 491.0; MS(ESI-): 489Ø
Example 30: N-[3-4-{[(3.4-Dichloro-phenXl)-methyl-amino]-methyl}-phenXl)-pvrazin-2-yll-2-trifluoromethyl-benzenesulfonamide F G G
F
.S, N
O NH
N\
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3,4-dichloro-N-methylaniline, the title compound was isolated as a yellow solid in 63% yield (91% purity by HPLC).
MS(ESI'): 569.6; MS(ESI-): 565.1.
Example 31: N-{3-[4-4-Cyano-phenoxymethXl)-phenyll-pvrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide N
~ F
F W
~ / F
O
\ \ I
~N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-cyanophenol, the title compound was isolated as a yellow solid in 73% yield (93% purity by HPLC).
MS(ESI'): 511.6; MS(ESI-): 509.6.
Example 32: N-{3-[4-(6-Fluoro-indol-1-ylmethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F
c:F-Q1 S N
O NH
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 6-fluoro-lH-indole, the title compound was isolated as a yellow solid in 77% yield (97% purity by HPLC).
MS(ESI'): 527.8; MS(ESI-): 525.6.
Example 33: 2-Chloro-N-{3-[4-(5-methoxy-2-methyl-indol-1-ylmethXl)-phen1l-pvrazin-2-yl} -benzenesulfonamide a G
O
/ I ~ O~
.S, N ~
ONH H
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(chloro) benzenesulfonamide (Intermediate 8), and 2-methyl-5-methoxyindole, the title compound was isolated as a yellow solid in 72% yield (98% purity by HPLC).
MS(ESI'): 520.2; MS(ESI-): 518.3.
Example 34: N-{3-[4-(4-Methoxy-phenoxymethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F C ~ OF I ~ O"
S, O
O NH
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 4-hydroxyanisole, the title compound was isolated as a yellow solid in 48% yield (91% purity by HPLC).
MS(ESI'): 516.6; MS(ESI-): 514.5.
Example 35: N-(3- {4-[(Benzyl-pyridin-2-yl-amino)-methyll-phenyl} -pyrazin-2-Xl)-2-1 o chloro-benzenesulfonamide G
.o nI
.S, N /
_\
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(chloro) benzenesulfonamide (Intermediate 8), and 2-benzylaminopyridine, the title compound was isolated as a yellow solid in 35% yield (94% purity by HPLC).
MS(ESI'): 543.3; MS(ESI-): 541.3.
Example 36: N-{3-[4-(2,3-Dihydro-indol-1-ylmethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F F
.S, O NH N
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-5 (chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2,3-dihydro-lH-indole, the title compound was isolated as a yellow solid in 66%
yield (94% purity by HPLC).
MS(ESI'): 511.6; MS(ESI-): 509.4.
Example 37: N-[3-4-{[(2,4-Dichloro-phenXl)-methyl-amino]-methyl}-phenXl)-pvrazin-2-10 yll-2-trifluoromethyl-benzenesulfonamide F CI
F _ F ~ ~ G
~
N~
N
~\ \ I
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2,4-dichloro-N-methylaniline, the title compound was isolated as a yellow solid in 15 69% yield (96% purity by HPLC).
MS(ESI'): 569.6; MS(ESI-): 566.8.
Example 38: N-{3-[4-(3-Chloro-phenoxymethyl -I)henyll-p,yrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide F a F _ G~~
F
O
S, N
'\
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 3-chlorophenol, the title compound was isolated as a yellow solid in 70% yield (98% purity by HPLC).
MS(ESI'): 521.0; MS(ESI-): 519Ø
Example 39: 2-Chloro-N-[3-(4-{j(2,4-difluoro-phenyl -methyl-aminol-methyI}--phenylL
pyrazin-2-vll-benzenesulfonamide F
aa - p ~ ~ F
.S, N-N\
N
Following the general method as outlined in Example 1(Method B), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(chloro) benzenesulfonamide (Intermediate 8), and 2,4-difluoro-N-methylaniline, the title compound was isolated as a yellow solid in 77%
yield (92% purity by HPLC).
MS(ESI'): 502.0; MS(ESI-): 500Ø
Example 40: N-{3-[4-(2-Methyl-indol-1-ylmethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F F
~ F
o N
~\ \ I
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-methyl-l-H-indole, the title compound was isolated as a yellow solid in 70%
yield (98% purity by HPLC).
MS(ESI'): 523.5; MS(ESI-): 521.5.
Example 41: 2-Chloro-N-{3-[4-(5-fluoro-indol-1-ylmethXl)-pheMll-pyrazin-2-yl}-benzenesulfonamide F C~/ ~ N N
\ /
N
.S' a O
\ ~
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 5-fluoroindole, the title compound was isolated as a yellow solid in 72%
yield (96%
purity by HPLC).
MS(ESI'): 493.9; MS(ESI-): 491.9 Example 42: 2-Chloro-N-[3-(4-{j(2-fluoro-phenyl -methyl-aminol-methyl}-phenyl)-pyrazin-2-vll-benzenesulfonamide N
N
F
HN O
O
Following the general method as outlined in Example 1(Method B), starting from chloro-N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}benzenesulfonamide (Intermediate 8), and 2-fluoro-N-methyl-aniline, the title compound was isolated as a yellow solid in 79%
yield (99% purity by HPLC).
MS(ESI'): 484.1; MS(ESI-): 482.1 Example 43: 2-Chloro-N-13-[4-(2-methyl-indol-1-ylmethyl -phenyll-pyrazin-2-I}~
benzenesulfonamide N=) ' N \ \ N
,S' a O
\ ~
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 2-methyl-l-H-indole, the title compound was isolated as a yellow solid in 81% yield (96% purity by HPLC).
MS(ESI'): 490.0; MS(ESI-): 488.1 Example 44: N-(3-{4-[Benzyl-p,yridin-2-yl-amino -methyll-phenLl}--pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide ~ F F y .S O F ~
N
~\
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-(chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and N-(2-pyridine)-benzylamine, the title compound was isolated as a yellow solid in 79% yield (98% purity by HPLC).
MS(ESI'): 576.6; MS(ESI-): 574.6.
Example 45: 2-Chloro-N-(3-{4-[(ethyl-pyridin-2-yl-amino)-methyll-phenyl}-pyrazin-2-Xl)-benzenesulfonamide QNiQp HN O
O
Following the general method as outlined in Example 1(Method B), starting from chloro-N- {3-[4-(chloromethyl)phenyl]pyrazin-2-yl }benzenesulfonamide (Intermediate 8), and 2-(ethylamino)-pyridine, the title compound was isolated as a yellow solid in 64%
yield (96% purity by HPLC).
MS(ESI'): 481.0; MS(ESI-): 478.1 Example 46: N-{3-[4-(5-Chloro-2-methyl-indol-l-ylmethyl --phenyll-p,yrazin-2-vl}-2-trifluoromethyl-benzenesulfonamide F F
wo F G
/ ~ ~
.S, N ~
N\
N
Following the general method as outlined in Example 1(Method A), starting from N-{3-[4-5 (chloromethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl) benzenesulfonamide (Intermediate 9), and 2-methyl-5-chloroindole, the title compound was isolated as a yellow solid in 71%
yield (95% purity by HPLC).
MS(ESI'): 558.3; MS(ESI-): 556.4.
Example 47: Preparation of a pharmaceutical formulation 10 The following formulation examples illustrate representative pharmaceutical compositions according to the present invention being not restricted thereto.
Formulation 1- Tablets A 2,3-substituted pyrazine sulfonamide derivative of formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of 15 magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active 2,3-substituted pyrazine sulfonamide compound per tablet) in a tablet press.
Formulation 2 - Capsules A 2,3-substituted pyrazine sulfonamide derivative of formula I is admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active 2,3-substituted pyrazine sulfonamide compound per capsule).
Formulation 3 - Liquid A 2,3-substituted pyrazine sulfonamide derivative of formula I(1250 mg), sucrose (1.75 g) and xanthan gum (4 mg) are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously prepared solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water. Sodium benzoate (10 mg), flavor, and color are diluted with water and added with stirring. Sufficient water is then added to produce a total volume of 5 ml.
Formulation 4 - Tablets A 2,3-substituted pyrazine sulfonamide derivative of formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active 2,3-substituted pyrazine sulfonamide compound) in a tablet press.
Formulation 5 - Injection A 2,3-substituted pyrazine sulfonamide derivative of formula (I) is dissolved in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/ml.
BIOLOGICAL ASSAYS
Example 48: Construction of pCEP4-hCRTH2 mammalian expression vector Human CRTH2 cDNA was amplified by PCR using a human urinary bladder cDNA
library as a template and specific primers containing HindIII and BamHI restriction sites for cloning into the pCEP4 vector (Invitrogen). The vector construction is described in detail in Sawyer et al., Br. J. Pharmoco12002, 137, 1163-72. The nucleotide sequence of the cloned cDNA was identical the previously reported hCRTH2 sequence (Nagata et al, 1999, J.
Immunol. 162, 1278-1286).
Example 49: Establishment of a pCEP4-hCRTH2-HEK293 (EBNA) line HEK293 (EBNA) cells were transfected with the pCEP4-hCRTH2 construct using the calcium phosphate technique. Cells were maintained in culture at 37 C in an atmosphere of 5% CO2 in Dulbecco's modified Eagle's F12 medium (Invitrogen), containing 10%
heat-inactivated foetal calf serum (TerraCell International, Canada), 2mM
Glutamine, 100units/ml of penicillin and 100 g/m1 streptomycin (Invitrogen). 48 hours after the transfection, cells were grown in presence of 300 g/ml of Hygromycin B(Invitrogen) for 4 weeks and antibiotic resistant cells were amplified for cell membrane preparation.
Example 50: Preparation of hCRTH2-expressing membranes Adherent HEK293 (EBNA) cells expressing hCRTH2 were cultured in 225 cm2 cell culture flasks (Coming, USA) in 30m1 of medium. After two rinses of phosphate buffered saline (PBS), cells were harvested in lOml of PBS containing 1mM EDTA, centrifuged at 500 x g for 5 min at 4 C and frozen at -80 C. The pellet was re-suspended in 50 mM
Tris-HC1, pH
7.4, 2mM EDTA, 250mM Sucrose, containing protease inhibitor cocktail tablets, (Complete EDTA-free, Roche, Germany) and incubated 30 min at 4 C. Cells were disrupted by nitrogen cavitation (Parr Instruments, USA) at 4 C (800 p.s.i.
for 30 min), and centrifuged at 500 x g for lOmin at 4 C. Pellet containing nuclei and cellular debris was discarded and supematant was centrifuged 60 min at 4 C at 45000 x g. Membrane pellet was re-suspended in storage buffer (10mM HEPES/KOH pH 7.4, 1mM EDTA, 250mM
sucrose, protease inhibitor cocktail tablets) using Dounce homogenization and frozen in liquid nitrogen, and stored at -80 C.
Example 51: Radioligand binding assay The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligand binding assay (Sawyer et al., Br. J. Pharmoco12002, 137, 1163-72). The radioligand binding assay was performed at room temperature in binding buffer (10mM HEPES/KOH pH 7.4, 10mM MnC12, with protease inhibitor cocktail tablets), containing 1.5nM [3H]PGD2 (Amersham, 156 Cie/mmol), and 10 g of hCRTH2 HEK293 (EBNA) cell membrane protein in a fmal volume of l00 1 in 96 well plates (Coming, USA). Non-specific binding was determined in the presence of 1 M PGD2 (Cayman, USA). Competing pyrazine sulfonamides were diluted in dimethylsulphoxide so that the totale volume of dimethylsulfoxide was kept constant at 1% dimethylsulphoxide (Me2S0). 10 1 of the pyrazine sulfonamides were added. Incubation (60min at room temperature) was terminated by rapid filtration through 96 wells hydrophobic GF/C Unifilter plates (Whatman, USA). Filters were washed twice with 250 1 of Tris-HC1 pH 7.4, 10mM MnC12, and residual radioligand bound to the filters was mixed to 100 1 of liquid scintillation cocktail (Optiphase Supermix, Perkin Elmer, USA) and binding activity was determined by counting residual radioligand using a 1450 Micro-beta scintillation counter (Wallac, UK). Results of the binding assay are shown in Table 1.
Table 1 Compound No. Name Structure Inhibition hCRTH2 [%J
1 4-{3-[4-(1H-indol-l- 94.5 -lmethyl)phenyl]pyrazin-2-yl}- N N
- N
HN F
trifluoromethyl)benzenesulfona 61S F
ide Compound No. Name Structure Inhibition hCRTH2 [%J
2 -chloro-N-{3-[4-({methyl[4- , F~F 91.5 trifluoromethoxy)phenyl]amino Ci } -methyl)phenyl]pyrazin-2- 5\NH
N
1} benzenesulfonamide 3 -(3-{4-[(2-ethyl-lH- 86.5 enZimidaz01-1- "
1)methyl]phenyl}pyrazin-2- F N 1)-2-(trifluoromethyl)benzene- o-5 ~ F
sulfonamide ~ i 4 84.5 -chloro-N-[3-(4-{ [methyl(phenyl)amino]methyl}
henyl)pyrazin-2- "~
o-s_o 1]benzenesulfonamide i ~
82.0 -chloro-N-(3-{4-[(2-aphthyloxy)methyl]phenyl}pyr N
zin-2-yl)-benzenesulfonamide HN N_ -s-- - .p ll 6 81.5 -chloro-N-{3-[4-(1H-indol-l-lmethyl)phenyl]-pyrazin-2-yl}- - "
enzenesulfonamide "'s ~o -t Compound No. Name Structure Inhibition hCRTH2 [%J
7 80.0 -chloro-N-(3-{4-[(5,6,7,8-etrahydronaphthalen-2- 0 N
loxy)methyl]-phenyl}pyrazin--y1)benzenesulfonamide HN N
-s-6c, 8 N~ ~ 79.0 -chloro-N-(3-{4-[(2-ethyl-lH- N
enzimidazol-l- ~ ~~
1)methyl]phenyl}pyrazin-2- oso c, 1)benzenesulfonamide 9 < 72.5 ~ /
4-(3-{4-[(1,3-benzodioxol-5- NH
lamino)methyl]-henyl } pyrazin-2-yl)-2-N
trifluoromethyl)benzenesulfona HN
ide 10 , 72.0 -[3-(4-{[(3-ethoxybenzyl)oxy]methyl}phe Yl)pyrazin-2-yl]-2- N~
trifluoromethyl)benzenesulfona o "~-~" F
ide F
11 3-chloro-N-{3-[4-({methyl[4- ' FF F 65.0 trifluoromethoxy)phenyl]-mino}-methyl)phenyl]pyrazin- " i -yl}benzenesulfonamide \
Compound No. Name Structure Inhibition hCRTH2 [%J
12 -[3-(4-1[(4- 65.0 hlorophenyl)(methyl)amino]- ethyl}phenyl)pyrazin-2-yl]-hiophene-2-sulfonamide 13 64.5 I-phenoxy-N-{3-[4-(quinolin-2- ~
lmethyl)piperazin-l-1]pyrazin-2-yl} - s=
N ""
enzenesulfonamide -"x N- I \ \
14 I-methyl-N-{3-[4-({methyl[4- F+F 53.0 trifluoromethoxy)phenyl]-mino}-methyl)phenyl]pyrazin- ~ ""
-yl} benzenesulfonamide N
15 r~NO 51.0 I-chloro-N-[3-(4- " Ho { [methyl(phenyl)amino]methyl}
henyl)pyrazin-2-yl]-enzenesulfonamide "/
16 N'i N 47.0 _ I-cyano-N-{3-[4-({methyl[4- H o -"
trifluoromethoxy)phenyl]-mino}methyl)phenyl]pyrazin- "--yl}benzenesulfonamide o XF
F F
Example 52: Determination of K;(Radioligand bindin agssay) Ki values were determined by equilibrium competition binding experiments against[3H]PGD2. Kl values were calculated from the formula below and represent the average of at least three independent dose response experiments. The Kl values give the ligand concentrations necessary to inhibit 50% of the binding of 3[H]PGD2 to CRTH2.
Ki= IC50/(1+[Concentration of Ligand]/Kd)]
All experiments were performed in 96 well plates, in a final volume of l00 1 according to the above described filtration assay. The concentration of membranes and 3[H]PGD2, as well as the positive and negative controls were identical to the conditions described above.
In one embodiment, the pyrazine sulfonamides of the present invention inhibit CRTH2 at a concentration of <100 M. In another embodiment, the pyrazine sulfonamides of the present invention inhibit CRTH2 at a concentration of <10 M. In a preferred embodiment, the pyrazine sulfonamides of the present invention inhibit CRTH2 at a concentration of <5 M. In a further preferred embodiment, the pyrazine sulfonamides of the present invention inhibit CRTH2 at a concentration of <1 M.
Kl values are shown in Table 2. It can be derived that said compounds according to Formula I showed a significant inhibition of the binding of PGD2 to CRTH2.
Table 2 Compound %,[ MJ Compoun %, [ MJ Compound %, [ MJ
No. No. No.
1 1.01 17 0.38 33 2.21 2 1.26 18 0.40 34 2.60 3 0.45 19 0.47 35 2.64 4 1.57 20 0.48 36 2.69 2.32 21 0.59 37 2.82 6 2.12 22 0.62 38 2.90 7 2.59 23 0.70 39 2.95 8 1.42 24 0.72 40 3.06 9 2.98 25 0.85 41 3.90 1.40 26 0.95 42 3.90 11 5.16 27 1.32 43 4.11 12 8.43 28 1.47 44 4.44 13 4.03 29 1.49 45 4.51 14 5.85 30 1.58 46 4.65 5.38 31 1.59 16 5.71 32 1.93 Example 53: [35S]GTPyS binding assaX
The [35S]GTPyS assay measures the increase in guanine nucleotide exchange at G-proteins in cell membranes, resulting from agonist (PGD2) binding to CRTH2. This process can be monitored in vitro by incubating cell membranes containing G-proteins and CRTH2 with GDP and [35S]GTPyS, a radiolabeled, hydrolysis-resistant analogue of GTP (see, Harrison et al., Life Sciences 74, 489-508, 2003). The addition of a pyrazine sulfonamide results in binding to CRTH2 and thus in an inhibition of agonist binding, which can be monitered as inhibition of the stimulation of GTP/GDP exchange.
Assay conditions were identical to conditions of radioligand binding assay as described in Example 21. The [35S]GTPyS binding assay was performed at 30 C with gentle agitation in 96-well scintillating white polystyrene plates (Perkin Elmer, USA), in a final volume of 200 1, containing 2% of dimethylsulphoxide (Me2SO). The 2,3 substituted pyrazine sulfonamides were incubated in 20mM HEPES/KOH pH 7.4, 10mM MgC12, 10 g/ml Saponin, 3 M GDP, 150mM NaC1 containing 10 g of membranes expressing the hCRTH2 receptor (Euroscreen, Belgium) for 10 min. Non-specific binding was determined in the presence of 10 M of GTPyS. Samples were incubated for 30 min in the presence of increasing concentrations of PGD2 for the determination of agonist activity, or with 8OnM
of PGD2 for determination of antagonist activity, respectively. 0.15nM of [35S]GTPyS were subsequently added to each sample and after incubation of 30min reactions were stopped by centrifugation at 1000 x g, at 4 C for 10 min. Supernatant was removed and [35S]GTPyS
binding was determined using a 1450 Micro-beta scintillation counter. Data were analysed using "Prism" (GraphPad Software, Inc. San Diego, USA). The determination of the IC50 values (i.e. the amount necessary to achieve 50% inhibition of binding (in M)) were performed in 96 well plates, in a final volume of l00 1 according to the above described filtration assay. The concentration of membranes and radioactive ligand, as well as the positive and negative controls were identical to the conditions used and described aboveExamples 21 and 22.
The compound of Example 1 showed an IC50 value of 1.9 M. The compound of Example 2 showed an IC50 value of 4.6 M and the compound of Example 3 showed an IC50 value of 1.4 M.
Example 54: CHS model 5 The contact hypersensitivity model can be used to evaluate the therapeutic efficacy of 2, 3-substituted pyrazine sulfonamides on skin inflammation mediated by T cells.
The model is well established for characterization of compound for dermatological indications like psoriasis and allergic contact dermatitis (Xu et al. J Exp Med. 183, 1001-12, 1996). It involves a sensitization phase and a subsequent challenge with an antigen (DNFB, 2,4-10 dinitrofluorbenzene). This results in skin inflammation with formation of edema and cellular infiltrates in the skin. The edema can be measured by caliper at the challenged site (ear of the mice). Intravenous administration of the compounds of the invention 30 min before challenge with DNFB results in a decrease of the swelling and therefore reduces inflammation in the skin compared to positive controls treated with vehicle only before 15 challenge with the antigen. Negative control mice are not sensitized, but challenged with DNFB, therefore no T cell dependent inflammation occurs and no edema is formed. Balb/c mice are obtained from CharlesRiver (Calcco, Italy). Animals are housed in a conventional animal facility. Treatment starts at an average age of 8 - 12 weeks.
DNFB (2,4-dinitrofluorbenzene) is purchased from Sigma-Aldrich (St.Louis, MO
USA) 20 Sensitization and challenge of CHS by DNFB
Mice are sensitized and challenged to elicit CHS to DNFB. The sensitization phase is followed by a challenge phase. DNFB is diluted in acetone/olive oil (4/1) immediately before use. Mice are sensitized to DNFB by applying 25 1 of 0.5%DNFB solution onto the shaved dorsal skin. Five days later, 10 1 of 0.2% DNFB are applied onto both sides of the 25 right ear (challenge). Ear thickness is monitored on day 6 (1 day affter challenge) using a caliper (Mitutoyo, Milan, Italy). Ear swelling is calculated as ((Tn-T5)right ear - (Tn-T5)left ear), wherein Tn and T5 represent values of ear thickness at day n of investigation and day 5 prior to challenge, respectively.
REFERENCE LIST
Cosmi et al. (2000) Eur. J. Immunol. 30, 2972-2979 Bush, R.K., Georgitis J.W., Handbook of asthma and rhinitis. 1st ed. (1997), Abingdon:
Blackwell Science. 270 Harrison et al.(2003) Life Sciences 74, 489-508 Hirai et al. (2001) J Exp. Med. 193, 255-261 Lewis et al. (1982) J. Immunol. 129, 1627 Matsuoka et al. (2000) Science 287, 2013-2017 Nagata et al. (1999) J. Immunol. 162, 1278-1286 Sawyer et al. (2002) Br. J. Pharmacol. 137, 1163-1172 Woodward et al. (1990) Invest. Ophthalomol Vis. Sci. 31, 138-146 Woodward et al. (1993) Eur. J. Pharmacol. 230, 327-333 Xu et al. (1996) J Exp Med. 183, 1001-12
Claims (16)
1. A compound according to Formula (I), as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, and tautomers, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein A is selected from the group consisting of with n being an integer independently selected from 0, 1, 2, 3 or 4;
m is either 1 or 2;
B is selected from the group consisting of C2-C6-alkynyl, C3-C8-cycloalkyl, C3-heterocycloalkyl, aryl, and monocyclic heteroaryl;
R1 is either hydrogen or C1-C6-alkyl;
R2 is selected from the group consisting of C1-C6-alkyl, aryl, heteroaryl, C3-cycloalkyl and C3-C8-heterocycloalkyl, wherein R2 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-alkyl, C1-C6-alkoxy, thioalkoxy and thioalkyl;
R3 is selected from the group consisting of C1-C6-alkyl, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl C3-C8-cycloalkyl and C3-C8-heterocycloalkyl wherein each of said C1-C6-alkyl, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl C3-C8-cycloalkyl and C3-C8-heterocycloalkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl, or wherein said aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl may be fused to one or more aryl, heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl groups and may be substituted with one or more substituents selected of the group consisting of C1-C6-alkyl, alkoxy, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, amino, amino carbonyl, nitro, sulfoxy, sulfonyl, sulfonamide and trihaloalkyl;
R7 is selected from the group consisting of hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, C3-C8-heterocycloalkyl, carboxyl, cyano, amino and hydroxy; and R8 is selected from the group consisting of hydrogen, C1-C6-alkyl, aryl, and heteroaryl;
for use as a medicament.
m is either 1 or 2;
B is selected from the group consisting of C2-C6-alkynyl, C3-C8-cycloalkyl, C3-heterocycloalkyl, aryl, and monocyclic heteroaryl;
R1 is either hydrogen or C1-C6-alkyl;
R2 is selected from the group consisting of C1-C6-alkyl, aryl, heteroaryl, C3-cycloalkyl and C3-C8-heterocycloalkyl, wherein R2 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-alkyl, C1-C6-alkoxy, thioalkoxy and thioalkyl;
R3 is selected from the group consisting of C1-C6-alkyl, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl C3-C8-cycloalkyl and C3-C8-heterocycloalkyl wherein each of said C1-C6-alkyl, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl C3-C8-cycloalkyl and C3-C8-heterocycloalkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl, or wherein said aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl may be fused to one or more aryl, heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl groups and may be substituted with one or more substituents selected of the group consisting of C1-C6-alkyl, alkoxy, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, amino, amino carbonyl, nitro, sulfoxy, sulfonyl, sulfonamide and trihaloalkyl;
R7 is selected from the group consisting of hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, C3-C8-heterocycloalkyl, carboxyl, cyano, amino and hydroxy; and R8 is selected from the group consisting of hydrogen, C1-C6-alkyl, aryl, and heteroaryl;
for use as a medicament.
2. The compound according to claim 1, wherein B is selected from the group consisting of aryl, C3-C8-heterocycloalkyl and C2-C6-alkynyl.
3. The compounds according to claim 1 or 2, wherein R2 is selected from the group consisting of an aryl, heteroaryl and C1-C6-alkyl.
4. The compound according to any one of claims 1 to 3, wherein R1 is hydrogen.
5. The compound according to any one claims 1 to 4, wherein R2 and R3 are independently substituted with 1-3 substituents selected from C1-C6-alkyl, alkoxy, cyano, amino or halogen, wherein said C1-C6-alkyl or alkoxy may be substituted with halogen.
6. The compound according to any one of claims 1 to 5, wherein said compound is selected from the group of N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl)-benzenesulfonamide, 2-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, N-(3-{4-[(2-ethyl-1H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, 2-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]-benzenesulfonamide, 2-chloro-N-(3-{4-[(2-naphthyloxy)methyl]phenyl}pyrazin-2-yl)benzene-sulfonamide, 2-chloro-N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}benzenesulfonamide, 2-chloro-N-(3-{4-[(5,6,7,8-tetrahydronaphthalen-2-yloxy)methyl]phenyl}-pyrazin2-yl)benzenesulfonamide, 2-chloro-N-(3-{4-[(2-ethyl-1H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)-benzenesulfonamide, N-(3-{4-[(1,3-benzodioxol-5-ylamino)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, N-[3-(4-{[(3-methoxybenzyl)oxy]methyl}phenyl)pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide, 3-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, N-[3-(4-{[(4-chlorophenyl)(methyl)amino]methyl}phenyl)pyrazin-2-yl]thiophene-2-sulfonamide, 4-phenoxy-N-{3-[4-(quinolin-2-ylmethyl)piperazin-1-yl]pyrazin-2-yl}-benzenesulfonamide, 4-methyl-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, 4-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]-benzenesulfonamide, 4-cyano-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]-amino}-methyl)phenyl]pyrazin-2-yl}benzenesulfonamide, N-[3-(4-{[(4-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-(3-{4-[(Methyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(4-Cyano-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(4-Fluoro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-(3-{4-[(Ethyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(2,3-Dihydro-benzo[1,4]oxazin-4-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(3-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(6-Chloro pyridin-3-yloxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(2-Pyridin-2-yl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(5-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-Phenoxymethyl-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(4-Chloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{[(4-cyano-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-benzenesulfonamide, N-[3-(4-{[(3,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(4-Cyano-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(6-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-methoxy-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-benzenesulfonamide, N-{3-[4-(4-Methoxy-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-chloro-benzenesulfonamide, N-{3-[4-(2,3-Dihydro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(2,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(3-Chloro phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{[(2,4-difluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-yl]-benzenesulfonamide, N-{3-[4-(2-Methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-benzenesulfonamide, 2-Chloro-N-[3-(4-{[(2-fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-benzenesulfonamide, 2-Chloro-N-{3-[4-(2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-benzenesulfonamide, N-(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-(3-{4-[(ethyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-benzenesulfonamide, and N-{3-[4-(5-Chloro-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide.
7. Use of a compound according to Formula (1):
wherein A is selected from the group consisting of with n being an integer selected from 0, 1, 2, 3 or 4;
m is either 1 or 2;
B is selected from the group consisting of C2-C6-alkynyl, C3-C8-cycloalkyl, C3-heterocycloalkyl, aryl, and monocyclic heteroaryl;
R1 is either hydrogen or C1-C6-alkyl;
R2 is selected from the group consisting of C1-C6-alkyl, aryl, heteroaryl, C3-cycloalkyl and C3-C8-heterocycloalkyl, wherein R2 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-alkyl, C1-C6-alkoxy, thioalkoxy and thioalkyl;
R3 is selected from the group consisting of C1-C6-alkyl, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl C3-C8-cycloalkyl and C3-C8-heterocycloalkyl wherein each of said C1-C6-alkyl, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl C3-C8-cycloalkyl and C3-C8-heterocycloalkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl, or wherein said aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl may be fused to one or more aryl, heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl groups and may be substituted with one or more substituents selected of the group consisting of C1-C6-alkyl, alkoxy, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, amino, amino carbonyl, nitro, sulfoxy, sulfonyl, sulfonamide and trihaloalkyl;
R7 is selected from the group consisting of C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, C3-C8-heterocycloalkyl, carboxyl, cyano, amino and hydroxy; and R8 is selected from the group consisting of hydrogen, C1-C6-alkyl, aryl, and heteroaryl;
as well as geometrical isomers, enantiomers, diastereomers, racemate forms, tautomers and pharmaceutically acceptable salts of said compounds for the preparation of a medicament for the treatment and/or prevention of allergic disease, inflammatory dermatoses, immunologocal disorders and neurodegenerative disorders.
wherein A is selected from the group consisting of with n being an integer selected from 0, 1, 2, 3 or 4;
m is either 1 or 2;
B is selected from the group consisting of C2-C6-alkynyl, C3-C8-cycloalkyl, C3-heterocycloalkyl, aryl, and monocyclic heteroaryl;
R1 is either hydrogen or C1-C6-alkyl;
R2 is selected from the group consisting of C1-C6-alkyl, aryl, heteroaryl, C3-cycloalkyl and C3-C8-heterocycloalkyl, wherein R2 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-alkyl, C1-C6-alkoxy, thioalkoxy and thioalkyl;
R3 is selected from the group consisting of C1-C6-alkyl, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl C3-C8-cycloalkyl and C3-C8-heterocycloalkyl wherein each of said C1-C6-alkyl, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl C3-C8-cycloalkyl and C3-C8-heterocycloalkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl, or wherein said aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl may be fused to one or more aryl, heteroaryl, C3-C8-cycloalkyl or C3-C8-heterocycloalkyl groups and may be substituted with one or more substituents selected of the group consisting of C1-C6-alkyl, alkoxy, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, amino, amino carbonyl, nitro, sulfoxy, sulfonyl, sulfonamide and trihaloalkyl;
R7 is selected from the group consisting of C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, C3-C8-heterocycloalkyl, carboxyl, cyano, amino and hydroxy; and R8 is selected from the group consisting of hydrogen, C1-C6-alkyl, aryl, and heteroaryl;
as well as geometrical isomers, enantiomers, diastereomers, racemate forms, tautomers and pharmaceutically acceptable salts of said compounds for the preparation of a medicament for the treatment and/or prevention of allergic disease, inflammatory dermatoses, immunologocal disorders and neurodegenerative disorders.
8. The use according to claim 7, wherein said allergic disease is selected from the group consisting of allergic asthma, allergic rhinitis, allergic conjunctivitis, systemic anaphylaxis or hypersensitivity responses.
9. The use according to claim 7, wherein said inflammatory dermatosis is selected from the group consisting of of atopic dermatitis, eczema, allergic contact dermatitis, and urticaria and myositis.
10. The use according to claim 7, wherein said disease is selected from the group consisting of rheumatoid arthritis, multiple, sclerosis, osteoarthritis, and inflammatory bowel disease (IBD).
11. The use according to claim 7, wherein said disease is neuropatic pain.
12. The use according to any one of claims 7 to 11, wherein said compound is a modulator, in particular an inhibitor, of the CRTH2 activity.
13. The use according to claims 7 to 12 wherein said compound is selected from the group consisting of N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl)-benzenesulfonamide, 2-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, N-(3-{4-[(2-ethyl-1H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, 2-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]-benzenesulfonamide, 2-chloro-N-(3-{4-[(2-naphthyloxy)methyl]phenyl}pyrazin-2-yl)benzene-sulfonamide, 2-chloro-N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}benzenesulfonamide, 2-chloro-N-(3-{4-[(5,6,7,8-tetrahydronaphthalen-2-yloxy)methyl]phenyl}-pyrazin-yl)benzenesulfonamide, 2-chloro-N-(3-{4-[(2-ethyl-1H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)-benzenesulfonamide, N-(3-{4-[(1,3-benzodioxol-5-ylamino)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, N-[3-(4-{[(3-methoxybenzyl)oxy]methyl}phenyl)pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide, 3-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, N-[3-(4-{[(4-chlorophenyl)(methyl)amino]methyl}phenyl)pyrazin-2-yl]thiophene-2-sulfonamide, 4-phenoxy-N-{3-[4-(quinolin-2-ylmethyl)piperazin-1-yl]pyrazin-2-yl}-benzenesulfonamide, 4-methyl-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, 4-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]-benzenesulfonamide, 4-cyano-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, N-[3-(4-{[(4-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-(3-{4-[(Methyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(4-Cyano-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(4-Fluoro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-(3-{4-[(Ethyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(2,3-Dihydro-benzo[1,4]oxazin-4-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(3-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(6-Chloro pyridin-3-yloxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(2-Pyridin-2-yl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(5-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-Phenoxymethyl-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(4-Chloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{[(4-cyano-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-benzenesulfonamide, N-[3-(4-{[(3,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(4-Cyano-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(6-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-methoxy-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-benzenesulfonamide, N-{3-[4-(4-Methoxy-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-chloro-benzenesulfonamide, N-{3-[4-(2,3-Dihydro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(2,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(3-Chloro phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{[(2,4-difluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-yl]-benzenesulfonamide, N-{3-[4-(2-Methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-benzenesulfonamide, 2-Chloro-N-[3-(4-{[(2-fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-benzenesulfonamide, 2-Chloro-N-{3-[4-(2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-benzenesulfonamide, N-(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-(3-{4-[(ethyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-benzenesulfonamide, and N-{3-[4-(5-Chloro-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide.
14. A 2,3 substituted pyrazine sulfonamide selected from the group consisting of N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}-2-(trifluoromethyl)-benzenesulfonamide, 2-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, N-(3-{4-[(2-ethyl-1H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, 2-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]-benzenesulfonamide, 2-chloro-N-(3-{4-[(2-naphthyloxy)methyl]phenyl}pyrazin-2-yl)benzene-sulfonamide, 2-chloro-N-{3-[4-(1H-indol-1-ylmethyl)phenyl]pyrazin-2-yl}benzenesulfonamide, 2-chloro-N-(3-{4-[(5,6,7,8-tetrahydronaphthalen-2-yloxy)methyl]phenyl}-pyrazin2-yl)benzenesulfonamide, 2-chloro-N-(3-{4-[(2-ethyl-1H-benzimidazol-1-yl)methyl]phenyl}pyrazin-2-yl)-benzenesulfonamide, N-(3-{4-[(1,3-benzodioxol-5-ylamino)methyl]phenyl}pyrazin-2-yl)-2-(trifluoromethyl)benzenesulfonamide, N-[3-(4-{[(3-methoxybenzyl)oxy]methyl}phenyl)pyrazin-2-yl]-2-(trifluoromethyl)benzenesulfonamide, 3-chloro-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, N-[3-(4-{[(4-chlorophenyl)(methyl)amino]methyl}phenyl)pyrazin-2-yl]thiophene-2-sulfonamide, 4-phenoxy-N-{3-[4-(quinolin-2-ylmethyl)piperazin-1-yl]pyrazin-2-yl}-benzenesulfonamide, 4-methyl-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]amino}methyl)phenyl]-pyrazin-2-yl}benzenesulfonamide, 4-chloro-N-[3-(4-{[methyl(phenyl)amino]methyl}phenyl)pyrazin-2-yl]-benzenesulfonamide, 4-cyano-N-{3-[4-({methyl[4-(trifluoromethoxy)phenyl]-amino}-methyl)phenyl]pyrazin-2-yl}benzenesulfonamide, N-[3-(4-{[(4-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-(3-{4-[(Methyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(4-Cyano-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(4-Fluoro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-(3-{4-[(Ethyl-phenyl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(2,3-Dihydro-benzo[1,4]oxazin-4-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(3-Fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(6-Chloro-pyridin-3-yloxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(2-Pyridin-2-yl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(5-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-Phenoxymethyl-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(4-Chloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{[(4-cyano-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-benzenesulfonamide, N-[3-(4-{[(3,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(4-Cyano-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(6-Fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-methoxy-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-benzenesulfonamide, N-{3-[4-(4-Methoxy-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-chloro-benzenesulfonamide, N-{3-[4-(2,3-Dihydro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, N-[3-(4-{[(2,4-Dichloro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-2-trifluoromethyl-benzenesulfonamide, N-{3-[4-(3-Chloro-phenoxymethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-[3-(4-{[(2,4-difluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-yl]-benzenesulfonamide, N-{3-[4-(2-Methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-{3-[4-(5-fluoro-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-benzenesulfonamide, 2-Chloro-N-[3-(4-{[(2-fluoro-phenyl)-methyl-amino]-methyl}-phenyl)-pyrazin-2-yl]-benzenesulfonamide, 2-Chloro-N-{3-[4-(2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-benzenesulfonamide, N-(3-{4-[(Benzyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-2-trifluoromethyl-benzenesulfonamide, 2-Chloro-N-(3-{4-[(ethyl-pyridin-2-yl-amino)-methyl]-phenyl}-pyrazin-2-yl)-benzenesulfonamide, and N-{3-[4-(5-Chloro-2-methyl-indol-1-ylmethyl)-phenyl]-pyrazin-2-yl}-2-trifluoromethyl-benzenesulfonamide.
15. A pharmaceutical composition containing at least one compound according to claim 14 and a pharmaceutically acceptable carrier, diluent or excipient thereof.
16. Process for the preparation of a compound according to claim 14, wherein one of the following reactions is performed:
wherein R4, R5, R6 are independently selected from the group of hydrogen, alkyl, aryl, heteroaryl, C3-C8-cycloalkyl and C3-C8-heterocycloalkyl or fused rings of said aryl, heteroaryl, cycloalkyl or heterocycloalkyl.
wherein R4, R5, R6 are independently selected from the group of hydrogen, alkyl, aryl, heteroaryl, C3-C8-cycloalkyl and C3-C8-heterocycloalkyl or fused rings of said aryl, heteroaryl, cycloalkyl or heterocycloalkyl.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05103254.8 | 2005-04-21 | ||
EP05103254 | 2005-04-21 | ||
US67538105P | 2005-04-27 | 2005-04-27 | |
US60/675,381 | 2005-04-27 | ||
PCT/EP2006/061706 WO2006111560A2 (en) | 2005-04-21 | 2006-04-20 | 2,3 substituted pyrazine sulfonamides as inhibitors of crth2 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2601979A1 true CA2601979A1 (en) | 2006-10-26 |
CA2601979C CA2601979C (en) | 2014-06-17 |
Family
ID=35219510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2601979A Expired - Fee Related CA2601979C (en) | 2005-04-21 | 2006-04-20 | 2,3 substituted pyrazine sulfonamides |
Country Status (18)
Country | Link |
---|---|
US (1) | US8796280B2 (en) |
EP (1) | EP1871374B1 (en) |
JP (1) | JP5677719B2 (en) |
KR (1) | KR101380448B1 (en) |
CN (1) | CN101217957B (en) |
AT (1) | ATE524182T1 (en) |
AU (1) | AU2006237365B2 (en) |
BR (1) | BRPI0610035A2 (en) |
CA (1) | CA2601979C (en) |
DK (1) | DK1871374T3 (en) |
ES (1) | ES2369714T3 (en) |
HK (1) | HK1119080A1 (en) |
MX (1) | MX2007012937A (en) |
PL (1) | PL1871374T3 (en) |
PT (1) | PT1871374E (en) |
RU (1) | RU2453540C2 (en) |
WO (1) | WO2006111560A2 (en) |
ZA (1) | ZA200709817B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5226513B2 (en) * | 2005-08-26 | 2013-07-03 | メルク セローノ ソシエテ アノニム | Pyrazine derivatives and uses thereof |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
EP2285803A4 (en) | 2008-05-23 | 2011-10-05 | Amira Pharmaceuticals Inc | 5-lipoxygenase-activating protein inhibitor |
US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
JP2013540141A (en) | 2010-10-20 | 2013-10-31 | メルク セローノ ソシエテ アノニム ジュネーブ | Process for preparing substituted N- (3-amino-quinoxalin-2-yl) -sulfonamides and their intermediates N- (3-chloro-quinoxalin-2-yl) sulfonamides |
KR20140113667A (en) | 2011-12-16 | 2014-09-24 | 아토픽스 테라퓨릭스 리미티드 | Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
CN106831556B (en) * | 2015-12-07 | 2020-09-01 | 成都海创药业有限公司 | Sulfonamide compound, preparation method thereof and application of sulfonamide compound as urate transporter inhibitor medicine |
WO2018005713A1 (en) * | 2016-06-29 | 2018-01-04 | Congxin Liang | Piperazine derivatives as trpml modulators |
WO2018165822A1 (en) * | 2017-03-13 | 2018-09-20 | 成都海创药业有限公司 | Sulfonamide compounds and preparation method therefor, and use of same as urate transporter inhibitor medicines |
MX2021003158A (en) | 2018-09-18 | 2021-07-16 | Nikang Therapeutics Inc | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors. |
EP3821947A1 (en) * | 2019-11-13 | 2021-05-19 | Libra Therapeutics, Inc. | Heterocyclic trpml1 agonists |
EP4294807A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL122332A0 (en) * | 1995-06-21 | 1998-04-05 | Shionogi & Co | Bicyclic amino derivatives and PGD2 antagonist containing the same |
KR20040084896A (en) * | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Heteroaryl compounds useful as inhibitors of gsk-3 |
US7239680B2 (en) | 2002-07-17 | 2007-07-03 | Broadcom Corporation | Methods for performing channel diagnostics |
US7480326B2 (en) * | 2002-07-17 | 2009-01-20 | Broadcom Corporation | Channel diagnostic systems and methods |
PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
EP1556356B1 (en) | 2002-10-21 | 2006-05-31 | Warner-Lambert Company LLC | Tetrahydroquinoline derivatives as crth2 antagonists |
AU2003297398B2 (en) * | 2002-12-20 | 2009-09-24 | Amgen Inc. | Asthma and allergic inflammation modulators |
WO2004058265A1 (en) | 2002-12-24 | 2004-07-15 | Biofocus Plc | Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors |
EP1471057B1 (en) | 2003-04-25 | 2006-01-18 | Actimis Pharmaceuticals, Inc. | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 |
SE0301569D0 (en) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0301650D0 (en) | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
SE0301653D0 (en) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
US20050038070A1 (en) | 2003-07-09 | 2005-02-17 | Amgen Inc. | Asthma and allergic inflammation modulators |
WO2005102338A1 (en) | 2004-04-20 | 2005-11-03 | Pfizer Limited | Method of treating neuropathic pain using a crth2 receptor antagonist |
SA05260265A (en) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | Novel compounds |
PL1838674T3 (en) * | 2005-01-14 | 2011-08-31 | Chemocentryx Inc | Heteroaryl sulfonamides and ccr2 |
-
2006
- 2006-04-20 RU RU2007142648/04A patent/RU2453540C2/en not_active IP Right Cessation
- 2006-04-20 BR BRPI0610035-0A patent/BRPI0610035A2/en not_active IP Right Cessation
- 2006-04-20 JP JP2008507083A patent/JP5677719B2/en not_active Expired - Fee Related
- 2006-04-20 EP EP06754765A patent/EP1871374B1/en active Active
- 2006-04-20 MX MX2007012937A patent/MX2007012937A/en active IP Right Grant
- 2006-04-20 DK DK06754765.3T patent/DK1871374T3/en active
- 2006-04-20 PL PL06754765T patent/PL1871374T3/en unknown
- 2006-04-20 CN CN2006800218062A patent/CN101217957B/en not_active Expired - Fee Related
- 2006-04-20 PT PT06754765T patent/PT1871374E/en unknown
- 2006-04-20 AT AT06754765T patent/ATE524182T1/en active
- 2006-04-20 WO PCT/EP2006/061706 patent/WO2006111560A2/en active Application Filing
- 2006-04-20 ZA ZA200709817A patent/ZA200709817B/en unknown
- 2006-04-20 KR KR1020077025817A patent/KR101380448B1/en not_active IP Right Cessation
- 2006-04-20 US US11/918,294 patent/US8796280B2/en not_active Expired - Fee Related
- 2006-04-20 CA CA2601979A patent/CA2601979C/en not_active Expired - Fee Related
- 2006-04-20 ES ES06754765T patent/ES2369714T3/en active Active
- 2006-04-20 AU AU2006237365A patent/AU2006237365B2/en not_active Ceased
-
2008
- 2008-11-28 HK HK08113046.9A patent/HK1119080A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US8796280B2 (en) | 2014-08-05 |
KR101380448B1 (en) | 2014-04-11 |
JP2008536892A (en) | 2008-09-11 |
CA2601979C (en) | 2014-06-17 |
EP1871374A2 (en) | 2008-01-02 |
RU2453540C2 (en) | 2012-06-20 |
AU2006237365A1 (en) | 2006-10-26 |
WO2006111560A3 (en) | 2007-05-03 |
DK1871374T3 (en) | 2011-12-05 |
CN101217957B (en) | 2012-04-04 |
BRPI0610035A2 (en) | 2010-05-18 |
AU2006237365B2 (en) | 2012-09-20 |
RU2007142648A (en) | 2009-05-27 |
MX2007012937A (en) | 2008-03-26 |
EP1871374B1 (en) | 2011-09-14 |
ATE524182T1 (en) | 2011-09-15 |
WO2006111560A2 (en) | 2006-10-26 |
KR20080004586A (en) | 2008-01-09 |
US20090054447A1 (en) | 2009-02-26 |
HK1119080A1 (en) | 2009-02-27 |
JP5677719B2 (en) | 2015-02-25 |
PL1871374T3 (en) | 2011-12-30 |
PT1871374E (en) | 2011-09-30 |
CN101217957A (en) | 2008-07-09 |
ES2369714T3 (en) | 2011-12-05 |
ZA200709817B (en) | 2009-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006237365B2 (en) | 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2 | |
US9622991B2 (en) | Hematopoietic growth factor mimetic small molecule compounds and their uses | |
CA2758071C (en) | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use | |
TW200902010A (en) | Anthranilamide inhibitors of aurora kinase | |
TW201010690A (en) | Organic compounds | |
AU2008263166A1 (en) | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | |
KR20150130415A (en) | Heterocyclic compounds useful in the treatment of disease | |
TW200918053A (en) | Heteroaryl benzene compound | |
KR20110031318A (en) | 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer | |
KR102519948B1 (en) | Compounds and compositions for the treatment of cancer | |
WO2008113255A1 (en) | Benzamide derivatives with anti-proliferative activity, pharmaceutical preparations thereof | |
TW200800912A (en) | Small-molecule modulators of TRP-P8 activity | |
WO2012159557A1 (en) | Substituted triazine phenylurea derivative and use thereof against tumors | |
EP3412664B1 (en) | Heterocyclic sulfonamide derivative and medicine containing same | |
JP2016505550A (en) | Substituted triazole and imidazole compounds | |
JP2007515412A (en) | Diacylhydrazine derivatives | |
JP2020506226A (en) | Amide compounds and uses thereof | |
WO2019157959A1 (en) | Pyrimidine compound, preparation method therefor and medical use thereof | |
IL279722B1 (en) | Novel lxr modulators with bicyclic core moiety | |
FR2911136A1 (en) | New N-(4-cyano-1H-pyrazol-3-yl)-methylamine derivatives, are cannabinoid CB1 receptor antagonists, useful e.g. for treating psychiatric, neurodegenerative or metabolic disorders | |
JP2007137810A (en) | Medicine containing indole compound | |
HRP20030608A2 (en) | Use of gal3 receptor antagonists for the treatment | |
WO2019119486A1 (en) | Class of pyrimidine derivative kinase inhibitors | |
JP2006001926A (en) | Indole compound | |
CN101094832A (en) | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20170420 |